


**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Cumulative Supplement 9

September 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

**CUMULATIVE SUPPLEMENT 9
September 2015**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 35th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AGILA SPECIALTIES PRIVATE LTD (AGILA SPECLTS)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
ONCO THERAPIES LTD (ONCO THERAPIES LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
REDKITT BENCKISER PHARMACEUTICALS INC (RECKITT BENCKISER)	INDIVIOR INC (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352	16543	16824	
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)	2613 (15.5%)	
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)	14211 (84.5%)	
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)	14089 (83.7%)	
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)	122 (0.7%)	
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)	75 (0.5%)	75 (0.4%)	
NEW MOLECULAR ENTITIES APPROVED	13	22	12	37	
NUMBER OF APPLICANTS	927	935	957	975	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL
FIORICET

@ ACTAVIS LABS UT INC 325MG;50MG;40MG A088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
FIORICET W/ CODEINE

AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA SUN PHARM INDS LTD 300MG;30MG A085868 001 Apr CAHN
AA 300MG;60MG A087083 001 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MIKART 325MG;2.5MG A040846 001 Jun 09, 2010 Feb CTEC
@ SUN PHARM INDS LTD 325MG;10MG A040826 001 Aug 16, 2007 Apr CAHN
NORCO

AA ACTAVIS LABS FL INC 325MG;2.5MG A040148 004 Jul 07, 2014 Feb NEWA
AA 325MG;5MG A040148 005 Jul 07, 2014 Feb NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL
DIAMOX

AB + TEVA BRANDED PHARM 500MG N012945 001 Jun CAHN

ACETOHEXAMIDE

TABLET;ORAL
ACETOHEXAMIDE

@ ANI PHARMS INC 250MG A070869 001 Feb 09, 1987 Jul CAHN
@ 500MG A070870 001 Feb 09, 1987 Jul CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS
ACETYLCYSTEINE

AP AKORN INC 6GM/30ML (200MG/ML) A203173 001 Mar 24, 2015 Mar NEWA
AP MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML) A203624 001 Jun 19, 2015 Jun NEWA

SOLUTION;INHALATION, ORAL
ACETYLCYSTEINE

>A> AN ALVOGEN INC 10% A204674 001 Feb 11, 2014 Sep CAHN
>A> AN 20% A203853 001 Jun 21, 2012 Sep CAHN
>D> AN INNOPHARMA LICENSING 10% A204674 001 Feb 11, 2014 Sep CAHN
>D> AN 20% A203853 001 Jun 21, 2012 Sep CAHN

ACITRETIN

CAPSULE;ORAL
ACITRETIN

AB MYLAN PHARMS INC 10MG A202148 001 Sep 10, 2015 Aug NEWA
AB 17.5MG A203707 001 Sep 10, 2015 Aug NEWA
AB 22.5MG A203707 002 Sep 10, 2015 Aug NEWA
AB 25MG A202148 002 Sep 10, 2015 Aug NEWA
AB SIGMAPHARM LABS LLC 10MG A204633 001 May 22, 2015 May NEWA
AB 17.5MG A204633 002 May 22, 2015 May NEWA
AB 22.5MG A204633 003 May 22, 2015 May NEWA
AB 25MG A204633 004 May 22, 2015 May NEWA

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION
TUDORZA PRESSAIR

+ ASTRAZENECA PHARMS 0.375MG/INH N202450 001 Jul 23, 2012 Apr CAHN
+ 0.4MG/INH N202450 001 Jul 23, 2012 Aug CPOT

ACYCLOVIRTABLET; ORAL
ACYCLOVIR

AB	SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Apr CAHN
AB		800MG	A074980	002	Sep 30, 1998	Apr CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

>A>	ADAPALENE AND BENZOYL PEROXIDE					
>A> AB	ACTAVIS MID ATLANTIC	0.1%;2.5%	A203790	001	Sep 30, 2015	Sep NEWA
	EPIDUO					
>D>	+ GALDERMA LABS LP	0.1%;2.5%	N022320	001	Dec 08, 2008	Sep CFTG
>A> AB	+ GALDERMA LABS	0.1%;2.5%	N022320	001	Dec 08, 2008	Sep CFTG
	EPIDUO FORTE					
	+ GALDERMA LABS	0.3%;2.5%	N207917	001	Jul 15, 2015	Aug CAHN
	+ GALDERMA R AND D	0.3%;2.5%	N207917	001	Jul 15, 2015	Jul NEWA

ADENOSINEINJECTABLE; INJECTION
ADENOSINE

AP	EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun CAHN
>A>	@	3MG/ML	A076501	001	Jun 16, 2004	Sep CAHN
>D>	@ HIKMA MAPLE	3MG/ML	A076501	001	Jun 16, 2004	Sep CAHN
	@ WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May DISC

ALBENDAZOLETABLET, CHEWABLE; ORAL
ALBENZA

+	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015	Jun NEWA
---	-------------------	-------	---------	-----	--------------	----------

ALBUTEROL SULFATEPOWDER, METERED; INHALATION
PROAIR RESPICLICK

+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015	Mar NEWA
---	--------------------	---------------------	---------	-----	--------------	----------

SYRUP; ORAL

ALBUTEROL SULFATE

AA	G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Apr CAHN
----	------------------	-----------------	---------	-----	--------------	----------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDEAEROSOL, METERED; INHALATION
COMBIVENT

@	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May DISC
---	----------------------	--------------------------------	---------	-----	--------------	----------

ALFUZOSIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

@	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Feb DISC
---	---------------	------	---------	-----	--------------	----------

UROXATRAL

AB	+ CONCORDIA PHARMS INC	10MG	N021287	001	Jun 12, 2003	Jun CAHN
----	------------------------	------	---------	-----	--------------	----------

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATETABLET; ORAL
TEKAMLO

@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010	May DISC
@		EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010	May DISC
@		EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010	May DISC
@		EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010	May DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDETABLET; ORAL
AMTURNIDE

@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010	May DISC
@		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010	May DISC
@		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010	May DISC
@		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010	May DISC
@		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010	May DISC

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	TEVA PHARMS USA	EQ 6.25MG BASE	A078027	001	Jul 07, 2015	Jun NEWA
AB		EQ 12.5MG BASE	A078027	002	Jul 07, 2015	Jun NEWA
	AXERT					
AB	JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Jun CFTG
AB	+	EQ 12.5MG BASE	N021001	002	May 07, 2001	Jun CFTG

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	ROXANE	EQ 0.5MG BASE	A200652	001	May 04, 2015	Apr NEWA
AB		EQ 1MG BASE	A200652	002	May 04, 2015	Apr NEWA
	LOTRONEX					
AB	PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr CFTG
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr CFTG

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

	@ ANI PHARMS INC	0.25MG	A074085	001	Feb 16, 1994	Jul CAHN
		0.5MG	A074085	002	Feb 16, 1994	Jul CAHN
		1MG	A074085	003	Feb 16, 1994	Jul CAHN
		2MG	A074085	004	Feb 26, 1996	Jul CAHN
AB	AUROBINDO PHARMA LTD	0.25MG	A203346	001	Jul 31, 2015	Jul NEWA
AB		0.5MG	A203346	002	Jul 31, 2015	Jul NEWA
AB		1MG	A203346	003	Jul 31, 2015	Jul NEWA
AB		2MG	A203346	004	Jul 31, 2015	Jul NEWA
AB	NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar NEWA
AB		0.5MG	A200739	002	Apr 15, 2015	Mar NEWA
AB		1MG	A200739	003	Apr 15, 2015	Mar NEWA
AB		2MG	A200739	004	Apr 15, 2015	Mar NEWA

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

>A>	AB	HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008	Sep CAHN
>A>	AB		1MG	A078489	002	Oct 17, 2008	Sep CAHN
>A>	AB		2MG	A078489	003	Oct 17, 2008	Sep CAHN
>A>	AB		3MG	A078489	004	Oct 17, 2008	Sep CAHN
>D>	AB	ZYDUS PHARMS USA INC	0.5MG	A078489	001	Oct 17, 2008	Sep CAHN
>D>	AB		1MG	A078489	002	Oct 17, 2008	Sep CAHN
>D>	AB		2MG	A078489	003	Oct 17, 2008	Sep CAHN
>D>	AB		3MG	A078489	004	Oct 17, 2008	Sep CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan CAHN
----	----------------------	-------	---------	-----	--------------	----------

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

	@ G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May CAHN
--	--------------------	----------	---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

	@ IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar CAHN
	@	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar CAHN

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	5MG	A204180	001	Aug 07, 2015	Jul NEWA
----	----------------------	-----	---------	-----	--------------	----------

AMINO ACIDS

INJECTABLE; INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

	@ BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984	Feb DISC
--	-------------------	----------------	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	3.5%; 51MG/100ML; 131MG/100ML; 218MG/100ML; 35MG/100ML	N020177	001	Oct 23, 1995	Feb	DISC
-------------------	--	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SYRUP; ORAL

AMINOCAPROIC ACID

AA	VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May	CAHN
----	----------------	------------	---------	-----	--------------	-----	------

TABLET; ORAL

AMINOCAPROIC

AB	VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

@ ANI PHARMS INC	10MG	A084910	003			Aug	CAHN
@	25MG	A085031	001			Aug	CAHN
@	50MG	A085032	001			Aug	CAHN
@	75MG	A085030	001			Aug	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

LIMBITROL

@ HERITAGE PHARMS INC	EQ 12.5MG BASE; 5MG	N016949	001			Jul	CAHN
-----------------------	---------------------	---------	-----	--	--	-----	------

LIMBITROL DS

@ HERITAGE PHARMS INC	EQ 25MG BASE; 10MG	N016949	002			Jul	CAHN
-----------------------	--------------------	---------	-----	--	--	-----	------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar	CAHN
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar	CAHN
>D> AB	MATRIX LABS LTD	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	Sep	CAHN
>D> AB		EQ 5MG BASE	A078224	002	Feb 27, 2008	Sep	CAHN
>D> AB		EQ 10MG BASE	A078224	003	Feb 27, 2008	Sep	CAHN
>A> AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	Sep	CAHN
>A> AB		EQ 5MG BASE	A078224	002	Feb 27, 2008	Sep	CAHN
>A> AB		EQ 10MG BASE	A078224	003	Feb 27, 2008	Sep	CAHN
AB	SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015	Jul	NEWA
AB		EQ 5MG BASE	A204900	002	Jul 23, 2015	Jul	NEWA
AB		EQ 10MG BASE	A204900	003	Jul 23, 2015	Jul	NEWA
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Apr	CAHN
AB		EQ 5MG BASE	A077974	002	Jul 09, 2007	Apr	CAHN
AB		EQ 10MG BASE	A077974	003	Jul 09, 2007	Apr	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	LUPIN LTD	5MG; 12.5MG; 160MG	A200797	001	Jun 03, 2015	May	NEWA
AB		5MG; 25MG; 160MG	A200797	002	Jun 03, 2015	May	NEWA
AB		10MG; 12.5MG; 160MG	A200797	003	Jun 03, 2015	May	NEWA
AB		10MG; 25MG; 160MG	A200797	004	Jun 03, 2015	May	NEWA
AB		10MG; 25MG; 320MG	A200797	005	Jun 03, 2015	May	NEWA
AB	PAR PHARM	5MG; 12.5MG; 160MG	A201087	001	Jun 01, 2015	May	NEWA
AB		5MG; 25MG; 160MG	A201087	002	Jun 01, 2015	May	NEWA
AB		10MG; 12.5MG; 160MG	A201087	003	Jun 01, 2015	May	NEWA
AB		10MG; 25MG; 160MG	A201087	004	Jun 01, 2015	May	NEWA
AB		10MG; 25MG; 320MG	A201087	005	Jun 01, 2015	May	NEWA
AB	TEVA PHARMS	5MG; 12.5MG; 160MG	A200435	001	Sep 25, 2012	May	CAIN
AB		5MG; 25MG; 160MG	A200435	002	Sep 25, 2012	May	CAIN
AB		10MG; 12.5MG; 160MG	A200435	005	Sep 25, 2012	May	CAIN
AB		10MG; 25MG; 160MG	A200435	003	Sep 25, 2012	May	CAIN
AB		10MG; 25MG; 320MG	A200435	004	Sep 25, 2012	May	CAIN
>D> AB	TORRENT PHARMS LTD	5MG; 12.5MG; 160MG	A201593	001	Jun 04, 2015	Sep	CMS1
>A> AB		5MG; 12.5MG; 160MG	A201593	001	Jun 03, 2015	Sep	CMS1
AB		5MG; 12.5MG; 160MG	A201593	001	Jun 04, 2015	May	NEWA
>D> AB		5MG; 25MG; 160MG	A201593	002	Jun 04, 2015	Sep	CMS1
>A> AB		5MG; 25MG; 160MG	A201593	002	Jun 03, 2015	Sep	CMS1
AB		5MG; 25MG; 160MG	A201593	002	Jun 04, 2015	May	NEWA
>D> AB		10MG; 12.5MG; 160MG	A201593	003	Jun 04, 2015	Sep	CMS1

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	10MG;12.5MG;160MG	A201593	003	Jun 03, 2015	Sep CMS1
	AB	10MG;12.5MG;160MG	A201593	003	Jun 04, 2015	May NEWA
>D>	AB	10MG;25MG;160MG	A201593	004	Jun 04, 2015	Sep CMS1
>A>	AB	10MG;25MG;160MG	A201593	004	Jun 03, 2015	Sep CMS1
	AB	10MG;25MG;160MG	A201593	004	Jun 04, 2015	May NEWA
>D>	AB	10MG;25MG;320MG	A201593	005	Jun 04, 2015	Sep CMS1
>A>	AB	10MG;25MG;320MG	A201593	005	Jun 03, 2015	Sep CMS1
	AB	10MG;25MG;320MG	A201593	005	Jun 04, 2015	May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan NEWA
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan NEWA
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar NEWA
AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr NEWA
	CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan NEWA
	PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015	Aug NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr CAHN

FOR SUSPENSION;ORAL

AMOXICILLIN

	@ SUN PHARM INDS LTD	200MG/5ML	A065113	001	Nov 29, 2002	Apr CAHN
	@	400MG/5ML	A065113	002	Nov 29, 2002	Apr CAHN

TABLET;ORAL							
AMOXICILLIN							
AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr	CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr	CAHN
TABLET, CHEWABLE;ORAL							
AMOXICILLIN							
AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr	CAHN
	@	200MG	A065060	001	Nov 29, 2000	Apr	CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr	CAHN
	@	400MG	A065060	002	Nov 29, 2000	Apr	CAHN
<u>AMOXICILLIN; CLAVULANATE POTASSIUM</u>							
FOR SUSPENSION;ORAL							
AMOXICILLIN AND CLAVULANATE POTASSIUM							
AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr	CAHN
TABLET;ORAL							
AMOXICILLIN AND CLAVULANATE POTASSIUM							
	@ SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr	CAHN
AB		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr	CAHN
TABLET, CHEWABLE;ORAL							
AMOXICILLIN AND CLAVULANATE POTASSIUM							
AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr	CAHN
AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr	CAHN
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE</u>							
TABLET;ORAL							
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May	NEWA
<u>AMPHETAMINE SULFATE</u>							
TABLET;ORAL							
EVEKEO							
	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar	CTNA
	+	10MG	A200166	002	Aug 09, 2012	Mar	CTNA
<u>AMPICILLIN SODIUM</u>							
INJECTABLE;INJECTION							
AMPICILLIN SODIUM							
AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015	Aug	NEWA
AP		EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015	Aug	NEWA
AP		EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015	Aug	NEWA
AP		EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015	Aug	NEWA
AP		EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015	Aug	NEWA
<u>AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID</u>							
FOR SUSPENSION;ORAL							
PROBAMPACIN							
	@ G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr	CAHN
<u>ANASTROZOLE</u>							
TABLET;ORAL							
ANASTROZOLE							
	@ KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar	CAHN
<u>ARGATROBAN</u>							
INJECTABLE;INJECTION							
ARGATROBAN							
AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr	CDFR
AP	+ PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Aug	CTNA
INJECTABLE;IV (INFUSION)							
ARGATROBAN							
AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar	NEWA

ARIPIPIRAZOLE

SOLUTION;ORAL

ARIPIPIRAZOLE

AA	AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Aug NEWA
>A> AA	APOTEX INC	1MG/ML	A204094	001	Sep 30, 2015	Sep NEWA
AA	SILARX PHARMS INC	1MG/ML	A204171	001	Aug 14, 2015	Aug NEWA

TABLET;ORAL

ABILIFY

AB	OTSUKA	2MG	N021436	006	Nov 15, 2002	Apr CFTG
AB	+	5MG	N021436	005	Nov 15, 2002	Apr CFTG
AB	+	10MG	N021436	001	Nov 15, 2002	Apr CFTG
AB		15MG	N021436	002	Nov 15, 2002	Apr CFTG
AB		20MG	N021436	003	Nov 15, 2002	Apr CFTG
AB		30MG	N021436	004	Nov 15, 2002	Apr CFTG

ARIPIPIRAZOLE

AB	ALEMBIC PHARMS LTD	2MG	A202101	001	Apr 28, 2015	Apr NEWA
AB		5MG	A202101	002	Apr 28, 2015	Apr NEWA
AB		10MG	A202101	003	Apr 28, 2015	Apr NEWA
AB		15MG	A202101	004	Apr 28, 2015	Apr NEWA
AB		20MG	A202101	005	Apr 28, 2015	Apr NEWA
AB		30MG	A202101	006	Apr 28, 2015	Apr NEWA
AB	APOTEX INC	2MG	A078583	001	Jul 24, 2015	Jul NEWA
AB		5MG	A078583	002	Jul 24, 2015	Jul NEWA
AB		10MG	A078583	003	Jul 24, 2015	Jul NEWA
AB		15MG	A078583	004	Jul 24, 2015	Jul NEWA
AB		20MG	A078583	005	Jul 24, 2015	Jul NEWA
AB		30MG	A078583	006	Jul 24, 2015	Jul NEWA
>A> AB	AUROBINDO PHARMA LTD	2MG	A203908	001	Oct 08, 2015	Sep NEWA
>A> AB		5MG	A203908	002	Oct 08, 2015	Sep NEWA
>A> AB		10MG	A203908	003	Oct 08, 2015	Sep NEWA
>A> AB		15MG	A203908	004	Oct 08, 2015	Sep NEWA
>A> AB		20MG	A203908	005	Oct 08, 2015	Sep NEWA
>A> AB		30MG	A203908	006	Oct 08, 2015	Sep NEWA
AB	HETERO LABS LTD V	2MG	A205064	001	Apr 28, 2015	Apr NEWA
AB		5MG	A205064	002	Apr 28, 2015	Apr NEWA
AB		10MG	A205064	003	Apr 28, 2015	Apr NEWA
AB		15MG	A205064	004	Apr 28, 2015	Apr NEWA
AB		20MG	A205064	005	Apr 28, 2015	Apr NEWA
AB		30MG	A205064	006	Apr 28, 2015	Apr NEWA
AB	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Apr NEWA
AB		5MG	A078607	002	Apr 28, 2015	Apr NEWA
AB		10MG	A078608	001	Apr 28, 2015	Apr NEWA
AB		15MG	A078708	001	Apr 28, 2015	Apr NEWA
AB		20MG	A078708	002	Apr 28, 2015	Apr NEWA
AB		30MG	A078708	003	Apr 28, 2015	Apr NEWA
AB	TORRENT PHARMS LTD	2MG	A201519	001	Apr 28, 2015	Apr NEWA
AB		10MG	A201519	003	Apr 28, 2015	Apr NEWA
AB		5MG	A201519	002	Apr 28, 2015	Apr NEWA
AB		15MG	A201519	004	Apr 28, 2015	Apr NEWA
AB		20MG	A201519	005	Apr 28, 2015	Apr NEWA
AB		30MG	A201519	006	Apr 28, 2015	Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

AB	+	OTSUKA	10MG	N021729	002	Jun 07, 2006	Apr CFTG
AB			15MG	N021729	003	Jun 07, 2006	Apr CFTG

ARIPIPIRAZOLE

AB	ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Apr NEWA
AB		15MG	A202102	002	Apr 28, 2015	Apr NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

@ IGI LABS INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jun CAHN
----------------	--	---------	-----	--------------	----------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID
 @ NOVEL LABS INC 4.7GM;100GM;1.015GM;5.9GM;2.691GM; A090145 001 Jan 25, 2012 Aug CTNA
 7.5GM

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

FOREST LABS LLC EQ 5MG BASE N022117 001 Aug 13, 2009 Jun CAHN
 + EQ 10MG BASE N022117 002 Aug 13, 2009 Jun CAHN

>A> ASPIRIN

>A> CAPSULE, EXTENDED RELEASE;ORAL

>A> DURLAZA

>A> + NEW HAVEN PHARMS 162.5MG N200671 001 Sep 04, 2015 Sep NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

FIORINAL

AA + ACTAVIS LABS UT INC 325MG;50MG;40MG N017534 005 Apr 16, 1986 Jan CAHN

TABLET;ORAL

FIORINAL

@ ACTAVIS LABS UT INC 325MG;50MG;40MG N017534 003 Apr 16, 1986 Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORINAL W/CODEINE

AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N019429 003 Oct 26, 1990 Jan CAHN

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

SYNALGOS-DC

+ SUN PHARM INDS 356.4MG;30MG;16MG N011483 004 Sep 06, 1983 Aug CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

NORGESIC

@ MEDICIS 385MG;30MG;25MG N013416 003 Oct 27, 1982 Mar DISC

NORGESIC FORTE

@ MEDICIS 770MG;60MG;50MG N013416 004 Oct 27, 1982 Mar DISC

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ 385MG;30MG;25MG A074654 001 Dec 31, 1996 Mar CTEC

+ 770MG;60MG;50MG A074654 002 Dec 31, 1996 Mar CTEC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA ACTAVIS LABS FL INC 325MG;4.8355MG A090084 001 Mar 22, 2011 Mar CAHN

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

+ BRISTOL MYERS SQUIBB EQ 300MG BASE;150MG N206353 001 Jan 29, 2015 Jan NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB ALVOGEN IPCO SARL 25MG A073646 001 Jul 31, 1992 Jul CAHN

AB 50MG A072303 001 Jul 15, 1988 Jul CAHN

AB 100MG A072304 001 Jul 15, 1988 Jul CAHN

@ DAVA PHARMS INC 25MG A074099 001 Apr 28, 1992 Jun DISC

TENORMIN

AB ALVOGEN IPCO SARL 25MG N018240 004 Apr 09, 1990 Feb CAHN

AB 50MG N018240 001 Feb CAHN

AB + 100MG N018240 002 Feb CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN IPCO SARL	50MG;25MG	A072301	001	May 31, 1990	Jul CAHN
AB		100MG;25MG	A072302	001	May 31, 1990	Jul CAHN
TENORETIC 100						
AB	+ ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb CAHN
TENORETIC 50						
AB	ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb CAHN

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar CAHN
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar CAHN
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar CAHN
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

@	MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May DISC
@		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May DISC
@		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May DISC
@		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar NEWA
----	-------------------	-------------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar NEWA
ATRACURIUM BESYLATE PRESERVATIVE FREE						
AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar NEWA

ATROPINE SULFATE

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

+	AKORN	1%	N206289	001	Jul 18, 2014	May CRLD
---	-------	----	---------	-----	--------------	----------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb CAHN
MOTOFEN HALF-STRENGTH						
@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@	ANI PHARMS INC	0.025MG;2.5MG	A086727	001		Jul CAHN
---	----------------	---------------	---------	-----	--	----------

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+	CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Feb NEWA
---	------------	------------------------	---------	-----	--------------	----------

AZELAIC ACID

AEROSOL, FOAM; TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N207071	001	Jul 29, 2015	Jul NEWA
---	----------------	-----	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL
AZELASTINE HYDROCHLORIDE

AB	BRECKENRIDGE PHARMS	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Jul	NEWA
----	---------------------	-----------------------	---------	-----	--------------	-----	------

AZITHROMYCIN

FOR SUSPENSION;ORAL
AZITHROMYCIN

AB	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	May	NEWA
AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	May	NEWA

INJECTABLE;INJECTION
AZITHROMYCIN

AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A203294	001	Jun 19, 2015	Jun	NEWA
----	----------------------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL
AZITHROMYCIN

AB	LUPIN LTD	EQ 250MG BASE	A065398	001	May 15, 2015	May	NEWA
AB		EQ 500MG BASE	A065399	001	May 15, 2015	May	NEWA
AB		EQ 600MG BASE	A065400	001	May 15, 2015	May	NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL
COLAZAL

AB	+ VALEANT PHARMS INTL	750MG	N020610	001	Jul 18, 2000	Jul	CAHN
----	-----------------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

BALSALAZIDE DISODIUM

AB	PAR PHARM INC	1.1GM	A206336	001	Sep 08, 2015	Aug	NEWA
----	---------------	-------	---------	-----	--------------	-----	------

GIAZO

AB	+ VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Aug	CFTG
	+	1.1GM	N022205	001	Feb 03, 2012	Jul	CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan	CAHN
AB		10MG	A076820	002	Feb 03, 2006	Jan	CAHN
AB		20MG	A076820	003	Feb 03, 2006	Jan	CAHN
AB		40MG	A076820	004	Feb 03, 2006	Jan	CAHN
AB	SUN PHARM INDS LTD	5MG	A076344	001	Feb 11, 2004	Apr	CAHN
AB		10MG	A076344	002	Feb 11, 2004	Apr	CAHN
AB		20MG	A076344	003	Feb 11, 2004	Apr	CAHN
AB		40MG	A076344	004	Feb 11, 2004	Apr	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Apr	CAHN
AB		10MG;12.5MG	A077483	002	Sep 08, 2005	Apr	CAHN
AB		20MG;12.5MG	A077483	003	Sep 08, 2005	Apr	CAHN
AB		20MG;25MG	A077483	004	Sep 08, 2005	Apr	CAHN

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA	APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan	NEWA
AA		200MG	A091310	002	Jan 16, 2015	Jan	NEWA
AA	BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan	CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan	CAHN
AA	CSPC NBP PHARM CO	200MG	A202765	001	Jul 31, 2015	Jul	NEWA
AA	STRIDES ARCOLAB LTD	100MG	A091133	001	Jul 30, 2015	Jul	NEWA
AA		200MG	A091133	002	Jul 30, 2015	Jul	NEWA
AA	STRIDES PHARMA	100MG	A091133	001	Jul 30, 2015	Aug	CAHN
AA		200MG	A091133	002	Jul 30, 2015	Aug	CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ACANYA

AB	+ DOW PHARM	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun	CFTG
----	-------------	-------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jun	NEWA
>A> AB	PERRIGO ISRAEL	5%;EQ 1% BASE	A202440	001	Sep 21, 2015	Sep	NEWA

GEL;TOPICAL
ONEXTON

+ DOW PHARM 3.75%;EQ 1.2% BASE N050819 002 Nov 24, 2014 Jan CRLD

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

ERYTHROMYCIN AND BENZOYL PEROXIDE

>A> AB LYNE 5%;3% A065385 001 Sep 18, 2015 Sep NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

AA + KVK TECH 50MG A090968 001 Jul 20, 2010 Jun CRLD

DIDREX

@ PHARMACIA AND UPJOHN 50MG N012427 002 Jun DISC

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA NUVO PHARM INC 0.5MG A204713 001 Apr 14, 2015 Mar NEWA

AA 1MG A204713 002 Apr 14, 2015 Mar NEWA

AA 2MG A204713 003 Apr 14, 2015 Mar NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB G AND W LABS INC EQ 0.05% BASE A071467 001 Aug 10, 1987 Apr CAHN

@ EQ 0.05% BASE A071882 001 Jun 06, 1988 Apr CAHN

BETAMETHASONE VALERATE

CREAM;TOPICAL

BETA-VAL

AB G AND W LABS INC EQ 0.1% BASE N018642 001 Mar 24, 1983 Aug CAHN

LOTION;TOPICAL

BETA-VAL

AB G AND W LABS INC EQ 0.1% BASE A070072 001 Jun 27, 1985 Apr CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA HERITAGE PHARMA 5MG A091256 001 May 04, 2010 Mar CAHN

AA 10MG A091256 002 May 04, 2010 Mar CAHN

AA 25MG A091256 003 May 04, 2010 Mar CAHN

AA 50MG A091256 004 May 04, 2010 Mar CAHN

AA LANNETT HOLDINGS INC 5MG A040703 001 Mar 27, 2008 Feb CMFD

AA 50MG A040677 001 Mar 27, 2008 Feb CMFD

DUVOID

AA WELLSRING PHARM 10MG A086262 001 Jan CMFD

AA 25MG A086263 001 May CMFD

AA 50MG A085882 003 May CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB BANNER LIFE SCIENCES 75MG A203174 001 Aug 12, 2014 Jun CMFD

@ 75MG A203174 001 Aug 12, 2014 Jan CAHN

TARGRETIN

AB + VALEANT LUXEMBOURG 75MG N021055 001 Dec 29, 1999 Jun CTEC

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB APOTEX INC 50MG A200274 001 May 21, 2015 May NEWA

AB STASON PHARMS 50MG A091011 001 Jun 10, 2015 May NEWA

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT ALCON RES LTD 0.03% A202565 001 May 05, 2015 Apr NEWA

AT APOTEX INC 0.03% A090449 001 Jul 20, 2015 Jul NEWA

AT + LUPIN LTD 0.03% A203991 001 Feb 20, 2015 Apr CTEC

+ 0.03% A203991 001 Feb 20, 2015 Mar CTEC

		SOLUTION/DROPS;OPHTHALMIC							
		BIMATOPROST							
AT	+	0.03%		A203991	001	Feb 20, 2015	Feb	NEWA	
<u>BIPERIDEN HYDROCHLORIDE</u>									
		TABLET;ORAL							
		AKINETON							
		@ ABBVIE		2MG	N012003	001		Aug	DISC
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE</u>									
		CAPSULE;ORAL							
		PYLERA							
		+ FOREST LABS LLC		140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jul	CAHN
<u>BIVALIRUDIN</u>									
		INJECTABLE;INTRAVENOUS							
		BIVALIRUDIN							
AP		HOSPIRA INC	250MG/VIAL	A090811	001	Jul 14, 2015	Jun	NEWA	
AP			250MG/VIAL	A090816	001	Jul 14, 2015	Jun	NEWA	
<u>BOSUTINIB MONOHYDRATE</u>									
		TABLET;ORAL							
		BOSULIF							
		+ WYETH PHARMS INC		EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun	CRLD
				EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun	CRLD
<u>BREXPIPIRAZOLE</u>									
		TABLET;ORAL							
		REXULTI							
		OTSUKA PHARM CO LTD		0.25MG	N205422	001	Jul 10, 2015	Jul	NEWA
				0.5MG	N205422	002	Jul 10, 2015	Jul	NEWA
				1MG	N205422	003	Jul 10, 2015	Jul	NEWA
				2MG	N205422	004	Jul 10, 2015	Jul	NEWA
				3MG	N205422	005	Jul 10, 2015	Jul	NEWA
		+		4MG	N205422	006	Jul 10, 2015	Jul	NEWA
<u>BROMFENAC SODIUM</u>									
		SOLUTION/DROPS;OPHTHALMIC							
>D>		BROMDAY							
>D>	AT2	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Sep	DISC
>A>			@	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Sep	DISC
	AT2	+		EQ 0.09% ACID	N021664	002	Oct 16, 2010	May	CTEC
		BROMFENAC SODIUM							
	AT2		APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May	CTEC
	AT1	+	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May	CRLD
	AT2		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May	CTEC
	AT1		PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan	NEWA
<u>BUDESONIDE</u>									
		AEROSOL, FOAM;RECTAL							
		UCERIS							
		+ VALEANT PHARMS INTL		2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr	CAHN
		SPRAY, METERED;NASAL							
		BUDESONIDE							
		APOTEX INC		0.032MG/INH	A078949	001	May 12, 2014	Mar	CTEC
		TABLET, EXTENDED RELEASE;ORAL							
		UCERIS							
		+ VALEANT PHARMS INTL		9MG	N203634	001	Jan 14, 2013	Aug	CAHN
<u>BUMETANIDE</u>									
		INJECTABLE;INJECTION							
		BUMETANIDE							
AP		EUROHLTH INTL SARL	0.25MG/ML	A079196	001	Apr 30, 2008	Jun	CAHN	
<u>BUPRENORPHINE HYDROCHLORIDE</u>									
		INJECTABLE;INJECTION							
		BUPRENORPHINE HYDROCHLORIDE							
AP		PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul	NEWA	
		TABLET;SUBLINGUAL							
		BUPRENORPHINE HYDROCHLORIDE							
AB		ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb	NEWA	

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb NEWA
AB	MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb NEWA
AB		EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb NEWA
AB	SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May NEWA
AB		EQ 8MG BASE	A090279	002	Jun 10, 2015	May NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

>A> FILM;BUCCAL, SUBLINGUAL

>A> SUBOXONE

>A>	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	Sep CDFR
>A>		EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	Sep CDFR
>A>		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Sep CDFR
>A>	+	EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Sep CDFR

>D> FILM;SUBLINGUAL

>D> SUBOXONE

>D>	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	Sep CDFR
>D>		EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	Sep CDFR
>D>		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Sep CDFR
>D>	+	EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Sep CDFR

TABLET;SUBLINGUAL

ZUBSOLV

	OREXO AB	EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jun NEWA
--	----------	------------------------------	---------	-----	--------------	----------

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb CAHN
		348MG	N022108	002	Apr 23, 2008	Feb CAHN
	+	522MG	N022108	003	Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	PRINSTON INC	100MG	A202304	001	May 26, 2015	May NEWA
AB1		150MG	A202304	002	May 26, 2015	May NEWA
AB1		200MG	A202304	003	May 26, 2015	May NEWA
AB2	SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar CAHN
	@ WOCHHARDT LTD	100MG	A201331	001	Aug 30, 2012	May DISC
	@	150MG	A201331	002	Aug 30, 2012	May DISC
	@	200MG	A201331	003	Aug 30, 2012	May DISC

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

>A> AB	EMCURE PHARMS USA	5MG	A204582	001	Sep 18, 2015	Sep NEWA
>A> AB		10MG	A204582	002	Sep 18, 2015	Sep NEWA
>A> AB		15MG	A204582	003	Sep 18, 2015	Sep NEWA
>A> AB		30MG	A204582	004	Sep 18, 2015	Sep NEWA

BUTABARBITAL SODIUM

ELIXIR;ORAL

BUTISOL SODIUM

@	MEDA PHARMS	30MG/5ML	A085380	001		Jul DISC
---	-------------	----------	---------	-----	--	----------

TABLET;ORAL

BUTISOL SODIUM

@	MEDA PHARMS	50MG	N000793	003		May DISC
---	-------------	------	---------	-----	--	----------

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

@	ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May CTNA
	GYNAZOLE-1					
+	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Jun CTNA

CAFFEINE CITRATESOLUTION;INTRAVENOUS
CAFFEINE CITRATE

>A>	AP	AUROBINDO PHARMA LTD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A205013	001	Sep 22, 2015	Sep NEWA
-----	----	----------------------	------------------------------------	---------	-----	--------------	----------

CALCIPOTRIENECREAM;TOPICAL
CALCIPOTRIENE

AB		GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015	May NEWA
----	--	---------------------	--------	---------	-----	--------------	----------

CALCITONIN SALMONINJECTABLE;INJECTION
CALCITONIN-SALMON

		@ IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar CAHN
--	--	----------------	-----------	---------	-----	--------------	----------

MIACALCIN

		@ MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug CAHN
--	--	---------------------	-----------	---------	-----	--------------	----------

+ 200 IU/ML

SPRAY, METERED;NASAL
MIACALCIN

AB	+	MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Aug CAHN
----	---	-------------------	--------------	---------	-----	--------------	----------

CALCITRIOLCAPSULE;ORAL
CALCITRIOL

AB		BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
----	--	----------------------	---------	---------	-----	--------------	----------

AB			0.5MCG	A091174	002	May 24, 2013	Jan CAHN
----	--	--	--------	---------	-----	--------------	----------

AB		STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan CAHN
----	--	----------------	---------	---------	-----	--------------	----------

AB			0.5MCG	A091356	002	Dec 12, 2014	Jan CAHN
----	--	--	--------	---------	-----	--------------	----------

INJECTABLE;INJECTION

CALCIJEX

		@ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	Jun DISC
--	--	----------	------------	---------	-----	--------------	----------

		@	0.002MG/ML	N018874	002	Sep 25, 1986	Jun DISC
--	--	---	------------	---------	-----	--------------	----------

CALCITRIOL

		@ AKORN	0.002MG/ML	A078066	002	Jan 29, 2008	Jun DISC
--	--	---------	------------	---------	-----	--------------	----------

		@ FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002	Jun DISC
--	--	----------------------	------------	---------	-----	--------------	----------

		@	0.002MG/ML	A075836	002	Dec 31, 2002	Jun DISC
--	--	---	------------	---------	-----	--------------	----------

		@ FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003	Jun DISC
--	--	-------------------	------------	---------	-----	--------------	----------

		@	0.002MG/ML	A075766	002	Feb 20, 2003	Jun DISC
--	--	---	------------	---------	-----	--------------	----------

		@ LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003	Jun DISC
--	--	------------	------------	---------	-----	--------------	----------

		@	0.002MG/ML	A075746	002	Sep 26, 2003	Jun DISC
--	--	---	------------	---------	-----	--------------	----------

		@ SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006	Jun DISC
--	--	-----------------	------------	---------	-----	--------------	----------

CALCIUM ACETATECAPSULE;ORAL
CALCIUM ACETATE

>A>	AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Sep CAHN
-----	----	---------------------	------------------	---------	-----	--------------	----------

AB		LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015	Jun NEWA
----	--	-----------	------------------	---------	-----	--------------	----------

>D>	AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Sep CAHN
-----	----	----------------------	------------------	---------	-----	--------------	----------

AB			EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Jun NEWA
----	--	--	------------------	---------	-----	--------------	----------

TABLET;ORAL

CALCIUM ACETATE

>A>	AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Sep CAHN
-----	----	---------------------	------------------	---------	-----	--------------	----------

>D>	AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Sep CAHN
-----	----	----------------------	------------------	---------	-----	--------------	----------

AB			EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan NEWA
----	--	--	------------------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+		GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan CPOT
---	--	--------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@		GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan CPOT
---	--	--------------------	--	---------	-----	--------------	----------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+		GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07	N021703	011	Oct 10, 2008	Jan CPOT
---	--	--------------------	---	---------	-----	--------------	----------

INJECTABLE; INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER									
GM/1000ML (5000ML)									
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER									
+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan	CPOT		
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER									
+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan	CPOT		
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER									
+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan	CPOT		
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER									
+	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan	CPOT		
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER									
@	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan	CPOT		
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER									
+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan	CPOT		
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER									
+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan	CPOT		
PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER									
@	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan	CPOT		
PRISMASOL BK 0/0 IN PLASTIC CONTAINER									
@	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan	CPOT		
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER									
+	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan	CPOT		
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER									
+	GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan	CPOT		
PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER									
@	GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan	CPOT		

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER								
+	GAMBRO LUNDIA	N/A/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan	NEWA	
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER								
+	GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan	NEWA	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

NAVSTEL

@ ALCON PHARMS LTD	0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N022193	001	Jul 24, 2008	Jun DISC
--------------------	--	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390	001		Mar DISC
-------------------	--	---------	-----	--	----------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML; 640MG/100ML; 496MG/100ML; 89.6MG/100ML	N017438	001		Mar DISC
-------------------	--	---------	-----	--	----------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+ GAMBRO LUNDIA	N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Feb CAIN
-----------------	--	---------	-----	--------------	----------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO LUNDIA	3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187	N207026	001	Jan 13, 2015	Feb CAIN
-----------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

>D> AT	+ BAXTER HLTHCARE	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019933	001	Aug 29, 1989	Sep DISC
--------	-------------------	--	---------	-----	--------------	----------

>A>	@	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019933	001	Aug 29, 1989	Sep DISC
-----	---	--	---------	-----	--------------	----------

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	16MG; 12.5MG	A204100	001	Feb 27, 2015	Feb NEWA
AB		32MG; 12.5MG	A204100	002	Feb 27, 2015	Feb NEWA
AB		32MG; 25MG	A204100	003	Feb 27, 2015	Feb NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr NEWA
AB		500MG	A202593	002	Apr 23, 2015	Apr NEWA

CAPTOPRIL

TABLET; ORAL

CAPOTEN

@ PAR PHARM	12.5MG	N018343	005	Jan 17, 1985	May DISC
@	25MG	N018343	002		May DISC
@	50MG	N018343	001		May DISC
@	100MG	N018343	003		May DISC

CAPTOPRIL

@ G AND W LABS INC	12.5MG	A074433	001	Feb 13, 1996	Jul CAHN
@	12.5MG	A074462	001	Feb 13, 1996	Apr CAHN
@	12.5MG	A074483	001	Feb 13, 1996	Jul CAHN
@	12.5MG	A074590	004	Aug 30, 1996	Apr CAHN
@	25MG	A074433	002	Feb 13, 1996	Jul CAHN
@	25MG	A074462	002	Feb 13, 1996	Apr CAHN
@	25MG	A074483	002	Feb 13, 1996	Jul CAHN
@	25MG	A074590	002	Aug 30, 1996	Apr CAHN
@	50MG	A074433	003	Feb 13, 1996	Jul CAHN

TABLET; ORAL
CAPTOPRIL

	@	50MG	A074462	003	Feb 13, 1996	Apr CAHN
	@	50MG	A074483	003	Feb 13, 1996	Jul CAHN
	@	50MG	A074590	001	Aug 30, 1996	Apr CAHN
	@	100MG	A074433	004	Feb 13, 1996	Jul CAHN
	@	100MG	A074462	004	Feb 13, 1996	Apr CAHN
	@	100MG	A074483	004	Feb 13, 1996	Jul CAHN
	@	100MG	A074590	003	Aug 30, 1996	Apr CAHN
AB	+	MYLAN	A074434	004	Feb 13, 1996	May CRLD

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Apr CAHN
AB		25MG;25MG	A074827	002	Dec 29, 1997	Apr CAHN
AB		50MG;15MG	A074827	004	Dec 29, 1997	Apr CAHN
AB		50MG;25MG	A074827	003	Dec 29, 1997	Apr CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May CAHN
AB		200MG	A076697	002	May 20, 2011	May CAHN
AB		300MG	A076697	003	May 20, 2011	May CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

IMPAX LABS INC

		23.75MG;95MG	N203312	001	Jan 07, 2015	Jan NEWA
		36.25MG;145MG	N203312	002	Jan 07, 2015	Jan NEWA
		48.75MG;195MG	N203312	003	Jan 07, 2015	Jan NEWA
+		61.25MG;245MG	N203312	004	Jan 07, 2015	Jan NEWA

SUSPENSION; ENTERAL

DUOPA

+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan NEWA
---	------------	-------------------	---------	-----	--------------	----------

>A> CARIPRAZINE HYDROCHLORIDE

>A> CAPSULE; ORAL

>A> VRAYLAR

>A>	FOREST RES INST INC	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Sep NEWA
>A>		EQ 3MG BASE	N204370	002	Sep 17, 2015	Sep NEWA
>A>		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Sep NEWA
>A>	+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Sep NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AB	INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun NEWA
AA		350MG	A205126	002	Jul 08, 2015	Jun NEWA
AB	+	MEDA PHARMS	N011792	004	Sep 13, 2007	Jun CTEC

CARVEDILOL

TABLET; ORAL

CARVEDILOL

	@ HIKMA	3.125MG	A077887	001	Sep 07, 2007	Jun DISC
	@	6.25MG	A077887	002	Sep 07, 2007	Jun DISC
	@	12.5MG	A077887	003	Sep 07, 2007	Jun DISC
	@	25MG	A077887	004	Sep 07, 2007	Jun DISC
AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
AB		6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
AB		12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
AB		25MG	A076989	004	Sep 05, 2007	Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan CAHN
AP		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan CAHN
AP	+	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan CAHN

SOLUTION; INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

>A>	BAXTER HLTHCARE	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Sep CAHN
>D>	CELERITY PHARMS	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Sep CAHN
		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Aug NEWA

CEFIXIME

FOR SUSPENSION; ORAL
CEFIXIME

AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr NEWA
	SUPRAX					
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr CFTG

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

@	IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May CAHN
@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar CAHN
@		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May CAHN
@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar CAHN
@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar CAHN

CEFOTAN IN PLASTIC CONTAINER

@	IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN

CEFTAZIDIME

INJECTABLE; INJECTION
FORTAZ

AP	+	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Jun CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

@	CONCORDIA PHARMS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun CAHN
+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun CAHN
+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; IV (INFUSION)
ZERBAXA

+	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Aug CAHN
---	-------------------	--------------------------------------	---------	-----	--------------	----------

CEFTRIAZONE SODIUMINJECTABLE;INJECTION
CEFTRIAZONE

AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan CAHN
	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
	CEFTRIAZONE					
	@ FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan CAHN
	@	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan CAHN
	@ FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006	Jul DISC

CEFUROXIME AXETILFOR SUSPENSION;ORAL
CEFUROXIME AXETIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr CAHN
AB		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr CAHN
	TABLET;ORAL					
	CEFUROXIME AXETIL					
AB	ANI PHARMS INC	EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul CAHN
AB		EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul CAHN
AB	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr CAHN
AB		EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr CAHN
AB		EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr CAHN

CEFUROXIME SODIUMINJECTABLE;INJECTION
CEFUROXIME SODIUM

AP	FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN
	ZINACEF					
AP	+ CONCORDIA PHARMS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun CAHN
AP	+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun CAHN
	ZINACEF IN PLASTIC CONTAINER					
	@ CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun CAHN
	+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun CAHN
	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
	CEFUROXIME SODIUM					
AB	FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN
	ZINACEF					
AB	+ CONCORDIA PHARMS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun CAHN

CELECOXIBCAPSULE;ORAL
CELECOXIB

AB	ALEMBIC PHARMS LTD	50MG	A204519	001	Aug 21, 2015	Aug NEWA
AB		100MG	A204519	002	Aug 21, 2015	Aug NEWA
AB		200MG	A204519	003	Aug 21, 2015	Aug NEWA
AB		400MG	A204519	004	Aug 21, 2015	Aug NEWA
AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May NEWA
AB		100MG	A204197	002	Jun 02, 2015	May NEWA
AB		200MG	A204197	003	Jun 02, 2015	May NEWA
>A> AB	CIPLA LTD	50MG	A207446	001	Sep 23, 2015	Sep NEWA
>A> AB		100MG	A207446	002	Sep 23, 2015	Sep NEWA
>A> AB		200MG	A207446	003	Sep 23, 2015	Sep NEWA
>A> AB		400MG	A207446	004	Sep 23, 2015	Sep NEWA
AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May NEWA
AB		200MG	A202240	003	Jun 09, 2015	May NEWA
AB		400MG	A202240	004	Jun 09, 2015	May NEWA
AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
AB		200MG	A078857	003	Feb 11, 2015	Jan NEWA
AB		400MG	A078857	004	Feb 11, 2015	Jan NEWA
AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
AB		100MG	A200562	002	Feb 11, 2015	Jan NEWA
AB		200MG	A200562	003	Feb 11, 2015	Jan NEWA
AB		400MG	A200562	004	Feb 11, 2015	Jan NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN

FOR SUSPENSION;ORAL									
CEPHALEXIN									
	@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr	CAHN		
	@	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr	CAHN		
<u>CETIRIZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
ZYRTEC									
AA	+ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Aug	CAHN		
<u>CHLOROTHIAZIDE SODIUM</u>									
INJECTABLE;INJECTION									
CHLOROTHIAZIDE SODIUM									
AP	SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May	NEWA		
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE									
	SPRIASO LLC	8MG;54.3MG	N206323	001	Jun 22, 2015	Jun	NEWA		
<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE</u>									
SOLUTION;ORAL									
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE									
AA	TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan	NEWA		
VITUZ									
AA	+ CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan	CFTG		
<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>									
SOLUTION;ORAL									
HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE									
AA	COASTAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Jul	NEWA		
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX</u>									
SUSPENSION, EXTENDED RELEASE;ORAL									
TUZISTRA XR									
	+ TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr	NEWA		
	+ VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun	CAHN		
<u>CHLORPROMAZINE HYDROCHLORIDE</u>									
CONCENTRATE;ORAL									
CHLORPROMAZINE HYDROCHLORIDE INTENSOL									
	@ CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983	Jun	CAHN		
	@	100MG/ML	A088158	001	Apr 27, 1983	Jun	CAHN		
INJECTABLE;INJECTION									
CHLORPROMAZINE HYDROCHLORIDE									
	+ EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb	CAHN		
TABLET;ORAL									
CHLORPROMAZINE HYDROCHLORIDE									
	@ CYCLE PHARMS LTD	10MG	A085331	001		Jun	CAHN		
	@	25MG	A085331	002		Jun	CAHN		
	@	50MG	A085331	003		Jun	CAHN		
	@	100MG	A085331	004		Jun	CAHN		
	@	200MG	A085331	005		Jun	CAHN		
	@ SANDOZ	10MG	A080439	001		May	DISC		
	@	25MG	A080439	002		May	DISC		
	@	50MG	A080439	003		May	DISC		
	@	100MG	A080439	004		May	DISC		
	@	200MG	A080439	005		May	DISC		
<u>CHLORTHALIDONE</u>									
TABLET;ORAL									
CHLORTHALIDONE									
	@ G AND W LABS INC	50MG	A088651	001	May 30, 1985	Apr	CAHN		
AB	MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar	CMFD		
AB	+ MYLAN	50MG	A086831	001		Jun	CTEC		
THALITONE									
	@ CITRON PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Jun	DISC		

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

@ ANI PHARMS INC

EQ 4GM RESIN/PACKET

A074554 001 Oct 02, 1996 Aug CAHN

@

EQ 4GM RESIN/SCOOPFUL

A074554 002 Oct 02, 1996 Aug CAHN

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

ASKLEPION PHARMS LLC

50MG

N205750 001 Mar 17, 2015 Mar NEWA

+

250MG

N205750 002 Mar 17, 2015 Mar NEWA

RTRX

50MG

N205750 001 Mar 17, 2015 Apr CAHN

+

250MG

N205750 002 Mar 17, 2015 Apr CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

>A> AB

ACTAVIS ELIZABETH

EQ 45MG FENOFIBRIC ACID

A200920 001 Oct 07, 2015 Sep NEWA

>A> AB

EQ 135MG FENOFIBRIC ACID

A200920 002 Oct 07, 2015 Sep NEWA

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

>D>

@ APOTEX INC

8%

A078172 001 Sep 18, 2007 Sep CMFD

>A> AT

8%

A078172 001 Sep 18, 2007 Sep CMFD

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP

+

MYLAN INSTITUTIONAL

EQ 75MG BASE/ML

A201276 001 Jun 27, 2012 May CRLD

VISTIDE

@ GILEAD SCIENCES INC

EQ 75MG BASE/ML

N020638 001 Jun 26, 1996 May DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ G AND W LABS INC

EQ 300MG BASE/5ML

A074176 001 Jun 01, 1994 Apr CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

AP

CLARIS PHARMASERVICE

200MG/20ML (10MG/ML)

A078062 001 Apr 29, 2008 Apr CAHN

AP

400MG/40ML (10MG/ML)

A078062 002 Apr 29, 2008 Apr CAHN

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP

CLARIS PHARMASERVICE

200MG/100ML

A078024 001 Mar 18, 2008 Apr CAHN

AP

400MG/200ML

A078024 002 Mar 18, 2008 Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB

SUN PHARM INDS LTD

EQ 250MG BASE

A075747 001 Jun 09, 2004 Apr CAHN

AB

EQ 500MG BASE

A075747 002 Jun 09, 2004 Apr CAHN

AB

EQ 750MG BASE

A075747 003 Jun 09, 2004 Apr CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP

FRESENIUS KABI USA

EQ 2MG BASE/ML

A203183 001 Feb 26, 2015 Feb NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP

FRESENIUS KABI USA

EQ 2MG BASE/ML

A203182 001 Feb 26, 2015 Feb NEWA

AP

EQ 10MG BASE/ML

A203182 002 Feb 26, 2015 Feb NEWA

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP

ACCORD HLTHCARE

1MG/ML

A206774 001 Aug 18, 2015 Aug NEWA

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr CAHN
AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr CAHN
AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr CAHN

CLARITHROMYCIN

FOR SUSPENSION; ORAL

CLARITHROMYCIN

AB	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr CAHN
AB		250MG/5ML	A065382	002	Aug 30, 2007	Apr CAHN

TABLET; ORAL

CLARITHROMYCIN

>A>	AB	HEC PHARM USA INC	250MG	A203584	001	Sep 28, 2015	Sep NEWA
>A>	AB		500MG	A203584	002	Sep 28, 2015	Sep NEWA
	AB	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr CAHN
	AB		500MG	A065174	002	Sep 24, 2004	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB	LUPIN LTD	500MG	A202532	001	Sep 15, 2015	Aug NEWA
AB	+ TEVA	500MG	A065154	001	May 18, 2005	Jan CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

@	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986	May DISC
@		EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985	May DISC
@		EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985	May DISC
@		EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May DISC
	TIMENTIN IN PLASTIC CONTAINER					
@	GLAXOSMITHKLINE	EQ 100MG BASE/100ML; EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989	May DISC

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

@	ANI PHARMS INC	1.34MG	A073282	001	Jan 31, 1992	Jul CAHN
---	----------------	--------	---------	-----	--------------	----------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr CAHN
AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr CAHN
AB	SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr CAHN
AB		EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

>A>	AP	ALVOGEN INC	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Sep CAHN
>A>	AP		EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Sep CAHN
>A>	AP		EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Sep CAHN
>D>	AP	HOSPIRA	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Sep CAHN
>D>	AP		EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Sep CAHN
>D>	AP		EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Sep CAHN
		@ IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989	Mar CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

	@	BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989	Jan CAHN
AT		VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	May NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB	ACTAVIS MID ATLANTIC	1.2%; 0.025%	A202564	001	Jun 12, 2015	Jun NEWA
	ZIANA					
AB	+ MEDICIS	1.2%; 0.025%	N050802	001	Nov 07, 2006	Jun CTEC

CLOBETASOL PROPIONATE

	CREAM;TOPICAL						
	CLOBETASOL PROPIONATE (EMOLLIENT)						
AB2	+	FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	May CRLD
	CORMAX						
AB1	+	HI TECH PHARMA	0.05%	A074220	001	May 16, 1997	Jun CRLD
	TEMOVATE						
	@	FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Jun DISC
	TEMOVATE E						
	@	FOUGERA PHARMS	0.05%	N020340	001	Jun 17, 1994	May DISC
	GEL;TOPICAL						
	CLOBETASOL PROPIONATE						
AB	+	FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	May CRLD
	TEMOVATE						
	@	FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	May DISC
	OINTMENT;TOPICAL						
	CLOBETASOL PROPIONATE						
AB		G AND W LABS INC	0.05%	A074089	001	Feb 16, 1994	Feb CAHN
	SOLUTION;TOPICAL						
	CLOBETASOL PROPIONATE						
AT		G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Mar CMFD

CLOMIPHENE CITRATE

TABLET;ORAL					
SEROPHENE					
@ EMD SERONO	50MG	N018361	001	Mar 22, 1982	Jun DISC

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL						
CLONIDINE						
AB	ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014	Mar CAHN
AB		0.2MG/24HR	A090873	002	May 06, 2014	Mar CAHN
AB		0.3MG/24HR	A090873	003	May 06, 2014	Mar CAHN

CLONIDINE HYDROCHLORIDE

	TABLET;ORAL					
	CLONIDINE HYDROCHLORIDE					
	@ DAVA PHARMS INC	0.1MG	A071783	001	Apr 05, 1988	May DISC
	@	0.2MG	A071784	001	Apr 05, 1988	May DISC
	@	0.3MG	A071785	001	Apr 05, 1988	May DISC
	TABLET, EXTENDED RELEASE;ORAL					
	CLONIDINE HYDROCHLORIDE					
AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	May NEWA
AB1		0.1MG	A203320	001	May 15, 2015	May NEWA
	@	0.2MG	A202792	002	May 15, 2015	Aug DISC
AB2		0.2MG	A202792	002	May 15, 2015	May NEWA
	@	0.2MG	A203320	002	May 15, 2015	Aug DISC
AB1		0.2MG	A203320	002	May 15, 2015	May NEWA
	@ ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Aug DISC
AB2		0.1MG	A202983	001	Apr 02, 2014	May CTEC
	@	0.2MG	A202983	002	Apr 02, 2014	Aug DISC
AB2		0.2MG	A202983	002	Apr 02, 2014	May CTEC
	CLONIDINE HYDROCHLORIDE					
AB1	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	May CTEC
	@	0.2MG	A202984	002	Sep 30, 2013	Aug DISC
AB1		0.2MG	A202984	002	Sep 30, 2013	May CTEC
	KAPVAY					
AB1	+ CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Aug CRLD
AB1		0.1MG	N022331	003	Sep 28, 2010	Jun CRLD
AB1	+	0.1MG	N022331	003	Sep 28, 2010	May CTEC
	@	0.2MG	N022331	004	Sep 28, 2010	Aug DISC
AB1	+	0.2MG	N022331	004	Sep 28, 2010	Jun CRLD
AB1		0.2MG	N022331	004	Sep 28, 2010	May CTEC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL									
CLORAZEPATE DIPOTASSIUM									
AB	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Apr	CAHN		
AB		7.5MG	A076911	002	Sep 29, 2004	Apr	CAHN		
AB		15MG	A076911	003	Sep 29, 2004	Apr	CAHN		

CLOZAPINETABLET;ORAL
CLOZAPINE

>A>	AB	ACTAVIS LABS FL INC	25MG	A203807	001	Sep 17, 2015	Sep NEWA
>A>	AB		100MG	A203807	002	Sep 17, 2015	Sep NEWA
		CLOZARIL					
	AB	HERITAGE LIFE	25MG	N019758	001	Sep 26, 1989	Aug CAHN
	AB	+	100MG	N019758	002	Sep 26, 1989	Aug CAHN
		TABLET, ORALLY DISINTEGRATING;ORAL					
		CLOZAPINE					
	AB	MYLAN PHARMS INC	25MG	A201824	002	Sep 15, 2015	Aug NEWA
	AB		100MG	A201824	003	Sep 15, 2015	Aug NEWA
		FAZACLO ODT					
	AB	JAZZ PHARMS III	25MG	N021590	001	Feb 10, 2004	Aug CFTG
	AB	+	100MG	N021590	002	Feb 10, 2004	Aug CFTG

COBICISTAT; DARUNAVIR ETHANOLATETABLET;ORAL
PREZCOBIX

	+	JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Jan NEWA
--	---	---------------	---------------------	---------	-----	--------------	----------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		AMNEAL PHARMS	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A200963	001	Aug 26, 2015	Aug NEWA
----	--	---------------	-------------------------------	---------	-----	--------------	----------

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

	@	ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jan DISC
--	---	--------	----------	---------	-----	--------------	----------

COLCHICINE

CAPSULE;ORAL

MITIGARE

		HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Jan CAHN
--	--	-------------------	-------	---------	-----	--------------	----------

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

	@	ANI PHARMS INC	0.5MG; 500MG	A083734	001		Aug CAHN
--	---	----------------	--------------	---------	-----	--	----------

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP		XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356	001	May 29, 2015	May NEWA
----	--	-------------------	--------------------	---------	-----	--------------	----------

CORTICOTROPIN

INJECTABLE;INJECTION

H.P. ACTHAR GEL

	@	MALLINCKRODT ARD	40 UNITS/ML	N008372	006		Aug CAHN
--	---	------------------	-------------	---------	-----	--	----------

	+		80 UNITS/ML	N008372	008		Aug CAHN
--	---	--	-------------	---------	-----	--	----------

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

	@	EUROHLTH INTL SARL	1MG/ML	A080515	002		Feb CAHN
--	---	--------------------	--------	---------	-----	--	----------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		ORIT LABS LLC	5MG	A078218	002	Jun 19, 2015	Jun NEWA
AB		SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Apr CAHN
AB			7.5MG	A078722	002	May 12, 2008	Apr CAHN
AB			10MG	A078722	003	May 12, 2008	Apr CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A> AA	MIRROR PHARMS LLC	4MG	A205087	001	Sep 23, 2015	Sep NEWA
--------	-------------------	-----	---------	-----	--------------	----------

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

	NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013	Mar CAHN
+		EQ 75MG BASE	N202806	002	May 29, 2013	Mar CAHN

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jul NEWA
+		EQ 60MG BASE	N206843	002	Jul 24, 2015	Jul NEWA

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

@	PFIZER INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Jun CAHN
@	PHARMACIA AND UPJOHN	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Apr CAHN

INJECTABLE; SUBCUTANEOUS

FRAGMIN

	PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Jun CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Jun CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Jun CAHN
@		10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Jun CAHN
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Jun CAHN
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Jun CAHN
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Jun CAHN
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Jun CAHN
@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun CAHN
	PHARMACIA AND UPJOHN	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Apr CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Apr CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Apr CAHN
@		10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Apr CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Apr CAHN
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Apr CAHN
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Apr CAHN
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Apr CAHN
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Apr CAHN
@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Apr CAHN

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

AB	ELITE LABS INC	25MG	A076686	001	Oct 24, 2005	May CAHN
AB		50MG	A076686	002	Oct 24, 2005	May CAHN
AB		100MG	A076686	003	Oct 24, 2005	May CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN HYDROBROMIDE

AB	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar NEWA
AB		EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar NEWA
	ENABLEX					
AB	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar CFTG
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar CFTG

DASATINIB

TABLET; ORAL

SPRYCEL

>D>	BRISTOL MYERS SQUIBB	100MG	N021986	004	May 30, 2008	Sep CRLD
>A>	+	100MG	N021986	004	May 30, 2008	Sep CRLD
>D>	+	140MG	N021986	006	Oct 28, 2010	Sep CRLD
>A>		140MG	N021986	006	Oct 28, 2010	Sep CRLD

DECITABINEINJECTABLE;INTRAVENOUS
DACOGEN

AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan CAHN
----	---	---------------------	-----------	---------	-----	--------------	----------

DEFERASIROXTABLET;ORAL
JADENU

		NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar NEWA
			180MG	N206910	002	Mar 30, 2015	Mar NEWA
	+		360MG	N206910	003	Mar 30, 2015	Mar NEWA

DEFERIPRONE>A> SOLUTION;ORAL
>A> FERRIPROX

>A>	+	AOPHARMA INC	100MG/ML	N208030	001	Sep 09, 2015	Sep NEWA
-----	---	--------------	----------	---------	-----	--------------	----------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	150MG	A065447	001	Aug 18, 2015	Aug NEWA
AB			300MG	A065447	002	Aug 18, 2015	Aug NEWA

DEOXYCHOLIC ACIDSOLUTION;SUBCUTANEOUS
KYBELLA

	+	KYATHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr NEWA
--	---	--------------------	--------------------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

>A>		ANI PHARMS INC	25MG	A071803	002	Dec 08, 1987	Sep CMS1
>A>			50MG	A071803	003	Dec 08, 1987	Sep CMS1
>A>			75MG	A071803	004	Dec 08, 1987	Sep CMS1
>A>			150MG	A071803	005	May 29, 1997	Sep CMS1

DESIRUDIN RECOMBINANTINJECTABLE;SUBCUTANEOUS
IPRIVASK

	+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	May CAHN
--	---	----------------------	-----------	---------	-----	--------------	----------

DESLORATADINESOLUTION;ORAL
CLARINEX

AA	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	Jun CFTG
----	---	-------------------	----------	---------	-----	--------------	----------

AA		TARO PHARM INDS	0.5MG/ML	A202592	001	Jun 30, 2015	Jun NEWA
----	--	-----------------	----------	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

TABLET;ORAL

DDAVP

AB		FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan CAHN
AB	+		0.2MG	N019955	002	Sep 06, 1995	Jan CAHN

DESMOPRESSIN ACETATE

AB		GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May NEWA
AB			0.2MG	A201831	002	May 28, 2015	May NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

BEKYREE

AB		LUPIN LTD	0.15MG,N/A;0.02MG,0.01MG	A202226	001	Aug 12, 2015	Jul NEWA
		CYCLESSA					

AB	+	ASPEN GLOBAL INC	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	N021090	001	Dec 20, 2000	Aug CAHN
----	---	------------------	--	---------	-----	--------------	----------

ISIBLOOM

AB		SANDOZ INC	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Jul NEWA
		KARIVA					

AB	+	BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr CTEC
		KIMIDESS					

AB		VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Apr NEWA
----	--	----------------	--------------------------	---------	-----	--------------	----------

DESONIDE

	CREAM; TOPICAL						
	DESONIDE						
AB	TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May	CMFD

DESOXIMETASONE

	CREAM; TOPICAL						
	DESOXIMETASONE						
AB	ACTAVIS MID ATLANTIC	0.25%	A205082	001	Sep 04, 2015	Aug	NEWA
AB	VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun	NEWA
	OINTMENT; TOPICAL						
	DESOXIMETASONE						
AB	PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr	NEWA

DESVENLAFAXINE SUCCINATE

	TABLET, EXTENDED RELEASE; ORAL						
	DESVENLAFAXINE SUCCINATE						
AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun	NEWA
AB	LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun	NEWA
AB	MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	NEWA
AB	SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun	NEWA
	PRISTIQ						
AB	+ WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun	CFTG
AB	+	EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun	CFTG

DEXAMETHASONE SODIUM PHOSPHATE

	INJECTABLE; INJECTION						
	DEXAMETHASONE SODIUM PHOSPHATE						
>A> AP	BD RX	EQ 4MG PHOSPHATE/ML	A203129	001	Sep 30, 2015	Sep	NEWA
	@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar	CAHN
AP	+	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

	OINTMENT; OPHTHALMIC						
	MAXITROL						
AT	+ ALCON LABS INC	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050065	002		Mar	CAHN
	SUSPENSION/DROPS; OPHTHALMIC						
	MAXITROL						
AT	+ ALCON LABS INC	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N050023	002		Mar	CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	DEXMEDETOMIDINE HYDROCHLORIDE						
>A> AP	FRESENIUS KABI USA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A201072	001	Sep 18, 2015	Sep	NEWA
AP	SUN PHARM INDS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	Aug	NEWA
	PRECEDEX						
	HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL						
	DEXMETHYLPHENIDATE HYDROCHLORIDE						
AB	MYLAN PHARMS INC	5MG	A204266	001	Aug 25, 2015	Aug	NEWA
AB		10MG	A204266	002	Aug 25, 2015	Aug	NEWA
AB		15MG	A204266	003	Aug 25, 2015	Aug	NEWA
AB		40MG	A204266	007	Aug 25, 2015	Aug	NEWA
AB	WATSON LABS INC	5MG	A079108	001	Aug 05, 2015	Jul	NEWA
AB		10MG	A079108	002	Aug 05, 2015	Jul	NEWA
	TABLET; ORAL						
	DEXMETHYLPHENIDATE HYDROCHLORIDE						
>A> AB	SUN PHARM INDS LTD	2.5MG	A201231	001	Sep 24, 2015	Sep	NEWA
>A> AB		5MG	A201231	002	Sep 24, 2015	Sep	NEWA
>A> AB		10MG	A201231	003	Sep 24, 2015	Sep	NEWA

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

5GM/100ML; 30MG/100ML; 37MG/100ML; 36 N017451 001

Mar DISC

8MG/100ML; 526MG/100ML; 502MG/100ML

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R

AP + LIEBEL-FLARSHEIM 66%; 10%

N019292 001 Sep 29, 1989 Feb CAHN

SOLUTION; ORAL, RECTAL

MD-GASTROVIEW

AA LIEBEL-FLARSHEIM 66%; 10%

A087388 001 Jan CAHN

DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

TARO

50MG

N011366 002 Aug 07, 2015 Aug NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

VOLTAREN

+ GLAXOSMITHKLINE CONS 1%

N022122 001 Oct 17, 2007 Aug CAHN

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT IGI LABS INC 1.5%

A202769 001 Jul 08, 2015 Jun NEWA

AT LUPIN LTD 1.5%

A204132 001 Aug 20, 2015 Aug NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

TENUATE

AA + ACTAVIS LABS UT INC 25MG

N011722 002 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

TENUATE DOSPAN

AB + ACTAVIS LABS UT INC 75MG

N012546 001 Mar CAHN

DIFLORASONE DIACETATE

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB VERSAPHARM INC 0.05%

A206572 001 Jul 24, 2015 Jul NEWA

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB HERITAGE PHARMA 500MG

A202845 001 Mar 08, 2012 Mar CAHN

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP EUROHLTH INTL SARL 0.25MG/ML

A083391 001 Feb CAHN

TABLET; ORAL

DIGOXIN

AB MYLAN PHARMS INC 0.125MG

A040282 001 Dec 23, 1999 Jan CTEC

AB 0.25MG

A040282 002 Dec 23, 1999 Jan CTEC

AB SUN PHARM INDS INC 0.125MG

A076363 001 Jan 31, 2003 Feb CMFD

AB 0.25MG

A076363 002 Jan 31, 2003 Feb CMFD

LANOXIN

AB CONCORDIA PHARMS INC 0.0625MG

N020405 001 Sep 30, 1997 Apr CAHN

AB 0.125MG

N020405 002 Sep 30, 1997 Apr CAHN

AB 0.1875MG

N020405 003 Sep 30, 1997 Apr CAHN

AB + 0.25MG

N020405 004 Sep 30, 1997 Apr CAHN

@ 0.375MG

N020405 005 Sep 30, 1997 Apr CAHN

@ 0.5MG

N020405 006 Sep 30, 1997 Apr CAHN

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB2	+	MYLAN	240MG	A075124	001	Mar 18, 1998	Feb CRLD
		TIAZAC					
AB4		VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb CAHN
AB4			180MG	N020401	002	Sep 11, 1995	Feb CAHN
AB4			240MG	N020401	003	Sep 11, 1995	Feb CAHN
AB4			300MG	N020401	004	Sep 11, 1995	Feb CAHN
AB4			360MG	N020401	005	Sep 11, 1995	Feb CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb CAHN
		INJECTABLE;INJECTION					
		DILTIAZEM HYDROCHLORIDE					
AP		EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008	Jun CAHN

DIPHENHYDRAMINE HYDROCHLORIDEINJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	50MG/ML	A080817	002		Jun CAHN
----	---	--------------------	---------	---------	-----	--	----------

DIPYRIDAMOLEINJECTABLE;INJECTION
DIPYRIDAMOLE

AP		EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996	Jun CAHN
----	--	--------------------	--------	---------	-----	--------------	----------

DISULFIRAMTABLET;ORAL
DISULFIRAM

AB		MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb NEWA
AB			500MG	A203916	002	Mar 04, 2015	Feb NEWA

DIVALPROEX SODIUMTABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

AB		AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May NEWA
AB			EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May NEWA
		@ G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Jul CAHN

DOBUTAMINE HYDROCHLORIDEINJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE
@ IGI LABS INC

EQ 12.5MG BASE/ML

A074098 001 Feb 21, 1995 Mar CAHN

DOCETAXELINJECTABLE;INJECTION
DOCETAXEL

AP		TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015	Aug NEWA
AP			80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015	Aug NEWA

DONEPEZIL HYDROCHLORIDETABLET;ORAL
DONEPEZIL HYDROCHLORIDE

AB		HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan NEWA
AB			10MG	A203034	002	Jan 30, 2015	Jan NEWA
AB		SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr CAHN
AB			10MG	A076786	002	Nov 26, 2010	Apr CAHN
AB			23MG	A204293	001	Jun 05, 2015	May NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
NAMZARICFOREST LABS LLC
+ 10MG;14MG
10MG;28MGN206439 001 Dec 23, 2014 Mar CAHN
N206439 002 Dec 23, 2014 Mar CAHNDOPAMINE HYDROCHLORIDEINJECTABLE;INJECTION
DOPAMINE HYDROCHLORIDE@ IGI LABS INC 40MG/ML
@ 40MG/ML
@ 80MG/ML
@ 80MG/MLA070087 001 Oct 23, 1985 Mar CAHN
N018656 001 Jun 28, 1983 Mar CAHN
A070089 001 Oct 23, 1985 Mar CAHN
A070090 001 Oct 23, 1985 Mar CAHN

INJECTABLE; INJECTION									
DOPAMINE HYDROCHLORIDE									
	@	80MG/ML	A070091	001	Oct 23, 1985	Mar	CAHN		
	@	160MG/ML	A070092	001	Oct 23, 1985	Mar	CAHN		
	@	160MG/ML	A070093	001	Oct 23, 1985	Mar	CAHN		
	@	160MG/ML	A070094	001	Oct 23, 1985	Mar	CAHN		
<u>DOXAPRAM HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
DOPRAM									
AP	+	EUROHLTH INTL SARL	20MG/ML	N014879	001		Jun	CAHN	
<u>DOXEPIIN HYDROCHLORIDE</u>									
CAPSULE; ORAL									
DOXEPIIN HYDROCHLORIDE									
AB	+	MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan	CRLD	
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan	CRLD	
CREAM; TOPICAL									
ZONALON									
	+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar	CAHN	
<u>DOXERCALCIFEROL</u>									
INJECTABLE; INJECTION									
DOXERCALCIFEROL									
AP		AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr	NEWA	
<u>DOXYCYCLINE</u>									
CAPSULE; ORAL									
DOXYCYCLINE									
AB		NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May	NEWA	
AB			EQ 75MG BASE	A204446	002	May 28, 2015	May	NEWA	
AB			EQ 100MG BASE	A204446	003	May 28, 2015	May	NEWA	
AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr	CAHN	
AB			EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr	CAHN	
AB			EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr	CAHN	
TABLET; ORAL									
DOXYCYCLINE									
AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr	CAHN	
AB			EQ 75MG BASE	A065356	002	May 31, 2006	Apr	CAHN	
AB			EQ 100MG BASE	A065356	003	May 31, 2006	Apr	CAHN	
<u>DOXYCYCLINE HYCLATE</u>									
INJECTABLE; INJECTION									
DOXYCYCLINE									
	@	EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun	CAHN	
	@		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun	CAHN	
<u>DROPERIDOL</u>									
INJECTABLE; INJECTION									
DROPERIDOL									
	@	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar	CAHN	
	@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar	CAHN	
	@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar	CAHN	
<u>DROSPIRENONE; ETHINYL ESTRADIOL</u>									
TABLET; ORAL									
DROSPIRENONE AND ETHINYL ESTRADIOL									
AB		GLENMARK PHARMS LTD	3MG;0.02MG	A204296	001	Aug 17, 2015	Aug	NEWA	
<u>DULOXETINE HYDROCHLORIDE</u>									
CAPSULE, DELAYED REL PELLETS; ORAL									
DULOXETINE HYDROCHLORIDE									
AB		ALKEM LABS LTD	EQ 20MG BASE	A203197	001	Aug 26, 2015	Aug	NEWA	
AB			EQ 30MG BASE	A203197	002	Aug 26, 2015	Aug	NEWA	
AB			EQ 60MG BASE	A203197	003	Aug 26, 2015	Aug	NEWA	

ECONAZOLE NITRATECREAM; TOPICAL
ECONAZOLE NITRATE

AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar CRLD
AB	+ PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar CRLD

EDOXABAN TOSYLATETABLET; ORAL
SAVAYSA

	DAIICHI SANKYO	EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan NEWA
		EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan NEWA
+		EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan NEWA

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION
ENLON

+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar CRLD
	TENSILON					
	@ IGI LABS INC	10MG/ML	N007959	001		Apr CAHN
	@ VALEANT PHARMS	10MG/ML	N007959	001		Mar DISC
	TENSILON PRESERVATIVE FREE					
	@ IGI LABS INC	10MG/ML	N007959	002		Apr CAHN
	@ VALEANT PHARMS	10MG/ML	N007959	002		Mar DISC

ELTROMBOPAG OLAMINEFOR SUSPENSION; ORAL
PROMACTA

+	NOVARTIS PHARMS CORP	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Aug NEWA
	TABLET; ORAL					
	PROMACTA					
	NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar CAHN
		EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar CAHN
		EQ 50MG ACID	N022291	002	Nov 20, 2008	May CRLD
+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar CAHN
+		EQ 75MG ACID	N022291	003	Sep 08, 2009	May CRLD
		EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar CAHN
+		EQ 100MG ACID	N022291	005	Nov 16, 2012	May CRLD
		EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar CAHN

ELUXADOLINETABLET; ORAL
VIBERZI

	FOREST TOSARA LTD	75MG	N206940	001	May 27, 2015	Jul CAHN
+		100MG	N206940	002	May 27, 2015	Jul CAHN
	FURIEX PHARMS	75MG	N206940	001	May 27, 2015	May NEWA
+		100MG	N206940	002	May 27, 2015	May NEWA

EMPAGLIFLOZIN; LINAGLIPTINTABLET; ORAL
GLYXAMBI

	BOEHRINGER INGELHEIM	10MG; 5MG	N206073	001	Jan 30, 2015	Jan NEWA
+		25MG; 5MG	N206073	002	Jan 30, 2015	Jan NEWA

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDETABLET; ORAL
SYNJARDY

	BOEHRINGER INGELHEIM	5MG; 500MG	N206111	001	Aug 26, 2015	Aug NEWA
		5MG; 1GM	N206111	002	Aug 26, 2015	Aug NEWA
		12.5MG; 500MG	N206111	003	Aug 26, 2015	Aug NEWA
+		12.5MG; 1GM	N206111	004	Aug 26, 2015	Aug NEWA

ENALAPRIL MALEATETABLET; ORAL
ENALAPRIL MALEATE

AB	SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB		5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB		10MG	A075459	001	Aug 22, 2000	Mar CMFD
AB		20MG	A075459	002	Aug 22, 2000	Mar CMFD
	@ SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
	@	5MG	A075556	002	Aug 22, 2000	Apr CAHN
	@	10MG	A075556	003	Aug 22, 2000	Apr CAHN

TABLET;ORAL

ENALAPRIL MALEATE

@

20MG

A075556 004 Aug 22, 2000 Apr CAHN

VASOTEC

AB VALEANT PHARMS NORTH 2.5MG

N018998 005 Jul 26, 1988 Apr CAHN

AB 5MG

N018998 001 Dec 24, 1985 Apr CAHN

AB 10MG

N018998 002 Dec 24, 1985 Apr CAHN

AB + 20MG

N018998 003 Dec 24, 1985 Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB G AND W LABS INC 5MG;12.5MG

A075727 001 Sep 18, 2001 Apr CAHN

AB 10MG;25MG

A075727 002 Sep 18, 2001 Apr CAHN

ENTACAPONE

TABLET;ORAL

ENTACAPONE

AB AUROBINDO PHARMA LTD 200MG

A203437 001 Jun 19, 2015 Jun NEWA

ENTECAVIR

TABLET;ORAL

ENTECAVIR

AB AUROBINDO PHARMA LTD 0.5MG

A206217 001 Aug 26, 2015 Aug NEWA

AB 1MG

A206217 002 Aug 26, 2015 Aug NEWA

AB HETERO LABS LTD V 0.5MG

A205740 001 Aug 21, 2015 Aug NEWA

AB 1MG

A205740 002 Aug 21, 2015 Aug NEWA

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N204200 001 Dec 07, 2012 Jul CAIN

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML)

N204640 001 Dec 18, 2013 Jul CAIN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>A> @ EUROHLTH INTL SARL 0.01MG/ML;1%

A080406 001 Sep CAHN

>A> @ 0.01MG/ML;2%

A080406 002 Sep CAHN

>D> @ HIKMA MAPLE 0.01MG/ML;1%

A080406 001 Sep CAHN

>D> @ 0.01MG/ML;2%

A080406 002 Sep CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEVETEN HCT

@ ABBVIE

600MG;12.5MG

N021268 001 Nov 01, 2001 Jun DISC

@

600MG;25MG

N021268 002 Nov 01, 2001 Jun DISC

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP TEVA PHARMS USA 2MG/ML

A090854 001 Jun 12, 2015 Jun NEWA

AP 75MG/100ML

A091555 001 Jun 05, 2015 May NEWA

INTEGRILIN

AP + SCHERING 2MG/ML

N020718 001 May 18, 1998 Jun CTEC

AP + 75MG/100ML

N020718 002 May 18, 1998 May CFTG

ERGOALCIFEROL

CAPSULE;ORAL

VITAMIN D

AA BANNER LIFE SCIENCES 50,000 IU

A080704 001 Jan CAHN

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOSTAT

@ WATSON LABS INC

2MG

A088337 001 Jun 08, 1984 Aug CAHN

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

>D>	AB	MYLAN PHARMS INC	EQ 25MG BASE	A091002	001	Jun 11, 2014	Sep DISC
>A>		@	EQ 25MG BASE	A091002	001	Jun 11, 2014	Sep DISC
>D>	AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	Sep DISC
>A>		@	EQ 100MG BASE	A091002	002	Jun 11, 2014	Sep DISC
>D>	AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	Sep DISC
>A>		@	EQ 150MG BASE	A091002	003	Jun 11, 2014	Sep DISC
	AB	TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Aug NEWA
	AB		EQ 150MG BASE	A091059	003	Aug 28, 2015	Aug NEWA
		TARCEVA					
>D>	AB	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Sep CTEC
>A>			EQ 25MG BASE	N021743	001	Nov 18, 2004	Sep CTEC

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

	@	G AND W LABS INC	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990	Apr CAHN
	@		EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990	Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

	@	ANI PHARMS INC	EQ 200MG BASE/5ML	A062055	001		Jul CAHN
--	---	----------------	-------------------	---------	-----	--	----------

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA		ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	May NEWA
----	--	-------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

ESCITALOPRAM OXALATE

AB		MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015	Apr NEWA
AB			EQ 10MG BASE	A077550	002	May 14, 2015	Apr NEWA
AB			EQ 20MG BASE	A077550	003	May 14, 2015	Apr NEWA
AB		PRINSTON INC	EQ 5MG BASE	A078032	001	Aug 28, 2015	Aug NEWA
AB			EQ 10MG BASE	A078032	002	Aug 28, 2015	Aug NEWA
AB			EQ 20MG BASE	A078032	003	Aug 28, 2015	Aug NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	10MG/ML	A205520	001	Jul 23, 2015	Jul NEWA
AP		LUITPOLD	10MG/ML	A201126	001	Feb 20, 2015	Feb NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	AB	DR REDDYS LABS LTD	EQ 20MG BASE	A078279	001	Sep 25, 2015	Sep NEWA
>A>	AB		EQ 40MG BASE	A078279	002	Sep 25, 2015	Sep NEWA
>A>	AB	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Sep NEWA
>A>	AB		EQ 40MG BASE	A202784	002	Sep 21, 2015	Sep NEWA
	AB	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Jan NEWA
	AB		EQ 40MG BASE	A078003	002	Jan 26, 2015	Jan NEWA
>D>	AB	MYLAN LABS LTD	EQ 20MG BASE	A078936	001	Aug 02, 2015	Sep CAHN
	AB		EQ 20MG BASE	A078936	001	Aug 02, 2015	Jul NEWA
>D>	AB		EQ 40MG BASE	A078936	002	Aug 03, 2015	Sep CAHN
	AB		EQ 40MG BASE	A078936	002	Aug 03, 2015	Jul NEWA
>A>	AB	MYLAN PHARMS INC	EQ 20MG BASE	A078936	001	Aug 02, 2015	Sep CAHN
>A>	AB		EQ 40MG BASE	A078936	002	Aug 03, 2015	Sep CAHN
		NEXIUM					
	AB	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153	001	Feb 20, 2001	Jan CFTG
	AB	+	EQ 40MG BASE	N021153	002	Feb 20, 2001	Jan CFTG

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

>A>	AP	ACCORD HLTHCARE	EQ 40MG BASE/VIAL	A205379	001	Sep 25, 2015	Sep NEWA
-----	----	-----------------	-------------------	---------	-----	--------------	----------

ESOMEPRAZOLE STRONTIUMCAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE STRONTIUMHANMI PHARM CO LTD 24.65MG
+ 49.3MGN202342 001 Aug 06, 2013 Aug CPOT
N202342 002 Aug 06, 2013 Aug CPOTESTRADIOLFILM, EXTENDED RELEASE;TRANSDERMAL
ALORABX ACTAVIS LABS UT INC 0.025MG/24HR
BX 0.05MG/24HR
BX 0.075MG/24HR
BX 0.1MG/24HRN020655 004 Apr 05, 2002 Mar CAHN
N020655 001 Dec 20, 1996 Mar CAHN
N020655 002 Dec 20, 1996 Mar CAHN
N020655 003 Dec 20, 1996 Mar CAHNMINIVELLE
NOVEN 0.025MG/24HR

N203752 005 Sep 23, 2014 Jan NEWA

TABLET;VAGINAL
ESTRADIOL

@ AMNEAL PHARMS 10MCG

A205256 001 May 29, 2015 May DISC

ESZOPICLONETABLET;ORAL
ESZOPICLONEAB MACLEODS PHARMS LTD 1MG
AB 2MG
AB 3MGA202929 001 Jan 30, 2015 Jan NEWA
A202929 002 Jan 30, 2015 Jan NEWA
A202929 003 Jan 30, 2015 Jan NEWAETHACRYNATE SODIUMINJECTABLE;INJECTION
EDECINAP + ATON EQ 50MG BASE/VIAL
ETHACRYNATE SODIUM

N016093 001 Jul CFTG

AP PAR STERILE PRODUCTS EQ 50MG BASE/VIAL

A205473 001 Jul 29, 2015 Jul NEWA

ETHAMBUTOL HYDROCHLORIDETABLET;ORAL
ETHAMBUTOL HYDROCHLORIDEAB VERSAPHARM INC 100MG
AB 400MGA075095 001 Nov 30, 1999 Jan CMFD
A075095 002 Nov 30, 1999 Jan CMFDETHINYL ESTRADIOL; LEVONORGESTRELTABLET;ORAL
ASHLYNAAB GLENMARK GENERICS 0.03MG;0.01MG;0.15MG,N/A
LEVONORGESTREL AND ETHINYL ESTRADIOL

A203163 001 Feb 23, 2015 Feb NEWA

AB GLENMARK GENERICS 0.02MG;0.09MG

A202791 001 Apr 09, 2015 Mar NEWA

AB GLENMARK PHARMS LTD 0.03MG;0.15MG

A203164 001 Jun 12, 2015 Jun NEWA

AB + WATSON LABS 0.02MG;0.09MG

A079218 001 Jun 06, 2011 Mar CTEC

TABLET;ORAL-28

LEVORA 0.15/30-28

AB + WATSON LABS 0.03MG;0.15MG

A073594 001 Dec 13, 1993 Aug CRLD

NORDETTE-28

@ TEVA BRANDED PHARM 0.03MG;0.15MG
VIENVA

N018782 001 Jul 21, 1982 Aug DISC

AB1 SANDOZ INC 0.02MG;0.1MG

A201088 001 May 21, 2015 May NEWA

ETHINYL ESTRADIOL; NORELGESTROMINFILM, EXTENDED RELEASE;TRANSDERMAL
XULANE

AB + MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR

A200910 001 Apr 16, 2014 Feb CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

@ ACTAVIS LABS UT INC 0.035MG;0.5MG
NORINYL 1+35 21-DAY

N017566 001 Mar CAHN

AB ACTAVIS LABS UT INC 0.035MG;1MG
TRI-NORINYL 21-DAY

N017565 001 Feb CAHN

@ ACTAVIS LABS UT INC 0.035MG,0.035MG,0.035MG;0.5MG,1MG,
0.5MG

N018977 001 Apr 13, 1984 Feb CAHN

TABLET;ORAL-28

BREVICON 28-DAY

AB	ACTAVIS LABS UT INC	0.035MG;0.5MG	N017743	001		Mar	CAHN
	NORETHINDRONE AND ETHINYL ESTRADIOL						
AB	FAMY CARE LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Apr	NEWA
AB	+ JAI PHARMA LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Jul	CRLD
	+ NORINYL 1+35 28-DAY	0.05MG;1MG	A203006	001	Aug 05, 2013	Jul	CTEC
AB	ACTAVIS LABS UT INC	0.035MG;1MG	N017565	002		Feb	CAHN
	OVCON-35						
	@ WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001		Jul	DISC
	TRI-NORINYL 28-DAY						
AB	+ ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	002	Apr 13, 1984	Feb	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

FEMHRT

AB	WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Mar	CTEC
	LARIN 24 FE						
AB	NOVAST LABS LTD	0.02MG;1MG	A202994	001	Feb 18, 2015	Feb	NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB	+ BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Mar	CTEC
AB	GLENMARK GENERICS	0.0025MG;0.5MG	A203038	001	Apr 02, 2015	Mar	NEWA
AB		0.005MG;1MG	A203038	002	Apr 02, 2015	Mar	NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	+ AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jan	CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	JAI PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A202132	001	Sep 09, 2015	Aug	NEWA
AB	OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG	A200383	001	Apr 07, 2015	Mar	NEWA
AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015	Mar	NEWA
	TRI-LO-ESTARYLLA						
AB	SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A091232	001	Jun 29, 2015	Jun	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

LOW-OGESTREL-28

AB	WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Feb	CMFD
----	-------------	--------------	---------	-----	--------------	-----	------

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan	CAHN
>A> AB	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Sep	CAHN
>D> AB	ZYDUS PHARMS USA INC	250MG	A200892	001	Sep 25, 2012	Sep	CAHN

ETODOLAC

TABLET;ORAL

ETODOLAC

>D>	@ AAIPHARMA LLC	400MG	A074927	001	Oct 30, 1997	Sep	CAHN
>A>	@ LEHIGH VALLEY	400MG	A074927	001	Oct 30, 1997	Sep	CAHN

ETONOGESTREL

IMPLANT;IMPLANTATION

IMPLANON

@ ORGANON USA INC 68MG/IMPLANT

N021529 001 Jul 17, 2006 Jun DISC

EZETIMIBE

TABLET;ORAL

EZETIMIBE

AB	@ GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Jun	DISC
	ZETIA	10MG	A078560	001	Jun 26, 2015	Jun	NEWA
	+ MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Jun	CTEC
AB	+	10MG	N021445	001	Oct 25, 2002	Jun	CFTG

FAMOTIDINEINJECTABLE;INJECTION
FAMOTIDINE

AP	+	EUROHLTH INTL SARL	10MG/ML	A075488	001	Apr 16, 2001	Jun CAHN
>A>		@	10MG/ML	A075799	001	Apr 30, 2002	Sep CAHN
>D>		@ HIKMA MAPLE	10MG/ML	A075799	001	Apr 30, 2002	Sep CAHN
		FAMOTIDINE PRESERVATIVE FREE					
AP	+	EUROHLTH INTL SARL	10MG/ML	A075486	001	Apr 16, 2001	Jun CAHN
		TABLET;ORAL					
		PEPCID					
AB		VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb CAHN
AB	+		40MG	N019462	002	Oct 15, 1986	Feb CAHN

FELODIPINETABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB		ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May NEWA
AB			5MG	A203032	002	May 21, 2015	May NEWA
AB			10MG	A203032	003	May 21, 2015	May NEWA
AB		SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr CAHN
AB			5MG	A091200	002	Dec 13, 2013	Apr CAHN
AB			10MG	A091200	003	Dec 13, 2013	Apr CAHN

FENOFIBRATECAPSULE;ORAL
FENOFIBRATE

AB		SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr CAHN
AB			130MG	A201748	002	Oct 31, 2014	Apr CAHN
		TABLET;ORAL					
		FENOFIBRATE					
AB		LUPIN LTD	54MG	A204019	001	Aug 17, 2015	Aug NEWA
AB			160MG	A204019	002	Aug 17, 2015	Aug NEWA
AB		SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr CAHN
			107MG	A076635	002	Oct 31, 2005	Apr CAHN
AB			160MG	A076635	003	Oct 31, 2005	Apr CAHN
AB		VALEANT PHARMS NORTH	48MG	A090715	001	Apr 05, 2012	Aug CAHN
AB			145MG	A090715	002	Apr 05, 2012	Aug CAHN

FENOFIBRIC ACIDTABLET;ORAL
FIBRICOR

		TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun CAHN
	+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENTANYLFILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

AB		ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
		FENTANYL-12					
AB		MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun NEWA
		FENTANYL-25					
AB		ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
		FENTANYL-50					
AB		ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
		FENTANYL-75					
AB		ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN

FENTANYL CITRATEFILM;BUCCAL
ONSOLIS

		@ BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar CAHN
		@	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar CAHN
		@	EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar CAHN
		@	EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar CAHN
		@	EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN
----	---	--------------------	-------------------	---------	-----	--------------	----------

FENTANYL HYDROCHLORIDESYSTEM; IONTOPHORESIS, TRANSDERMAL
IONSYS

@ THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr CAHN
+	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun CMFD

FERRIC CITRATETABLET; ORAL
AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan CTNA
---	-----------------	---------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATESOLUTION; IV (INFUSION)
TRIFERIC

+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan NEWA
---	----------------------	----------------------------------	---------	-----	--------------	----------

FIDAXOMICINTABLET; ORAL
DIFICID

+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Aug CAHN
---	-------------------	-------	---------	-----	--------------	----------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr CAHN
AB		100MG	A075882	002	Oct 28, 2002	Apr CAHN
AB		150MG	A075882	003	Oct 28, 2002	Apr CAHN
AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun NEWA
AB		100MG	A202821	002	Jul 08, 2015	Jun NEWA
AB		150MG	A202821	003	Jul 08, 2015	Jun NEWA
AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr CAHN
AB		100MG	A076421	002	Mar 28, 2003	Apr CAHN
AB		150MG	A076421	003	Mar 28, 2003	Apr CAHN

FLIBANSERINTABLET; ORAL
ADDYI

+	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015	Aug NEWA
---	---------------	-------	---------	-----	--------------	----------

FLUCONAZOLEFOR SUSPENSION; ORAL
FLUCONAZOLE

AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr CAHN
AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr CAHN

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr NEWA
		100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr CAHN

TABLET; ORAL

FLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May CMFD
AB		100MG	A078423	002	Mar 07, 2011	May CMFD
AB		150MG	A078423	003	Mar 07, 2011	May CMFD
AB		200MG	A078423	004	Mar 07, 2011	May CMFD

FLUDEOXYGLUCOSE F-18INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	IBA MOLECULAR N AM	20-300mCi/ML	A203591	001	Aug 31, 2015	Aug NEWA
AP	METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr NEWA
AP	MIPS CRF	20-300mCi/ML	A204472	001	Sep 11, 2015	Aug NEWA
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar NEWA
	QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Aug NEWA

	INJECTABLE;INTRAVENOUS						
	FLUDEOXYGLUCOSE F18						
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr	NEWA
AP	UNIV MICHIGAN	20-300mCi/ML	A204531	001	Jul 17, 2015	Jul	NEWA

FLUMAZENIL

	INJECTABLE;INJECTION						
	FLUMAZENIL						
	@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr	CAHN
	@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr	CAHN
AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun	CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun	CAHN

FLUOCINOLONE ACETONIDE

	OIL;TOPICAL						
	FLUOCINOLONE ACETONIDE						
AT	VERSAPHARM INC	0.01%	A091514	001	Jun 25, 2015	Jun	NEWA
	SOLUTION;TOPICAL						
	FLUOCINOLONE ACETONIDE						
AT	GAVIS PHARMS LLC	0.01%	A206422	001	Sep 02, 2015	Aug	NEWA

FLUOCINONIDE

	GEL;TOPICAL						
	FLUOCINONIDE						
AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr	CAHN

FLUOROURACIL

	CREAM;TOPICAL						
	CARAC						
AB	+ VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr	CFTG
	+	0.5%	N020985	001	Oct 27, 2000	Feb	CAHN
	FLUOROURACIL						
AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr	NEWA
>A>	TOLAK						
>A>	+ HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015	Sep	NEWA

FLUOXETINE HYDROCHLORIDE

	CAPSULE;ORAL						
	FLUOXETINE HYDROCHLORIDE						
	@ ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar	DISC
	@	EQ 20MG BASE	A076287	002	May 20, 2008	Mar	DISC
	+ MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CRLD
		EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CTEC
	@ SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar	DISC
	@	EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar	DISC
AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar	NEWA
AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar	NEWA
AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN

FLURANDRENOLIDE

	OINTMENT;TOPICAL						
	CORDRAN						
	+ AQUA PHARMS	0.05%	N012806	001		Jun	CRLD
		0.05%	N012806	001		May	CMFD
	TAPE;TOPICAL						
	CORDRAN						
	+ ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar	CAHN

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

	POWDER;INHALATION						
	BREO ELLIPTA						
	GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr	NEWA

FLUVASTATIN SODIUM

	TABLET, EXTENDED RELEASE;ORAL						
	FLUVASTATIN SODIUM						
AB	MYLAN PHARMS INC	80MG	A202458	001	Sep 11, 2015	Aug	NEWA
	LESCOL XL						
AB	+ NOVARTIS	80MG	N021192	001	Oct 06, 2000	Aug	CFTG

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001	Jul CAHN
	@	25MG	A075898	001	Mar 12, 2001	Jul CAHN
AB		50MG	A075897	002	Jan 25, 2001	Jul CAHN
	@	50MG	A075898	002	Mar 12, 2001	Jul CAHN
AB		100MG	A075897	003	Jan 25, 2001	Jul CAHN
	@	100MG	A075898	003	Mar 12, 2001	Jul CAHN

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Aug CAHN
AA	NUVO PHARM INC	1MG	A204418	001	Jul 28, 2015	Jul NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Apr CAHN
AB		20MG;12.5MG	A076739	002	Dec 17, 2004	Apr CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

	@ IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar CAHN
	@	10MG/ML	A070096	001	Sep 09, 1985	Mar CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr CAHN
AB		300MG	A076606	002	Oct 07, 2005	Apr CAHN
AB		400MG	A076606	003	Oct 07, 2005	Apr CAHN

TABLET; ORAL

GABAPENTIN

	@ HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jun DISC
	@	800MG	A078782	002	Jul 21, 2011	Jun DISC

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb CAHN
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb CAHN
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb CAHN
	OPTIMARK IN PLASTIC CONTAINER					
+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb CAHN
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb CAHN

GEFITINIB

TABLET; ORAL

IRESSA

+	ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015	Jul NEWA
---	--------------------	-------	---------	-----	--------------	----------

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB	AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015	Aug NEWA
----	----------------------	-------	---------	-----	--------------	----------

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

AB	+ LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun CFTG
	GEMIFLOXACIN MESYLATE					
AB	ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun NEWA

GLATIRAMER ACETATEINJECTABLE;SUBCUTANEOUS
COPAXONE

AP	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar CFTG
AP		SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar NEWA

GLIMEPIRIDETABLET;ORAL
GLIMEPIRIDE

@	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr DISC
@		2MG	A078952	002	Aug 01, 2013	Apr DISC
@		4MG	A078952	003	Aug 01, 2013	Apr DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATETABLET;ORAL
AVANDARYL

@	SB PHARMCO	1MG; 4MG	N021700	001	Nov 23, 2005	Jun DISC
@		2MG; 4MG	N021700	002	Nov 23, 2005	Jun DISC
@		2MG; 8MG	N021700	004	Mar 30, 2007	Jun DISC
@		4MG; 4MG	N021700	003	Nov 23, 2005	Jun DISC
@		4MG; 8MG	N021700	005	Mar 30, 2007	Jun DISC

GLIPIZIDETABLET;ORAL
GLIPIZIDE

@	ANI PHARMS INC	5MG	A074387	001	Mar 04, 1996	Aug CAHN
@		10MG	A074387	002	Mar 04, 1996	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL
GLIPIZIDE

AB		MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May NEWA
AB			5MG	A202298	002	May 19, 2015	May NEWA
AB			10MG	A202298	003	May 19, 2015	May NEWA

GLUCAGON HYDROCHLORIDEPOWDER;INTRAMUSCULAR, INTRAVENOUS
GLUCAGON

+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May NEWA
---	--------------------	------------------	---------	-----	--------------	----------

GLYBURIDETABLET;ORAL
DIABETA

>D>	BX		SANOFI AVENTIS US	1.25MG	N017532	001	May 01, 1984	Sep CFTG
>A>	AB2			1.25MG	N017532	001	May 01, 1984	Sep CFTG
>D>	BX			2.5MG	N017532	002	May 01, 1984	Sep CFTG
>A>	AB2			2.5MG	N017532	002	May 01, 1984	Sep CFTG
>D>	BX	+		5MG	N017532	003	May 01, 1984	Sep CFTG
>A>	AB2	+		5MG	N017532	003	May 01, 1984	Sep CFTG

GLYBURIDE

>D>	AB		AUROBINDO PHARMA	1.25MG	A077537	001	Oct 18, 2007	Sep CTEC
>A>	AB1			1.25MG	A077537	001	Oct 18, 2007	Sep CTEC
>D>	AB			2.5MG	A077537	002	Oct 18, 2007	Sep CTEC
>A>	AB1			2.5MG	A077537	002	Oct 18, 2007	Sep CTEC
>D>	AB			5MG	A077537	003	Oct 18, 2007	Sep CTEC
>A>	AB1			5MG	A077537	003	Oct 18, 2007	Sep CTEC
>D>	AB		COREPHARMA	1.25MG	A076257	001	Jun 27, 2002	Sep CTEC
>A>	AB1			1.25MG	A076257	001	Jun 27, 2002	Sep CTEC
>A>	AB2			1.25MG	A206079	001	Sep 30, 2015	Sep NEWA
>D>	AB			2.5MG	A076257	002	Jun 27, 2002	Sep CTEC
>A>	AB1			2.5MG	A076257	002	Jun 27, 2002	Sep CTEC
>A>	AB2			2.5MG	A206079	002	Sep 30, 2015	Sep NEWA
>D>	AB			5MG	A076257	003	Jun 27, 2002	Sep CTEC
>A>	AB1			5MG	A076257	003	Jun 27, 2002	Sep CTEC
>A>	AB2			5MG	A206079	003	Sep 30, 2015	Sep NEWA
>D>	AB		HERITAGE PHARMS INC	1.25MG	A090937	001	Feb 28, 2011	Sep CTEC
>A>	AB1			1.25MG	A090937	001	Feb 28, 2011	Sep CTEC
>D>	AB			2.5MG	A090937	002	Feb 28, 2011	Sep CTEC
>A>	AB1			2.5MG	A090937	002	Feb 28, 2011	Sep CTEC
>D>	AB			5MG	A090937	003	Feb 28, 2011	Sep CTEC
>A>	AB1			5MG	A090937	003	Feb 28, 2011	Sep CTEC
>D>	AB		TEVA	1.25MG	A074388	001	Aug 29, 1995	Sep CTEC

TABLET;ORAL
GLYBURIDE

>A>	AB1	1.25MG	A074388	001	Aug 29, 1995	Sep CTEC
>D>	AB	2.5MG	A074388	002	Aug 29, 1995	Sep CTEC
>A>	AB1	2.5MG	A074388	002	Aug 29, 1995	Sep CTEC
>D>	AB +	5MG	A074388	003	Aug 29, 1995	Sep CTEC
>A>	AB1 +	5MG	A074388	003	Aug 29, 1995	Sep CTEC

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL
RAVICTI

+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May CAHN
---	---------------------	----------	---------	-----	--------------	----------

GLYCOPYRROLATE

INJECTABLE;INJECTION
ROBINUL

AP	+	EUROHLTH INTL SARL	0.2MG/ML	N017558	001	Jun CAHN
----	---	--------------------	----------	---------	-----	----------

TABLET;ORAL
GLYCOPYRROLATE

AA		SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr CAHN
AA			2MG	A040844	002	Aug 18, 2009	Apr CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION
GRANISETRON HYDROCHLORIDE

AP		BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@	CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr CAHN
	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr CAHN
AP		EUROHLTH INTL SARL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun CAHN
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
FLOWTUSS

>D>		MIKART INC	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	Sep CAHN
			200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	May NEWA
>A>		MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL
HYCOFENIX

+	MIKART INC	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	May NEWA
---	------------	------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May NEWA
AB			EQ 2MG BASE	A202578	002	Jun 02, 2015	May NEWA
AB			EQ 3MG BASE	A202578	003	Jun 02, 2015	May NEWA
AB			EQ 4MG BASE	A202578	004	Jun 02, 2015	May NEWA
AB		SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May NEWA
AB			EQ 2MG BASE	A202568	002	Jun 03, 2015	May NEWA
AB			EQ 3MG BASE	A202568	003	Jun 03, 2015	May NEWA
AB			EQ 4MG BASE	A202568	004	Jun 03, 2015	May NEWA
AB		TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May NEWA
AB			EQ 2MG BASE	A201382	002	Jun 02, 2015	May NEWA
AB			EQ 3MG BASE	A201382	003	Jun 02, 2015	May NEWA
AB			EQ 4MG BASE	A201382	004	Jun 02, 2015	May NEWA
AB		TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May NEWA
AB			EQ 2MG BASE	A201408	002	Jun 02, 2015	May NEWA
AB			EQ 3MG BASE	A201408	003	Jun 02, 2015	May NEWA
AB			EQ 4MG BASE	A201408	004	Jun 02, 2015	May NEWA

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL

@	CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May CAHN
@		1MG	A071129	001	Feb 17, 1987	Jun CAHN
@		5MG	A071131	001	Feb 17, 1987	Jun CAHN

TABLET; ORAL
HALOPERIDOL

@	10MG	A071132	001	May 12, 1987	Jun CAHN
@	20MG	A071133	001	May 12, 1987	May CAHN
@ ROXANE	2MG	A071130	001	Feb 17, 1987	Jun CAHN

HALOPERIDOL LACTATECONCENTRATE; ORAL
HALOPERIDOL INTENSOL

@ CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May CAHN
--------------------	----------------	---------	-----	--------------	----------

INJECTABLE; INJECTION
HALOPERIDOL

@ CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr CAHN
@	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May CAHN

HEPARIN SODIUMINJECTABLE; INJECTION
HEPARIN SODIUM

	@ EUROHLTH INTL SARL	1,000 UNITS/ML	N017007	001		Aug CAHN
AP	+	1,000 UNITS/ML	N017037	001		Jun CAHN
	@	2,500 UNITS/ML	N017007	007		Aug CAHN
	@	5,000 UNITS/ML	N017007	002		Aug CAHN
	@	5,000 UNITS/0.5ML	N017007	010		Aug CAHN
AP	+	5,000 UNITS/ML	N017037	002		Jun CAHN
	@	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jun CAHN
	@	7,500 UNITS/ML	N017007	003		Aug CAHN
	@	10,000 UNITS/ML	N017007	004		Aug CAHN
AP	+	10,000 UNITS/ML	N017037	003		Jun CAHN
	@	15,000 UNITS/ML	N017007	005		Aug CAHN
	@	20,000 UNITS/ML	N017007	006		Aug CAHN

HYDRALAZINE HYDROCHLORIDEINJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb CRLD
AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb CRLD
AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015	Jun NEWA

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>A>	@ HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010	Sep CAHN
>A>	@	25MG	A040858	002	Feb 26, 2010	Sep CAHN
>A>	@	50MG	A040858	003	Feb 26, 2010	Sep CAHN
>A>	@	100MG	A040858	004	Feb 26, 2010	Sep CAHN
>D>	@ ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010	Sep CAHN
>D>	@	25MG	A040858	002	Feb 26, 2010	Sep CAHN
>D>	@	50MG	A040858	003	Feb 26, 2010	Sep CAHN
>D>	@	100MG	A040858	004	Feb 26, 2010	Sep CAHN

HYDROCHLOROTHIAZIDECAPSULE; ORAL
HYDROCHLOROTHIAZIDE

@ SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014	Aug DISC
----------------------	--------	---------	-----	--------------	----------

MICROZIDE

AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb CAHN
----	---	---------------------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	12.5MG; 10MG	A076007	001	Jul 01, 2002	Apr CAHN
AB			12.5MG; 20MG	A076007	002	Jul 01, 2002	Apr CAHN
AB			25MG; 20MG	A076007	003	Jul 01, 2002	Apr CAHN

ZESTORETIC

AB		ALVOGEN IPCO SARL	12.5MG; 10MG	N019888	003	Nov 18, 1993	Feb CAHN
AB	+		12.5MG; 20MG	N019888	001	Sep 20, 1990	Feb CAHN
AB	+		25MG; 20MG	N019888	002	Jul 20, 1989	Feb CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATETABLET, EXTENDED RELEASE; ORAL
DUTOPROL

	CONCORDIA PHARMS INC	12.5MG; EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun CAHN
		12.5MG; EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun CAHN
+		12.5MG; EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ ANI PHARMS INC	25MG;40MG	A070704	001	Oct 01, 1986	Jul	CAHN
AB		25MG;40MG	A072042	001	Mar 14, 1988	Aug	CAHN
	@	25MG;80MG	A070705	001	Oct 01, 1986	Jul	CAHN
AB		25MG;80MG	A072043	001	Mar 14, 1988	Aug	CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Apr	CAHN
AB		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Apr	CAHN
AB		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Apr	CAHN

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC 25MG;37.5MG

A074970 001 Jan 06, 1998 Aug CAHN

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	ANI PHARMS INC	50MG;75MG	A073467	001	Jan 31, 1996	Aug	CAHN
----	----------------	-----------	---------	-----	--------------	-----	------

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013	Apr	CAHN
		15MG	N202880	002	Oct 25, 2013	Apr	CAHN
		20MG	N202880	003	Oct 25, 2013	Apr	CAHN
		30MG	N202880	004	Oct 25, 2013	Apr	CAHN
		40MG	N202880	005	Oct 25, 2013	Apr	CAHN
		50MG	N202880	006	Oct 25, 2013	Apr	CAHN
+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Jun	CAHN
		15MG	N202880	002	Oct 25, 2013	Jun	CAHN
		20MG	N202880	003	Oct 25, 2013	Jun	CAHN
		30MG	N202880	004	Oct 25, 2013	Jun	CAHN
		40MG	N202880	005	Oct 25, 2013	Jun	CAHN
		50MG	N202880	006	Oct 25, 2013	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA

+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar	CRLD
---	------------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

AT	RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar	CAHN
----	-------------------	------	---------	-----	--------------	-----	------

POWDER;FOR RX COMPOUNDING

HYDRO-RX

@ X GEN PHARMS 100%

A085982 001 Apr DISC

TABLET;ORAL

HYDROCORTISONE

AB	HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb	NEWA
AB		10MG	A083365	003	Feb 23, 2015	Feb	NEWA
AB		20MG	A083365	001		Feb	CMFD

HYDROCORTISONE ACETATE

POWDER;FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

@ X GEN PHARMS 100%

A085981 001 Apr DISC

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

@ G AND W LABS INC 0.2%

A074489 001 Aug 12, 1998 Apr CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS;OTIC
CORTISPORIN

AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001			Jun CMS2
----	---	-------------------	-------------------------------------	---------	-----	--	--	----------

HYDROMORPHONE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
HYDROMORPHONE HYDROCHLORIDE

AB		PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar	NEWA
AB			12MG	A204278	002	Apr 06, 2015	Mar	NEWA
AB			16MG	A204278	003	Apr 06, 2015	Mar	NEWA

HYDROXOCOBALAMININJECTABLE;INJECTION
CYANOKIT

	@	SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr	CAHN
	+		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	CAHN

HYDROXYCHLOROQUINE SULFATETABLET;ORAL
PLAQUENIL

AB	+	CONCORDIA PHARMS INC	200MG	N009768	001		Jun	CAHN
----	---	----------------------	-------	---------	-----	--	-----	------

HYDROXYPROGESTERONE CAPROATEINJECTABLE;INJECTION
HYDROXYPROGESTERONE CAPROATE

	@	ACTAVIS LABS UT INC	125MG/ML	N017439	001		Mar	CAHN
	@		250MG/ML	N017439	002		Mar	CAHN
	+	MCGUFF	250MG/ML	A200271	001	Aug 24, 2015	Aug	NEWA

HYDROXYZINE HYDROCHLORIDETABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

AB		ELITE LABS INC	10MG	A040600	001	Dec 28, 2004	Jun	CAHN
AB			25MG	A040602	001	Dec 28, 2004	Jun	CAHN
AB			50MG	A040604	001	Dec 28, 2004	Jun	CAHN
AB		HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar	CAHN
AB			25MG	A204279	002	Aug 20, 2014	Mar	CAHN
AB			50MG	A204279	003	Aug 20, 2014	Mar	CAHN
AB		MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar	CMFD
AB			25MG	A040602	001	Dec 28, 2004	Mar	CMFD
AB			50MG	A040604	001	Dec 28, 2004	Mar	CMFD
	@	MUTUAL PHARM	10MG	A089381	001	May 19, 1986	Jul	DISC
	@		25MG	A089382	001	May 19, 1986	Jul	DISC
	@		50MG	A089383	001	May 19, 1986	Jul	DISC
	@	WATSON LABS	10MG	A088348	001	Sep 15, 1983	Jul	DISC
	@		25MG	A088349	001	Sep 15, 1983	Jul	DISC
	@		50MG	A088350	001	Sep 15, 1983	Jul	DISC

HYDROXYZINE PAMOATECAPSULE;ORAL
HYDROXYZINE PAMOATE

AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CAHN
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CAHN

IBANDRONATE SODIUMINJECTABLE;INTRAVENOUS
IBANDRONATE SODIUM

AP		AUROBINDO PHARMA LTD	EQ 3MG BASE/3ML	A205332	001	Aug 19, 2015	Aug	NEWA
----	--	----------------------	-----------------	---------	-----	--------------	-----	------

IBUPROFENTABLET;ORAL
IBUPROFEN

AB		GRANULES INDIA LTD	400MG	A091625	001	Sep 15, 2015	Aug	NEWA
AB			600MG	A091625	002	Sep 15, 2015	Aug	NEWA
AB			800MG	A091625	003	Sep 15, 2015	Aug	NEWA
	@	VINTAGE PHARMS	300MG	A071230	001	Oct 22, 1986	Jul	DISC
	@		400MG	A071231	001	Oct 22, 1986	Jul	DISC
	@		600MG	A071232	001	Oct 22, 1986	Jul	DISC
	@		800MG	A072004	001	Nov 18, 1987	Jul	DISC

ILOPERIDONE

TABLET; ORAL

FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan CAHN
		2MG	N022192	002	May 06, 2009	Jan CAHN
		4MG	N022192	003	May 06, 2009	Jan CAHN
		6MG	N022192	004	May 06, 2009	Jan CAHN
		8MG	N022192	005	May 06, 2009	Jan CAHN
		10MG	N022192	006	May 06, 2009	Jan CAHN
		12MG	N022192	007	May 06, 2009	Jan CAHN

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr CAHN
----	------------------	----	---------	-----	--------------	----------

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AB	ANI PHARMS INC	1.25MG	A074299	002	Apr 29, 1996	Jul CAHN
	@	1.25MG	A074498	002	Feb 12, 1998	Jul CAHN
AB		2.5MG	A074299	001	Jul 27, 1995	Jul CAHN
	@	2.5MG	A074498	001	Oct 31, 1996	Jul CAHN

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

>A> AB	JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015	Sep NEWA
--------	-------------------	------	---------	-----	--------------	----------

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

+	LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	May CRLD
---	---------------	--------	---------	-----	--------------	----------

>A> INSULIN DEGLUDEC

SOLUTION; SUBCUTANEOUS

RYZODEG 70/30

>A>	+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N203313	001	Sep 25, 2015	Sep NEWA
>A>		TRESIBA					
>A>		NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N203314	001	Sep 25, 2015	Sep NEWA
>A>	+		600 UNITS/3ML (200 UNITS/ML)	N203314	002	Sep 25, 2015	Sep NEWA

INSULIN GLARGINE RECOMBINANT

SOLUTION; SUBCUTANEOUS

TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Feb NEWA
---	--------------------	-----------------------------	---------	-----	--------------	----------

INSULIN LISPRO RECOMBINANT

SOLUTION; SUBCUTANEOUS

HUMALOG KWIKPEN

+	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015	May NEWA
---	------------------	--------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

AFREZZA

	SANOFI AVENTIS	12 UNITS/INH	N022472	003	Apr 17, 2015	Apr NEWA
--	----------------	--------------	---------	-----	--------------	----------

IOHEXOL

FOR SOLUTION; ORAL

ORALTAG

	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar NEWA
--	----------------------	-----------	---------	-----	--------------	----------

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-250

@	FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan DISC
	IOPAMIDOL-300					
@	FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997	Jan DISC
	IOPAMIDOL-370					
@	FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997	Jan DISC

INJECTABLE; INJECTION							
ISOVUE-200							
+	BRACCO	41%	N018735	006	Jul 07, 1987	Feb	CTEC
ISOVUE-250							
+	BRACCO	51%	N018735	007	Jul 06, 1992	Feb	CTEC
+		51%	N020327	002	Oct 12, 1994	Feb	CTEC
ISOVUE-300							
+	BRACCO	61%	N020327	003	Oct 12, 1994	Feb	CTEC
ISOVUE-370							
+	BRACCO	76%	N020327	004	Oct 12, 1994	Feb	CTEC
SCANLUX-300							
AP	MYLAN INSTITUTIONAL	61%	A090394	001	Jun 18, 2010	Aug	CAHN
SCANLUX-370							
AP	MYLAN INSTITUTIONAL	76%	A090394	002	Jun 18, 2010	Aug	CAHN
<u>IOTHALAMATE MEGLUMINE</u>							
INJECTABLE; INJECTION							
CONRAY							
+	LIEBEL-FLARSHEIM	60%	N013295	001		Feb	CAHN
CONRAY 30							
+	LIEBEL-FLARSHEIM	30%	N016983	001		Feb	CAHN
CONRAY 43							
+	LIEBEL-FLARSHEIM	43%	N013295	002		Feb	CAHN
SOLUTION; INTRAVESICAL							
CYSTO-CONRAY II							
	LIEBEL-FLARSHEIM	17.2%	N017057	002		Feb	CAHN
<u>IOVERSOL</u>							
INJECTABLE; INJECTION							
OPTIRAY 160							
@	LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988	Feb	CAHN
OPTIRAY 240							
+	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	Feb	CAHN
@		51%	N020923	001	May 28, 1998	Feb	CAHN
OPTIRAY 300							
+	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992	Feb	CAHN
+		64%	N020923	004	May 13, 1999	Feb	CAHN
OPTIRAY 320							
+	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	Feb	CAHN
@		68%	N020923	002	May 29, 1998	Feb	CAHN
OPTIRAY 350							
+	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	Feb	CAHN
+		74%	N020923	003	May 28, 1998	Feb	CAHN
<u>IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM</u>							
INJECTABLE; INJECTION							
HEXABRIX							
@	GUERBET	39.3%; 19.6%	N018905	002	Jul 26, 1985	May	DISC
<u>IRBESARTAN</u>							
TABLET; ORAL							
IRBESARTAN							
AB	JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015	Feb	NEWA
AB		150MG	A203534	002	Feb 23, 2015	Feb	NEWA
AB		300MG	A203534	003	Feb 23, 2015	Feb	NEWA
<u>IRON DEXTRAN</u>							
INJECTABLE; INJECTION							
INFED							
BP	ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001		Mar	CAHN
<u>ISAVUCONAZONIUM SULFATE</u>							
CAPSULE; ORAL							
CRESEMBA							
+	ASTELLAS	186MG	N207500	001	Mar 06, 2015	Mar	NEWA
POWDER; IV (INFUSION)							
CRESEMBA							
+	ASTELLAS	372MG	N207501	001	Mar 06, 2015	Mar	NEWA

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB	VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb CAHN
+		40MG	N012093	001	Jul 29, 1988	Feb CAHN

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

	RANBAXY	25MG	N021951	005	Aug 15, 2014	Feb NEWA
		35MG	N021951	006	Aug 15, 2014	Feb NEWA

MYORISAN

AB	DOUGLAS PHARMS	30MG	A076485	004	Aug 25, 2015	Aug NEWA
----	----------------	------	---------	-----	--------------	----------

SOTRET

AB	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr CAHN
AB		20MG	A076041	002	Dec 24, 2002	Apr CAHN
AB		30MG	A076503	001	Jun 20, 2003	Apr CAHN
AB		40MG	A076041	003	Dec 24, 2002	Apr CAHN

ZENATANE

AB	DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb NEWA
----	--------------------	------	---------	-----	--------------	----------

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB	ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar CAHN
AB		5MG	A077169	002	Apr 24, 2006	Mar CAHN

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Apr NEWA
+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr NEWA

IVACAFTOR

GRANULE; ORAL

KALYDECO

	VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015	Mar NEWA
+		75MG/PACKET	N207925	002	Mar 17, 2015	Mar NEWA

IVACAFTOR; LUMACAFTOR

TABLET; ORAL

ORKAMBI

+	VERTEX PHARMS INC	125MG; 200MG	N206038	001	Jul 02, 2015	Jul NEWA
---	-------------------	--------------	---------	-----	--------------	----------

IXABEPILONE

INJECTABLE; IV (INFUSION)

IXEMPRA KIT

+	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007	Jun CAHN
+		45MG/VIAL	N022065	002	Oct 16, 2007	Jun CAHN

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN

@	EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324	001		Jun CAHN
@		EQ 500MG BASE/2ML	A062324	002		Jun CAHN
@		EQ 1GM BASE/3ML	A062324	003		Jun CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>A> AP	BD RX	15MG/ML	A203242	001	Oct 07, 2015	Sep NEWA
>A> AP		30MG/ML	A203242	002	Oct 07, 2015	Sep NEWA
	@ CLARIS PHARMASERVICE	15MG/ML	A075631	002	Jun 29, 2001	Apr CAHN
	@	30MG/ML	A075631	001	Jun 29, 2001	Apr CAHN
	@ EUROHLTH INTL SARL	15MG/ML	A075772	001	Jul 21, 2004	Jun CAHN
	@	30MG/ML	A075772	002	Jul 21, 2004	Jun CAHN

SPRAY, METERED; NASAL

SPRIX

+	EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010	Jan CAHN
---	---------------	---------------	---------	-----	--------------	----------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

+	OMEROS	EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Feb CPOT
---	--------	--------------------------------------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

@ CLARIS PHARMASERVICE 5MG/ML

A076051	001	Jul 05, 2002	Apr CAHN
---------	-----	--------------	----------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999	Jan CMFD
AB		200MG	A075215	002	Jul 29, 1999	Jan CMFD
AB		300MG	A075215	003	Jul 29, 1999	Jan CMFD

LACTULOSE

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	BIO-PHARM INC	10GM/15ML	A203762	001	Mar 27, 2015	Mar NEWA
----	---------------	-----------	---------	-----	--------------	----------

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET; ORAL

DUTREBIS

@ MERCK SHARP DOHME 150MG; EQ 300MG BASE

N206510	001	Feb 06, 2015	Aug DISC
---------	-----	--------------	----------

+ 150MG; EQ 300MG BASE

N206510	001	Feb 06, 2015	Feb NEWA
---------	-----	--------------	----------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	HETERO LABS LTD III	150MG; 300MG	A079124	001	Sep 17, 2015	Aug NEWA
AB	STRIDES ARCOLAB LTD	150MG; 300MG	A079128	001	May 13, 2015	Apr NEWA
AB	STRIDES PHARMA	150MG; 300MG	A079128	001	May 13, 2015	Aug CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ HIKMA PHARMS 25MG

A078134	001	Apr 19, 2011	May DISC
---------	-----	--------------	----------

@ 100MG

A078134	002	Apr 19, 2011	May DISC
---------	-----	--------------	----------

@ 150MG

A078134	003	Apr 19, 2011	May DISC
---------	-----	--------------	----------

@ 200MG

A078134	004	Apr 19, 2011	May DISC
---------	-----	--------------	----------

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar CAHN
---	----------------------	---------------	---------	-----	--------------	----------

LENVATINIB MESYLATE

CAPSULE; ORAL

LENVIMA

EISAI INC EQ 4MG BASE

N206947	001	Feb 13, 2015	Feb NEWA
---------	-----	--------------	----------

+ EQ 10MG BASE

N206947	002	Feb 13, 2015	Feb NEWA
---------	-----	--------------	----------

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jul NEWA
----	--------------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

LEVETIRACETAM

AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May NEWA
----	-------------	----------	---------	-----	--------------	----------

TABLET; ORAL

SPRITAM

APRECIA PHARMS CO 250MG

N207958	001	Jul 31, 2015	Jul NEWA
---------	-----	--------------	----------

500MG

N207958	002	Jul 31, 2015	Jul NEWA
---------	-----	--------------	----------

750MG

N207958	003	Jul 31, 2015	Jul NEWA
---------	-----	--------------	----------

1GM

N207958	004	Jul 31, 2015	Jul NEWA
---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

APOTEX INC 1GM

A202958	001	Feb 25, 2015	Feb NEWA
---------	-----	--------------	----------

AB	DEXCEL PHARMA	500MG	A202167	001	Sep 04, 2015	Aug NEWA
----	---------------	-------	---------	-----	--------------	----------

AB		750MG	A202167	002	Sep 04, 2015	Aug NEWA
----	--	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

AB	PHARMADAX INC	500MG	A201464	001	May 25, 2012	Aug CAHN
AB		750MG	A201464	002	May 25, 2012	Aug CAHN
AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May NEWA
AB		750MG	A203468	002	May 21, 2015	May NEWA

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

@	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr DISC
---	-----------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb NEWA
AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr CAHN
AP	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015	Jul NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015	Jul NEWA
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr CAHN
AP	HOSPIRA INC	EQ 250MG/50ML (EQ 5MG/ML)	A078579	001	Sep 03, 2015	Aug NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A078579	002	Sep 03, 2015	Aug NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A078579	003	Sep 03, 2015	Aug NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT	+ NEXUS PHARMS	0.5%	A077700	001	Dec 20, 2010	Jul CRLD
	QUIXIN					
	@ SANTEN	0.5%	N021199	001	Aug 18, 2000	Jul DISC

TABLET;ORAL

LEVOFLOXACIN

AB	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun NEWA
AB		500MG	A203613	002	Jun 19, 2015	Jun NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

	SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb NEWA
	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb NEWA
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

LILETTA

	MEDICINES360	52MG	N206229	001	Feb 26, 2015	Feb NEWA
--	--------------	------	---------	-----	--------------	----------

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

+	SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000	Apr CAHN
---	---------------------	-----	---------	-----	--------------	----------

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	AMNEAL PHARMS	5%	A206297	001	Aug 07, 2015	Jul NEWA
>A>	@ BELMORA LLC	5%	A080210	001		Sep CAHN
>D>	@ GRAHAM CHEM	5%	A080210	001		Sep CAHN

PATCH;TOPICAL

LIDOCAINE

AB	ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar CAHN
AB	MYLAN TECHNOLOGIES	5%	A202346	001	Aug 07, 2015	Jul NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION									
LIDOCAINE HYDROCHLORIDE									
AP	@	EUROHLTH INTL SARL	1%	A080407	001			Mar	CAHN
	@		2%	A080407	002			Mar	CAHN
		LUITPOLD	1%	A091564	001	Aug 14, 2015		Aug	NEWA
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE								
	@	EUROHLTH INTL SARL	1%	A084625	001			Feb	CAHN
	@		2%	A084625	002			Feb	CAHN
JELLY; TOPICAL									
ANESTACON									
	@	BANNER LIFE SCIENCES	2%	A080429	001			Jan	CAHN
LIDOCAINE HYDROCHLORIDE									
	@	G AND W LABS INC	2%	A081318	001	Apr 29, 1993		Apr	CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL									
EMLA									
AB	+	ACTAVIS LABS UT INC	2.5%; 2.5%	N019941	001	Dec 30, 1992		Feb	CAHN

LINACLOTIDE

CAPSULE; ORAL									
LINZESS									
		FOREST LABS LLC	145MCG	N202811	001	Aug 30, 2012		Mar	CAHN
	+		290MCG	N202811	002	Aug 30, 2012		Mar	CAHN

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION									
LINCOCIN									
AP	+	PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001			May	CFTG
LINCOMYCIN									
AP		X-GEN PHARMS INC	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015		May	NEWA

LINEZOLID

FOR SUSPENSION; ORAL									
LINEZOLID									
AB		ROXANE	100MG/5ML	A200068	001	Jun 03, 2015		May	NEWA
ZYVOX									
AB	+	PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000		May	CFTG
SOLUTION; IV (INFUSION)									
LINEZOLID									
AP		HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015		Jun	NEWA
AP		SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015		Jul	NEWA
AP			600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015		Jul	NEWA
AP		TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012		May	CDFR
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
	+	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015		Jun	NEWA
ZYVOX									
AP		PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000		Jul	CTEC
			200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000		May	CDFR
			400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000		May	NEWA
AP	+		600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000		May	NEWA
TABLET; ORAL									
LINEZOLID									
AB		TEVA PHARMS USA	600MG	A078061	001	May 18, 2015		May	NEWA
ZYVOX									
AB	+	PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000		May	CFTG

LISINAPRIL

TABLET; ORAL									
LISINAPRIL									
AB		SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002		Apr	CAHN
AB			5MG	A075944	002	Jul 01, 2002		Apr	CAHN
AB			10MG	A075944	003	Jul 01, 2002		Apr	CAHN
AB			20MG	A075944	004	Jul 01, 2002		Apr	CAHN
AB			30MG	A075944	006	Feb 11, 2003		Apr	CAHN
AB			40MG	A075944	005	Jul 01, 2002		Apr	CAHN
ZESTRIL									
AB		ALVOGEN IPCO SARL	2.5MG	N019777	005	Apr 29, 1993		Feb	CAHN
AB			5MG	N019777	001	May 19, 1988		Feb	CAHN

TABLET;ORAL									
ZESTRIL									
AB		10MG	N019777	002	May 19, 1988		Feb	CAHN	
AB		20MG	N019777	003	May 19, 1988		Feb	CAHN	
AB		30MG	N019777	006	Jan 20, 1999		Feb	CAHN	
AB	+	40MG	N019777	004	May 19, 1988		Feb	CAHN	
<u>LITHIUM CARBONATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
LITHIUM CARBONATE									
AB	ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015		May	NEWA	
	@ HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003		Feb	DISC	
AB	UNIQUE PHARM LABS	300MG	A204779	001	Jul 27, 2015		Jul	NEWA	
<u>LOMITAPIDE MESYLATE</u>									
CAPSULE;ORAL									
JUXTAPID									
	AEGERION	EQ 30MG BASE	N203858	004	Apr 23, 2015		Apr	NEWA	
		EQ 40MG BASE	N203858	005	Apr 23, 2015		Apr	NEWA	
		EQ 60MG BASE	N203858	006	Apr 23, 2015		Apr	NEWA	
<u>LOMUSTINE</u>									
CAPSULE;ORAL									
GLEOSTINE									
	CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014		Jan	NEWA	
<u>LOPERAMIDE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
IMODIUM									
	@ J AND J CONSUMER INC	2MG	N017690	001			Jul	CAHN	
AB	+	2MG	N017694	001			Jul	CAHN	
<u>LOPINAVIR; RITONAVIR</u>									
CAPSULE;ORAL									
KALETRA									
	@ ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000		Jun	DISC	
<u>LORAZEPAM</u>									
INJECTABLE;INJECTION									
ATIVAN									
AP	+ EUROHLTH INTL SARL	2MG/ML	N018140	001			Jun	CAHN	
AP	+	4MG/ML	N018140	002			Jun	CAHN	
TABLET;ORAL									
LORAZEPAM									
AB	SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001		Apr	CAHN	
AB		1MG	A076045	002	Aug 29, 2001		Apr	CAHN	
AB		2MG	A076045	003	Aug 29, 2001		Apr	CAHN	
<u>LOSARTAN POTASSIUM</u>									
TABLET;ORAL									
LOSARTAN POTASSIUM									
AB	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015		Jul	NEWA	
AB		50MG	A203835	002	Aug 12, 2015		Jul	NEWA	
AB		100MG	A203835	003	Aug 12, 2015		Jul	NEWA	
AB	WATSON LABS	25MG	A091129	001	Oct 06, 2010		Feb	CMFD	
AB		50MG	A091129	002	Oct 06, 2010		Feb	CMFD	
AB		100MG	A091129	003	Oct 06, 2010		Feb	CMFD	
<u>LOVASTATIN</u>									
TABLET, EXTENDED RELEASE;ORAL									
ALTOPREV									
	@ COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002		May	CAHN	
		20MG	N021316	002	Jun 26, 2002		May	CAHN	
		40MG	N021316	003	Jun 26, 2002		May	CAHN	
	+	60MG	N021316	004	Jun 26, 2002		May	CAHN	
<u>LOXAPINE HYDROCHLORIDE</u>									
CONCENTRATE;ORAL									
LOXITANE C									
	@ ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001			Mar	CAHN	

INJECTABLE; INJECTION

LOXITANE IM

@ ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001		Mar	CAHN
-----------------------	-----------------	---------	-----	--	-----	------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

AB	ELITE LABS INC	EQ 5MG BASE	A076868	001	Aug 04, 2005	May	CAHN
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May	CAHN
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May	CAHN
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May	CAHN

LOXITANE

@ ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Mar	CAHN
@	EQ 10MG BASE	N017525	002		Mar	CAHN
@	EQ 25MG BASE	N017525	003		Mar	CAHN
@	EQ 50MG BASE	N017525	004		Mar	CAHN

TABLET; ORAL

LOXITANE

@ ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar	CAHN
@	EQ 25MG BASE	N017525	007		Mar	CAHN
@	EQ 50MG BASE	N017525	008		Mar	CAHN

LUCINACTANTSUSPENSION; INTRATRACHEAL
SURFAXIN

@ DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May	DISC
------------------	-------	---------	-----	--------------	-----	------

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	32MG/100ML; 128MG/100ML; 234MG/100ML	N019047	001	Jun 15, 1984	Mar	DISC
-------------------	--------------------------------------	---------	-----	--------------	-----	------

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr	CDFR
AP	+ FRESENIUS KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr	CPOT
AP	+ HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr	CDFR
	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr	NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+ FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr	NEWA
----------------------	--------------------	---------	-----	--------------	-----	------

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

@ BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A; N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013	Aug	DISC
------------------	--	---------	-----	--------------	-----	------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

@ IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar	CAHN
@	12.5GM/50ML	A089240	001	May 06, 1987	Mar	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@ ANI PHARMS INC	12.5MG	A084975	001		Aug	CAHN
@	25MG	A084657	001		Aug	CAHN
@ VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997	Jun	DISC
@	25MG	A040179	002	Jan 30, 1997	Jun	DISC

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
NAMENDA XR

FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar CAHN
	14MG	N022525	002	Jun 21, 2010	Mar CAHN
	21MG	N022525	003	Jun 21, 2010	Mar CAHN
+	28MG	N022525	004	Jun 21, 2010	Mar CAHN

SOLUTION;ORAL

>A> MEMANTINE HYDROCHLORIDE

>A> AA	MACLEODS PHARMS LTD	2MG/ML	A202790	001	Oct 13, 2015	Sep NEWA
>A> AA	SILARX PHARMS INC	2MG/ML	A204033	001	Oct 13, 2015	Sep NEWA

NAMENDA

>D>	+	FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Sep CFTG
>A> AA	+		2MG/ML	N021627	001	Apr 18, 2005	Sep CFTG
	+		2MG/ML	N021627	001	Apr 18, 2005	Mar CAHN

TABLET;ORAL

MEMANTINE

AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar CMFD
AB		10MG	A090058	002	May 05, 2010	Mar CMFD

MEMANTINE HYDROCHLORIDE

>A> AB	ALEMBIC PHARMS LTD	5MG	A200891	001	Oct 13, 2015	Sep NEWA
>A> AB		10MG	A200891	002	Oct 13, 2015	Sep NEWA
AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar NEWA
AB		10MG	A090041	002	Apr 10, 2015	Mar NEWA
>A> AB	AUROBINDO PHARMA LTD	5MG	A203175	001	Oct 13, 2015	Sep NEWA
>A> AB		10MG	A203175	002	Oct 13, 2015	Sep NEWA
AB	DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun CMFD
AB		10MG	A090048	002	Apr 14, 2010	Jun CMFD
>A> AB	JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Sep NEWA
>A> AB		10MG	A091585	002	Oct 13, 2015	Sep NEWA
AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar NEWA
AB		10MG	A090051	002	Apr 10, 2015	Mar NEWA
>A> AB	MACLEODS PHARMS LTD	5MG	A202840	001	Oct 13, 2015	Sep NEWA
>A> AB		10MG	A202840	002	Oct 13, 2015	Sep NEWA
AB	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun CMFD
@		5MG	A079225	001	Jan 30, 2015	Mar DISC
AB		5MG	A079225	001	Jan 30, 2015	Jan NEWA
AB		10MG	A079225	002	Jan 30, 2015	Jun CMFD
@		10MG	A079225	002	Jan 30, 2015	Mar DISC
AB		10MG	A079225	002	Jan 30, 2015	Jan NEWA
AB	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May CMFD
AB		10MG	A090052	002	Oct 25, 2011	May CMFD
>A> AB	TORRENT PHARMS LTD	5MG	A200155	001	Oct 13, 2015	Sep NEWA
>A> AB		10MG	A200155	002	Oct 13, 2015	Sep NEWA
>A> AB	UNICHEM LABS LTD	5MG	A200022	001	Oct 13, 2015	Sep NEWA
>A> AB		10MG	A200022	002	Oct 13, 2015	Sep NEWA
AB	UPSHER SMITH	5MG	A090043	001	Jul 31, 2015	Jul NEWA
AB		10MG	A090043	002	Jul 31, 2015	Jul NEWA
AB	WOCKHARDT LTD	5MG	A090073	001	Sep 04, 2015	Aug NEWA
AB		10MG	A090073	002	Sep 04, 2015	Aug NEWA

NAMENDA

AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar CAHN
AB	+	10MG	N021487	002	Oct 16, 2003	Mar CAHN

MENOTROPINS (FSH;LH)INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
REPRONEX

@ FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May DISC
-----------	-----------------------	---------	-----	--------------	----------

MEPERIDINE HYDROCHLORIDEINJECTABLE;INJECTION
MEPERIDINE HYDROCHLORIDE

AP	EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb CAHN
AP		50MG/ML	A080445	002		Feb CAHN
AP		75MG/ML	A080445	003		Feb CAHN
AP		100MG/ML	A080445	004		Feb CAHN
@	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May CAHN
@		50MG/ML	A089782	001	Mar 31, 1989	Mar CAHN
@		50MG/ML	A089783	001	Mar 31, 1989	Mar CAHN
@		50MG/ML	A089784	001	Mar 31, 1989	Mar CAHN
@		75MG/ML	A089785	001	Mar 31, 1989	Mar CAHN
@		100MG/ML	A089786	001	Mar 31, 1989	Mar CAHN

INJECTABLE; INJECTION							
MEPERIDINE HYDROCHLORIDE							
@	100MG/ML	A089787	001	Mar 31, 1989	Mar	CAHN	
@	100MG/ML	A089788	001	Mar 31, 1989	Mar	CAHN	
<u>MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
MEPERGAN							
@	EUROHLTH INTL SARL 25MG/ML; 25MG/ML	N011730	001		Jun	CAHN	
<u>MEROPENEM</u>							
POWDER; IV (INFUSION)							
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER							
B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Apr	NEWA	
	1GM/VIAL	N202106	002	Apr 30, 2015	Apr	NEWA	
<u>MESALAMINE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
APRISO							
+	VALEANT PHARMS INTL 375MG	N022301	001	Oct 31, 2008	Jul	CAHN	
ENEMA; RECTAL							
MESALAMINE							
AB	G AND W LABS INC 4GM/60ML	A076841	001	Sep 30, 2004	Aug	CAHN	
SUPPOSITORY; RECTAL							
CANASA							
@	FOREST LABS LLC 500MG	N021252	001	Jan 05, 2001	Aug	CAHN	
+	1GM	N021252	002	Nov 05, 2004	Aug	CAHN	
<u>MESTRANOL; NORETHINDRONE</u>							
TABLET; ORAL-20							
NORINYL							
@	ACTAVIS LABS UT INC 0.1MG; 2MG	N013625	004		Mar	CAHN	
TABLET; ORAL-21							
NORINYL 1+50 21-DAY							
@	ACTAVIS LABS UT INC 0.05MG; 1MG	N013625	002		Mar	CAHN	
TABLET; ORAL-28							
NORINYL 1+50 28-DAY							
+	ACTAVIS LABS UT INC 0.05MG; 1MG	N016659	001		Mar	CAHN	
<u>METAPROTERENOL SULFATE</u>							
SOLUTION; INHALATION							
METAPROTERENOL SULFATE							
@	MYLAN SPECLT 0.4%	A071786	001	Aug 05, 1988	Apr	DISC	
@	0.6%	A070804	001	Aug 17, 1987	Apr	DISC	
@	WOCKHARDT 0.4%	A075586	001	May 30, 2002	Apr	DISC	
@	0.6%	A075586	002	May 30, 2002	Apr	DISC	
SYRUP; ORAL							
METAPROTERENOL SULFATE							
@	G AND W LABS INC 10MG/5ML	A072761	001	Feb 27, 1992	Apr	CAHN	
@	10MG/5ML	A073034	001	Aug 30, 1991	Apr	CAHN	
<u>METAXALONE</u>							
TABLET; ORAL							
METAXALONE							
	COREPHARMA 400MG	A040486	001	Feb 27, 2015	Feb	NEWA	
	640MG	N022503	001	Jun 01, 2015	Jun	NEWA	
<u>METFORMIN HYDROCHLORIDE</u>							
SOLUTION; ORAL							
RIOMET							
+	SUN PHARM INDS LTD 500MG/5ML	N021591	001	Sep 11, 2003	Apr	CAHN	
<u>METFORMIN HYDROCHLORIDE; REPAGLINIDE</u>							
TABLET; ORAL							
PRANDIMET							
AB	NOVO NORDISK INC 500MG; 1MG	N022386	001	Jun 23, 2008	Jun	CFTG	
AB	+	N022386	002	Jun 23, 2008	Jun	CFTG	
REPAGLINIDE AND METFORMIN HYDROCHLORIDE							
AB	LUPIN LTD 500MG; 1MG	A200624	001	Jul 15, 2015	Jun	NEWA	
AB	500MG; 2MG	A200624	002	Jul 15, 2015	Jun	NEWA	

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

@ SB PHARMCO

500MG;EQ 2MG BASE

N021410 002 Oct 10, 2002 May DISC

@

500MG;EQ 4MG BASE

N021410 003 Oct 10, 2002 May DISC

@

1GM;EQ 2MG BASE

N021410 004 Aug 25, 2003 May DISC

@

1GM;EQ 4MG BASE

N021410 005 Aug 25, 2003 May DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA

500MG;EQ 2MG BASE

A077337 001 May 07, 2014 May CTEC

500MG;EQ 4MG BASE

A077337 002 May 07, 2014 May CTEC

+

1GM;EQ 4MG BASE

A077337 004 May 07, 2014 May CRLD

1GM;EQ 2MG BASE

A077337 003 May 07, 2014 May CTEC

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HYDROCHLORIDE

AA AUROLIFE PHARMA LLC

5MG

A203502 001 Aug 31, 2015 Aug NEWA

AA

10MG

A203502 002 Aug 31, 2015 Aug NEWA

AA

COREPHARMA

5MG

A090065 001 Aug 18, 2015 Aug NEWA

AA

10MG

A090065 002 Aug 18, 2015 Aug NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB HERITAGE PHARMA

5MG

A040734 001 Dec 14, 2007 Mar CAHN

AB

10MG

A040734 002 Dec 14, 2007 Mar CAHN

METHOCARBAMOL

SOLUTION; IM-IV

ROBAXIN

AP + EUROHLTH INTL SARL

1GM/10ML (100MG/ML)

N011790 001

Jun CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP FRESENIUS KABI USA

EQ 25MG BASE/ML

A040265 001 Feb 26, 1999 May CMFD

METHOXSALLEN

CAPSULE; ORAL

METHOXSALLEN

AB ACTAVIS INC

10MG

A202603 001 Jun 09, 2015 May NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

APTENSIO XR

RHODES PHARMS

10MG

N205831 001 Apr 17, 2015 Apr NEWA

15MG

N205831 002 Apr 17, 2015 Apr NEWA

20MG

N205831 003 Apr 17, 2015 Apr NEWA

30MG

N205831 004 Apr 17, 2015 Apr NEWA

40MG

N205831 005 Apr 17, 2015 Apr NEWA

50MG

N205831 006 Apr 17, 2015 Apr NEWA

+

60MG

N205831 007 Apr 17, 2015 Apr NEWA

METHYLPHENIDATE HYDROCHLORIDE

>A> AB2

MALLINCKRODT INC

10MG

A203583 001 Sep 29, 2015 Sep NEWA

>A> AB2

20MG

A203583 002 Sep 29, 2015 Sep NEWA

>A> AB2

30MG

A203583 003 Sep 29, 2015 Sep NEWA

>A> AB2

40MG

A203583 004 Sep 29, 2015 Sep NEWA

>A> AB2

50MG

A203583 005 Sep 29, 2015 Sep NEWA

>A> AB2

60MG

A203583 006 Sep 29, 2015 Sep NEWA

RITALIN LA

AB1

NOVARTIS

40MG

N021284 003 Jun 05, 2002 Feb CRLD

+

60MG

N021284 005 Oct 27, 2014 Feb CRLD

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA NOVEL LABS INC

5MG/5ML

A204602 001 Aug 14, 2015 Aug NEWA

AA

10MG/5ML

A204602 002 Aug 14, 2015 Aug NEWA

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A> AB

ASCENT PHARMS INC

5MG

A207416 001 Sep 22, 2015 Sep NEWA

>A> AB

10MG

A207416 002 Sep 22, 2015 Sep NEWA

>A> AB

20MG

A207416 003 Sep 22, 2015 Sep NEWA

TABLET, CHEWABLE;ORAL
METHYLIN

AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb CFTG
AB		5MG	N021475	002	Apr 15, 2003	Feb CFTG
AB	+	10MG	N021475	003	Apr 15, 2003	Feb CFTG
	METHYLPHENIDATE HYDROCHLORIDE					
AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb NEWA
AB		5MG	A204115	002	Feb 25, 2015	Feb NEWA
AB		10MG	A204115	003	Feb 25, 2015	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL
METHYLIN ER

AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May CTEC
	METHYLPHENIDATE HYDROCHLORIDE					
AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May NEWA
AB		20MG	A207488	002	Jun 09, 2015	May NEWA

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

>A>	AB	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Sep NEWA
		TESTRED					
>D>	+	VALEANT PHARM INTL	10MG	A083976	001		Sep CTEC
>A>	AB	+	10MG	A083976	001		Sep CTEC

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr CAHN
	TABLET;ORAL					
	METOPROLOL TARTRATE					
	MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar NEWA
		75MG	A076704	005	Mar 18, 2015	Mar NEWA

METRONIDAZOLE

CREAM;TOPICAL

NORITATE

+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb CAHN
---	----------------------	----	---------	-----	--------------	----------

GEL;VAGINAL

METRONIDAZOLE

+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CAHN
	NUVESSA					
+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CTNA

INJECTABLE;INJECTION

METRONIDAZOLE

	@ EUROHLTH INTL SARL	500MG/100ML	N018907	001	Mar 30, 1984	Aug CAHN
	METRONIDAZOLE IN PLASTIC CONTAINER					
AP	CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr CAHN

TABLET;ORAL

METRONIDAZOLE

>A>	AB	APPCO PHARMA LLC	250MG	A205245	001	Sep 23, 2015	Sep NEWA
>A>	AB		500MG	A205245	002	Sep 23, 2015	Sep NEWA
	AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May NEWA
	AB		500MG	A203974	002	May 29, 2015	May NEWA

MICONAZOLE

TABLET;BUCCAL

ORAVIG

+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr CAHN
---	------------------	------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr CAHN
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr CAHN
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun CAHN
AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun CAHN
	@ IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000	Apr CAHN
	@ WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar DISC
	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar DISC
	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar DISC
	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar DISC

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	Apr CAHN
----	--------------------	----------------	---------	-----	--------------	----------

MIGLITOL

TABLET;ORAL

GLYSET

AB	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Mar CTEC
AA		25MG	N020682	001	Dec 18, 1996	Feb CFTG
AB		50MG	N020682	002	Dec 18, 1996	Mar CTEC
AA		50MG	N020682	002	Dec 18, 1996	Feb CFTG
AB	+	100MG	N020682	003	Dec 18, 1996	Mar CTEC
AA	+	100MG	N020682	003	Dec 18, 1996	Feb CFTG

MIGLITOL

AB	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Mar CTEC
AA		25MG	A203965	001	Feb 24, 2015	Feb NEWA
AB		50MG	A203965	002	Feb 24, 2015	Mar CTEC
AA		50MG	A203965	002	Feb 24, 2015	Feb NEWA
AB		100MG	A203965	003	Feb 24, 2015	Mar CTEC
AA		100MG	A203965	003	Feb 24, 2015	Feb NEWA

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP	BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CRLD	
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun CAHN	
>A>	@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Sep CAHN	
AP	+	HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010	Jan CRLD
>D>	@	HIKMA MAPLE	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Sep CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065062	001	Nov 30, 2000	Apr CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Apr CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun CAHN

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

@ SUN PHARM INDS LTD

@

@

@

@

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065156	001	Jan 06, 2004	Apr CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Apr CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

>D>	AB	SANDOZ	EQ 135MG BASE	A090422	003	Aug 13, 2009	Sep CRLD
>A>	AB	+	EQ 135MG BASE	A090422	003	Aug 13, 2009	Sep CRLD
	AB	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr CAHN
	AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr CAHN
	AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr CAHN
	AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr CAHN
	AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr CAHN
		SOLODYN					
>D>	+	MEDICIS	EQ 55MG BASE	N050808	008	Aug 27, 2010	Sep CRLD
>A>			EQ 55MG BASE	N050808	008	Aug 27, 2010	Sep CRLD
>D>	AB	+	EQ 80MG BASE	N050808	007	Aug 27, 2010	Sep CRLD
>A>	AB		EQ 80MG BASE	N050808	007	Aug 27, 2010	Sep CRLD
>D>	AB		EQ 115MG BASE	N050808	005	Jul 23, 2009	Sep CRLD
>A>	AB	+	EQ 115MG BASE	N050808	005	Jul 23, 2009	Sep CRLD

MIVACURIUM CHLORIDE

SOLUTION; INTRAVENOUS

MIVACRON

ABBVIE

EQ 10MG BASE/5ML (EQ 2MG BASE/ML)

N020098 004

Jan 22, 1992

Jan NEWA

+

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

N020098 005

Jan 22, 1992

Jan NEWA

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE

COREPHARMA

5MG

A090453 001

Mar 20, 2015

Mar NEWA

10MG

A090453 002

Mar 20, 2015

Mar NEWA

+

25MG

A090453 003

Mar 20, 2015

Mar NEWA

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB AJANTA PHARMA LTD

EQ 4MG BASE/PACKET

A203438 001

Jul 31, 2015

Jul NEWA

TABLET; ORAL

MONTELUKAST SODIUM

AB AJANTA PHARMA LTD

EQ 10MG BASE

A203432 001

Jul 31, 2015

Jul NEWA

AB AMNEAL PHARMS

EQ 10MG BASE

A204604 001

Sep 04, 2015

Aug NEWA

AB KREMERS URBAN PHARMS

EQ 10MG BASE

A201522 001

Aug 03, 2012

Mar CAHN

>A> AB UNICHEM LABS LTD

EQ 10MG BASE

A204290 001

Oct 08, 2015

Sep NEWA

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB AJANTA PHARMA LTD

EQ 4MG BASE

A203328 001

Jul 31, 2015

Jul NEWA

AB

EQ 5MG BASE

A203328 002

Jul 31, 2015

Jul NEWA

AB HETERO LABS LTD V

EQ 4MG BASE

A204093 001

May 22, 2015

May NEWA

AB

EQ 5MG BASE

A204093 002

May 22, 2015

May NEWA

AB JUBILANT GENERICS

EQ 4MG BASE

A203795 001

Feb 27, 2015

Feb NEWA

AB

EQ 5MG BASE

A203795 002

Feb 27, 2015

Feb NEWA

AB KREMERS URBAN PHARMS

EQ 4MG BASE

A200405 001

Aug 03, 2012

Mar CAHN

AB

EQ 5MG BASE

A200405 002

Aug 03, 2012

Mar CAHN

AB MACLEODS PHARMS LTD

EQ 4MG BASE

A203582 001

Mar 12, 2015

Feb NEWA

AB

EQ 5MG BASE

A203582 002

Mar 12, 2015

Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

>D> AVINZA

>D> AB2 KING PHARMS LLC

30MG

N021260 001

Mar 20, 2002

Sep DISC

>A> @

30MG

N021260 001

Mar 20, 2002

Sep DISC

>D> AB2

45MG

N021260 005

Dec 18, 2008

Sep DISC

>A> @

45MG

N021260 005

Dec 18, 2008

Sep DISC

>D> AB2

60MG

N021260 002

Mar 20, 2002

Sep DISC

>A> @

60MG

N021260 002

Mar 20, 2002

Sep DISC

>D> AB2

75MG

N021260 006

Dec 18, 2008

Sep DISC

>A> @

75MG

N021260 006

Dec 18, 2008

Sep DISC

>D> AB2

90MG

N021260 003

Mar 20, 2002

Sep DISC

>A> @

90MG

N021260 003

Mar 20, 2002

Sep DISC

>D> AB2 +

120MG

N021260 004

Mar 20, 2002

Sep DISC

>A> @

120MG

N021260 004

Mar 20, 2002

Sep DISC

KADIAN

AB1 + ACTAVIS LABS UT INC

10MG

N020616 008

Apr 20, 2007

Mar CAHN

AB1

20MG

N020616 001

Jul 03, 1996

Mar CAHN

AB1

30MG

N020616 004

Mar 09, 2001

Mar CAHN

AB1

40MG

N020616 009

Jul 09, 2012

May CTEC

AB1

40MG

N020616 009

Jul 09, 2012

Mar CAHN

AB1

50MG

N020616 002

Jul 03, 1996

Mar CAHN

AB1

60MG

N020616 005

Mar 09, 2001

Mar CAHN

AB1

70MG

N020616 010

Jul 09, 2012

May CTEC

AB1

70MG

N020616 010

Jul 09, 2012

Mar CAHN

AB1

80MG

N020616 006

Oct 27, 2006

Mar CAHN

AB1 +

100MG

N020616 003

Jul 03, 1996

Mar CAHN

AB1

130MG

N020616 011

Jul 09, 2012

Mar CAHN

AB1

150MG

N020616 012

Jul 09, 2012

Mar CAHN

AB1 +

200MG

N020616 007

Feb 27, 2007

Mar CAHN

MORPHINE SULFATE

>D> AB2 ACTAVIS ELIZABETH

30MG

A079040 001

Jan 16, 2013

Sep CTEC

>A>

30MG

A079040 001

Jan 16, 2013

Sep CTEC

>D> AB2

45MG

A079040 002

Jan 16, 2013

Sep CTEC

>A>

45MG

A079040 002

Jan 16, 2013

Sep CTEC

>D> AB2

60MG

A079040 003

Jan 16, 2013

Sep CTEC

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

>A>		60MG	A079040	003	Jan 16, 2013	Sep CTEC
>D>	AB2	75MG	A079040	004	Jan 16, 2013	Sep CTEC
>A>		75MG	A079040	004	Jan 16, 2013	Sep CTEC
>D>	AB2	90MG	A079040	005	Jan 16, 2013	Sep CTEC
>A>		90MG	A079040	005	Jan 16, 2013	Sep CTEC
>D>	AB2	120MG	A079040	006	Jan 16, 2013	Sep CTEC
>A>	+	120MG	A079040	006	Jan 16, 2013	Sep CTEC
	AB1	TEVA PHARMS USA	A202718	007	Jun 03, 2015	May NEWA
	AB1	70MG	A202718	008	Jun 03, 2015	May NEWA

INJECTABLE;INJECTION
DURAMORPH PF

AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun CAHN
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun CAHN
		INFUMORPH					
	+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun CAHN
	+		25MG/ML	N018565	004	Jul 19, 1991	Jun CAHN

MORPHINE SULFATE

AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May NEWA
AP			8MG/ML	A205758	002	May 21, 2015	May NEWA
AP			10MG/ML	A205758	003	May 21, 2015	May NEWA
AP	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May CFTG
AP	+		8MG/ML	N202515	003	Nov 14, 2011	May CFTG
AP	+		10MG/ML	N202515	004	Nov 14, 2011	May CFTG

SOLUTION;ORAL

MORPHINE SULFATE

AA		TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May NEWA
AA			100MG/5ML	A203518	002	May 12, 2015	May NEWA

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar NEWA
AB			30MG	A203849	002	Apr 06, 2015	Mar NEWA
AB			60MG	A203849	003	Apr 06, 2015	Mar NEWA
AB			100MG	A203849	004	Apr 06, 2015	Mar NEWA
AB			200MG	A203849	005	Apr 06, 2015	Mar NEWA
AB		SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr CAHN
AB			30MG	A078761	002	May 11, 2012	Apr CAHN
AB			60MG	A078761	003	May 11, 2012	Apr CAHN
AB			100MG	A078761	004	May 11, 2012	Apr CAHN
AB			200MG	A078761	005	May 11, 2012	Apr CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

MOXIFLOXACIN HYDROCHLORIDE

+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr NEWA
---	--------------------	--	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

MOXEZA

AT2	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CFTG
		MOXIFLOXACIN HYDROCHLORIDE					
AT1		LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May CTEC
AT2			EQ 0.5% BASE	A204079	001	May 28, 2015	May NEWA
AT1		WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May CTEC
AT			EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb NEWA

VIGAMOX

AT1	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May CTEC
-----	---	------------------	--------------	---------	-----	--------------	----------

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 400MG BASE	A204635	001	Aug 31, 2015	Aug NEWA
----	--	------------------	---------------	---------	-----	--------------	----------

NADOLOL

TABLET;ORAL

NADOLOL

AB		ORION CORP ORION	40MG	A201893	001	Sep 16, 2015	Aug NEWA
AB			80MG	A201893	002	Sep 16, 2015	Aug NEWA

NALBUPHINE HYDROCHLORIDEINJECTABLE; INJECTION
NALBUPHINE HYDROCHLORIDE

@ IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar CAHN
@	10MG/ML	A072071	001	Apr 10, 1989	Mar CAHN
@	10MG/ML	A072072	001	Apr 10, 1989	Mar CAHN
@	20MG/ML	A072073	001	Apr 10, 1989	Mar CAHN
@	20MG/ML	A072074	001	Apr 10, 1989	Mar CAHN
@	20MG/ML	A072075	001	Apr 10, 1989	Mar CAHN

NALMEFENE HYDROCHLORIDEINJECTABLE; INJECTION
REVEX

@ EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun CAHN
@	EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun CAHN

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION
NALOXONE

@ EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar CAHN
NALOXONE HYDROCHLORIDE					
@ IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar CAHN
@	0.02MG/ML	A072083	001	Apr 11, 1989	Mar CAHN
@	0.02MG/ML	A072084	001	Apr 11, 1989	Mar CAHN
@	0.02MG/ML	A072085	001	Apr 11, 1989	Mar CAHN
@	0.4MG/ML	A072086	001	Apr 11, 1989	Mar CAHN
@	0.4MG/ML	A072087	001	Apr 11, 1989	Mar CAHN
@	0.4MG/ML	A072088	001	Apr 11, 1989	Mar CAHN
@	0.4MG/ML	A072089	001	Apr 11, 1989	Mar CAHN
@	0.4MG/ML	A072090	001	Apr 11, 1989	Mar CAHN
@	1MG/ML	A072091	001	Apr 11, 1989	Mar CAHN
@	1MG/ML	A072092	001	Apr 11, 1989	Mar CAHN
@	1MG/ML	A072093	001	Apr 11, 1989	Mar CAHN
NARCAN					
@ ADAPT	0.02MG/ML	N016636	002		Aug CAHN
@	0.4MG/ML	N016636	001		Aug CAHN
@	1MG/ML	N016636	003	Jun 14, 1982	Aug CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 0.5MG BASE; EQ 50MG BASE	A075523	001	Mar 17, 2000	Apr CAHN
----	--------------------	-----------------------------	---------	-----	--------------	----------

NAPROXENSUSPENSION; ORAL
NAPROSYN

AB	+ PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Apr CAHN
----	------------------	---------	---------	-----	--------------	----------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

PERNIX IRELAND LTD 60MG; EQ 10MG BASE

N021926	002	May 14, 2015	Jun NEWA
---------	-----	--------------	----------

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

@ ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun DISC
	EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun NEWA
@	EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun DISC
	EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun NEWA
@	EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun DISC
	EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun NEWA
@	EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun DISC
	EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun NEWA
@ AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Apr DISC
AB	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar NEWA
@	EQ 5MG BASE	A203659	002	Apr 16, 2015	Apr DISC
AB	EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar NEWA
@	EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr DISC
AB	EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar NEWA
@	EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr DISC

TABLET;ORAL									
NEBIVOLOL HYDROCHLORIDE									
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar	NEWA		
	@ INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul	DISC		
		EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul	NEWA		
	@	EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul	DISC		
		EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul	NEWA		
	@	EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul	DISC		
		EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul	NEWA		
	@	EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul	DISC		
		EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul	NEWA		
<u>NEFAZODONE HYDROCHLORIDE</u>									
TABLET;ORAL									
NEFAZODONE HYDROCHLORIDE									
	@ IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr	CAHN		
	@	100MG	A076072	002	Sep 16, 2003	Apr	CAHN		
	@	150MG	A076072	003	Sep 16, 2003	Apr	CAHN		
	@	200MG	A076072	004	Sep 16, 2003	Apr	CAHN		
	@	250MG	A076072	005	Sep 16, 2003	Apr	CAHN		
AB	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr	CAHN		
AB		100MG	A076409	002	Sep 16, 2003	Apr	CAHN		
AB		150MG	A076409	003	Sep 16, 2003	Apr	CAHN		
AB		200MG	A076409	004	Sep 16, 2003	Apr	CAHN		
AB		250MG	A076409	005	Sep 16, 2003	Apr	CAHN		
<u>NELARABINE</u>									
INJECTABLE;IV (INFUSION)									
ARRANON									
+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar	CAHN		
<u>NEOSTIGMINE METHYLSULFATE</u>									
SOLUTION;INTRAVENOUS									
NEOSTIGMINE METHYLSULFATE									
	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan	NEWA		
		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan	NEWA		
<u>NEVIRAPINE</u>									
TABLET, EXTENDED RELEASE;ORAL									
NEVIRAPINE									
AB	ALVOGEN PINE BROOK	400MG	A204621	001	Jul 10, 2015	Jun	NEWA		
<u>NIACIN</u>									
TABLET, EXTENDED RELEASE;ORAL									
NIACIN									
AB	AMNEAL PHARMS	500MG	A203578	001	Jul 24, 2015	Jul	NEWA		
AB		1GM	A203578	002	Jul 24, 2015	Jul	NEWA		
<u>NIFEDIPINE</u>									
CAPSULE;ORAL									
NIFEDIPINE									
AB	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar	CAHN		
AB		20MG	A202644	002	Apr 25, 2013	Mar	CAHN		
TABLET, EXTENDED RELEASE;ORAL									
NIFEDIPINE									
AB2	VALEANT PHARMS NORTH	30MG	A075289	002	Feb 06, 2001	Aug	CAHN		
AB2		60MG	A075289	001	Sep 27, 2000	Aug	CAHN		
<u>NILUTAMIDE</u>									
TABLET;ORAL									
NILANDRON									
	@ CONCORDIA PHARMS INC	50MG	N020169	001	Sep 19, 1996	Apr	CAHN		
+		150MG	N020169	002	Apr 30, 1999	Apr	CAHN		
<u>NIMODIPINE</u>									
CAPSULE;ORAL									
NIMODIPINE									
AB	+ BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008	Jan	CAHN		
AB	SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015	Jul	NEWA		

NINTEDANIB ESYLATECAPSULE;ORAL
OFEVBOEHRINGER INGELHEIM EQ 100MG BASE
+ EQ 150MG BASEN205832 001 Oct 15, 2014 Mar CAIN
N205832 002 Oct 15, 2014 Mar CAINNITRIC OXIDEGAS;INHALATION
INOMAX

@ INO 100PPM

N020845 002 Dec 23, 1999 Jun DISC

NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
MACRODANTINAB ALVOGEN INC 25MG
NITROFURANTOIN

N016620 003 Jun CTEC

AB ACTAVIS LABS FL INC 25MG
AB 50MG
AB 100MGA091095 001 Jun 18, 2015 Jun NEWA
A091095 002 Jun 18, 2015 Jun NEWA
A091095 003 Jun 18, 2015 Jun NEWANITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB WATSON LABS INC 75MG;25MG

A202250 001 Jul 08, 2015 Jun NEWA

NORETHINDRONETABLET;ORAL-28
NOR-QD

AB1 + ACTAVIS LABS UT INC 0.35MG

N017060 001 Mar CAHN

NORGESTRELTABLET;ORAL
OVRETTE

@ LABORATOIRE HRA 0.075MG

N017031 001 Jun CAHN

NYSTATINCREAM;TOPICAL
NYSTATINAT G AND W LABS INC 100,000 UNITS/GM
SUSPENSION;ORAL

A061966 001 Jun CMFD

AA G AND W LABS INC 100,000 UNITS/ML
@ 100,000 UNITS/MLA062349 001 Jul 14, 1982 Apr CAHN
A062776 001 Dec 17, 1987 Apr CAHNNYSTATIN; TRIAMCINOLONE ACETONIDECREAM;TOPICAL
MYKACETAT G AND W LABS INC 100,000 UNITS/GM;0.1%
OINTMENT;TOPICAL
MYKACET

A062367 001 May 28, 1985 Mar CMFD

AT G AND W LABS INC 100,000 UNITS/GM;0.1%

A062733 001 Mar 09, 1987 Mar CMFD

OFLOXACINTABLET;ORAL
OFLOXACIN

AB LARKEN LABS 400MG

A076093 003 Sep 02, 2003 Jul CMFD

OLANZAPINETABLET;ORAL
OLANZAPINE

AB IVAX PHARMS INC 20MG

A077301 001 Apr 29, 2015 Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINEAB MACLEODS PHARMS LTD 5MG
AB 10MG
AB 15MG
AB 20MG
AB ORCHID HLTHCARE 5MG
AB 10MG
AB 15MGA203044 001 Feb 20, 2015 Feb NEWA
A203044 002 Feb 20, 2015 Feb NEWA
A203044 003 Feb 20, 2015 Feb NEWA
A203044 004 Feb 20, 2015 Feb NEWA
A202937 001 Mar 02, 2015 Feb NEWA
A202937 002 Mar 02, 2015 Feb NEWA
A202937 003 Mar 02, 2015 Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL					
OLANZAPINE					
AB	20MG	A202937	004	Mar 02, 2015	Feb NEWA
<u>OLAPARIB</u>					
CAPSULE;ORAL					
LYNPARZA					
	ASTRAZENECA PHARMS 50MG	N206162	001	Dec 19, 2014	Jan CTNA
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE</u>					
SPRAY, METERED; INHALATION					
STIOLTO RESPIMAT					
+	BOEHRINGER INGELHEIM EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015	May NEWA
<u>OLOPATADINE HYDROCHLORIDE</u>					
SOLUTION/DROPS;OPHTHALMIC					
OLOPATADINE HYDROCHLORIDE					
AT	BARR LABS INC EQ 0.2% BASE	A090848	001	Jul 13, 2015	Jun NEWA
PATADAY					
AT	+ ALCON PHARMS LTD EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun CFTG
PAZEO					
+	ALCON RES LTD EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jan NEWA
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR</u>					
TABLET;ORAL					
TECHNIVIE					
+	ABBVIE INC 12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Aug CMS1
+	12.5MG;75MG;50MG	N207931	001	Jul 25, 2015	Jul NEWA
<u>OMEPRAZOLE</u>					
CAPSULE, DELAYED REL PELLETS;ORAL					
OMEPRAZOLE					
AB	AUROBINDO PHARMA USA 10MG	A203270	001	Aug 19, 2015	Aug NEWA
AB	20MG	A203270	002	Aug 19, 2015	Aug NEWA
AB	40MG	A203270	003	Aug 19, 2015	Aug NEWA
AB	LUPIN LTD 40MG	A202384	001	Aug 25, 2015	Aug NEWA
<u>ONDANSETRON</u>					
TABLET, ORALLY DISINTEGRATING;ORAL					
ONDANSETRON					
AB	SUN PHARM INDS LTD 4MG	A078602	001	Feb 24, 2011	Apr CAHN
AB	8MG	A078602	002	Feb 24, 2011	Apr CAHN
ZOFTRAN ODT					
AB	NOVARTIS PHARMS CORP 4MG	N020781	001	Jan 27, 1999	Mar CAHN
AB	+ 8MG	N020781	002	Jan 27, 1999	Mar CAHN
<u>ONDANSETRON HYDROCHLORIDE</u>					
INJECTABLE;INJECTION					
ONDANSETRON HYDROCHLORIDE					
AP	ACCORD HLTHCARE EQ 2MG BASE/ML	A206846	001	Jul 13, 2015	Jun NEWA
AP	CLARIS PHARMASERVICE EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr CAHN
AP	EUROHLTH INTL SARL EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun CAHN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	CLARIS PHARMASERVICE EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr CAHN
AP	EUROHLTH INTL SARL EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun CAHN
	@ TARO PHARMS IRELAND EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan DISC
ZOFTRAN					
AP	+ NOVARTIS PHARMS CORP EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CAHN
ZOFTRAN PRESERVATIVE FREE					
AP	+ NOVARTIS PHARMS CORP EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CAHN
SOLUTION;ORAL					
ZOFTRAN					
AA	+ NOVARTIS PHARMS CORP EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar CAHN
TABLET;ORAL					
ZOFTRAN					
AB	NOVARTIS PHARMS CORP EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar CAHN
AB	EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar CAHN
AB	+ EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar CAHN

ORPHENADRINE CITRATEINJECTABLE;INJECTION
NORFLEX@ IGI LABS INC 30MG/ML
@ MEDICIS 30MG/MLN013055 001
N013055 001Apr CAHN
Mar DISC

ORPHENADRINE CITRATE

AP + AKORN 30MG/ML

A040484 001 May 24, 2006 Mar CRLD

OXACILLIN SODIUM

CAPSULE;ORAL

OXACILLIN SODIUM

@ ANI PHARMS INC EQ 250MG BASE
@ EQ 500MG BASEA062222 001
A062222 002Aug CAHN
Aug CAHNOXANDROLONE

TABLET;ORAL

OXANDRIN

AB GEMINI LABS LLC 2.5MG
AB + 10MGN013718 001
N013718 002Aug CAHN
Nov 05, 2001 Aug CAHNOXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB SUN PHARM INDS LTD 300MG/5ML

A078734 001 Jun 26, 2009 Apr CAHN

OXYBUTYNINFILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROLAB + ACTAVIS LABS UT INC 3.9MG/24HR
GEL, METERED;TRANSDERMAL

N021351 002

Feb 26, 2003 Mar CAHN

GELNIQUE 3%

+ ACTAVIS LABS UT INC 3%

N202513 001

Dec 07, 2011 Mar CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

+ ACTAVIS LABS UT INC 10%(100MG/PACKET)

N022204 001

Jan 27, 2009 Mar CAHN

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB AVANTHI INC 5MG
AB NOVEL LABS INC 5MGA202773 001
A204752 001Aug 17, 2015 Aug NEWA
Aug 24, 2015 Aug NEWA

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA ANI PHARMS INC 5MG/5ML
AA NOVEL LABS INC 100MG/5ML
AA WOCKHARDT BIO AG 5MG/5MLA204979 001
A204603 001
A206456 001Jun 01, 2015 May NEWA
Apr 29, 2015 Apr NEWA
Jun 16, 2015 Jun NEWA

TABLET;ORAL

OXAYDO

ACURA PHARMS INC 5MG
7.5MG
EGALET LTD 5MG
7.5MG
EGALET US INC 5MG
7.5MGN202080 001
N202080 002
N202080 001
N202080 002
N202080 001
N202080 002Jun 17, 2011 Mar CTNA
Jun 17, 2011 Mar CTNA
Jun 17, 2011 May CAHN
Jun 17, 2011 May CAHN
Jun 17, 2011 Jul CAHN
Jun 17, 2011 Jul CAHN

OXYCODONE HYDROCHLORIDE

AB ACTAVIS ELIZABETH 5MG
>A> AB EPIC PHARMA LLC 5MG
>A> AB 10MG
>A> AB 15MG
>A> AB 30MG
AB VINTAGE PHARMS 10MG
AB 20MGA076636 003
A202662 001
A202662 002
A202662 003
A202662 004
A077712 004
A077712 005Apr 07, 2015 Mar NEWA
Sep 22, 2015 Sep NEWA
Sep 22, 2015 Sep NEWA
Sep 22, 2015 Sep NEWA
Sep 22, 2015 Sep NEWA
Apr 13, 2015 Mar NEWA
Apr 13, 2015 Mar NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	5MG		A203506	001	Apr 24, 2015	Apr	NEWA
AB			7.5MG		A203506	002	Apr 24, 2015	Apr	NEWA
AB			10MG		A203506	003	Apr 24, 2015	Apr	NEWA
AB			15MG		A203506	004	Apr 24, 2015	Apr	NEWA
AB			20MG		A203506	005	Apr 24, 2015	Apr	NEWA
AB			30MG		A203506	006	Apr 24, 2015	Apr	NEWA
AB			40MG		A203506	007	Apr 24, 2015	Apr	NEWA

OXYTOCIN

INJECTABLE;INJECTION
OXYTOCIN

AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001			Feb	CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007		Feb	CAHN

PALBOCICLIB

CAPSULE;ORAL
IBRANCE

		PFIZER INC	75MG	N207103	001	Feb 03, 2015		Feb	NEWA
			100MG	N207103	002	Feb 03, 2015		Feb	NEWA
	+		125MG	N207103	003	Feb 03, 2015		Feb	NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL
INVEGA

AB		JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008		Jul	CFTG
AB			3MG	N021999	001	Dec 19, 2006		Jul	CFTG
AB	+		6MG	N021999	002	Dec 19, 2006		Jul	CFTG
AB			9MG	N021999	003	Dec 19, 2006		Jul	CFTG
		PALIPERIDONE							
AB		ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015		Jul	NEWA
AB			3MG	A202645	002	Aug 03, 2015		Jul	NEWA
AB			6MG	A202645	003	Aug 03, 2015		Jul	NEWA
AB			9MG	A202645	004	Aug 03, 2015		Jul	NEWA
>A> AB		MYLAN PHARMS INC	1.5MG	A203802	001	Sep 24, 2015		Sep	NEWA
>A> AB			3MG	A203802	002	Sep 24, 2015		Sep	NEWA
>A> AB			6MG	A203802	003	Sep 24, 2015		Sep	NEWA
>A> AB			9MG	A203802	004	Sep 24, 2015		Sep	NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA TRINZA

		JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015		May	NEWA
			410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015		May	NEWA
			546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015		May	NEWA
	+		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015		May	NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
ALOXI

>D>	+	HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008		Sep	CFTG
>A> AP	+		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008		Sep	CFTG
>D>	+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003		Sep	CFTG
>A> AP	+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003		Sep	CFTG
>A>		PALONOSETRON HYDROCHLORIDE							
>A> AP		SANDOZ INC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202521	001	Oct 13, 2015		Sep	NEWA
>A> AP		TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Oct 13, 2015		Sep	NEWA
>A> AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Oct 13, 2015		Sep	NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE

@ IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar CAHN
@	2MG/ML	A072211	001	Mar 31, 1988	Mar CAHN
@	2MG/ML	A072212	001	Mar 31, 1988	Mar CAHN
@	2MG/ML	A072213	001	Mar 31, 1988	Mar CAHN

PANOBIINOSTAT

CAPSULE; ORAL
FARYDAK

NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb NEWA
	15MG	N205353	002	Feb 23, 2015	Feb NEWA
+	20MG	N205353	003	Feb 23, 2015	Feb NEWA

PANOBIINOSTAT LACTATE

CAPSULE; ORAL
FARYDAK

NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CAIN
	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CPOT
	EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CAIN
	EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CPOT
+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CAIN
+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CPOT

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Jun NEWA
	TABLET, DELAYED RELEASE; ORAL					
	PANTOPRAZOLE SODIUM					
AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar CAHN
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr CAHN

PARICALCITOL

CAPSULE; ORAL
PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL
VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar CAHN
@		EQ 400MG BASE	N022465	002	Oct 19, 2009	Aug DISC
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb CAHN
----	----------------	-------	---------	-----	--------------	----------

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
BONTRIL

@	VALEANT	105MG	A088021	001	Sep 21, 1982	Jan DISC
	PHENDIMETRAZINE TARTRATE					
+	SANDOZ	105MG	N018074	001		Jan CTEC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIBENZYLINE

AB	+	CONCORDIA PHARMS INC	10MG	N008708	001	Jun CAHN
----	---	----------------------	------	---------	-----	----------

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

AA	MIKAH PHARMA LLC	37.5MG	A040228	001	Jun 19, 1997	Jun CMFD
----	------------------	--------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

>D>	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Sep CRLD
>A>	+	2.5%	N207926	001	Jan 15, 2015	Sep CRLD
		2.5%	N207926	001	Jan 15, 2015	Jan NEWA
>D>		10%	N207926	002	Jan 15, 2015	Sep CRLD
>A>	+	10%	N207926	002	Jan 15, 2015	Sep CRLD
		10%	N207926	002	Jan 15, 2015	Jan NEWA
>D>	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Sep CRLD
>A>	+	2.5%	N203510	001	Mar 21, 2013	Sep CRLD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH VC PLAIN

AA	+	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jul CAHN
----	---	------------------	--------------------	---------	-----	--------------	----------

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

@ WOCKHARDT 30MG EXTENDED

A040759 001 Dec 18, 2007 Jun DISC

@ WOCKHARDT USA 100MG EXTENDED

A040732 001 Jan 30, 2008 Jun DISC

PHENYTOIN SODIUM

AB	AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May NEWA
----	----------------------	----------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP	+	EUROHLTH INTL SARL	50MG/ML	A084307	001	Feb CAHN
----	---	--------------------	---------	---------	-----	----------

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

@ IGI LABS INC 1MG/0.5ML

N012223 002 Apr CAHN

@ 10MG/ML

N012223 001 Apr CAHN

PILOCARPINE HYDROCHLORIDE

GEL;OPHTHALMIC

PILOPINE HS

@ ALCON 4%

N018796 001 Oct 01, 1984 Aug DISC

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB	ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	Mar CAHN
----	----------------------	-----	---------	-----	--------------	----------

PIMOZIDE

TABLET;ORAL

ORAP

>D>	TEVA	1MG	N017473	003	Aug 27, 1997	Sep CFTG
>A>	AB	1MG	N017473	003	Aug 27, 1997	Sep CFTG
>D>	+	2MG	N017473	001	Jul 31, 1984	Sep CFTG
>A>	AB	2MG	N017473	001	Jul 31, 1984	Sep CFTG
>A>	PIMOZIDE					
>A>	AB	1MG	A204521	001	Sep 28, 2015	Sep NEWA
>A>	AB	2MG	A204521	002	Sep 28, 2015	Sep NEWA

PINDOLOL

TABLET;ORAL

PINDOLOL

@ G AND W LABS INC 5MG

A073661 001 Oct 31, 1993 Apr CAHN

@ 5MG

A073687 001 Feb 26, 1993 Apr CAHN

@ 5MG

A074123 001 Apr 17, 1997 Apr CAHN

@ 10MG

A073661 002 Oct 31, 1993 Apr CAHN

@ 10MG

A073687 002 Feb 26, 1993 Apr CAHN

@ 10MG

A074123 002 Apr 17, 1997 Apr CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

@ MEDICIS

EQ 0.2MG BASE/INH

N020014 001 Nov 30, 1992 Jan DISC

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

+ GENENTECH INC

267MG

N022535 001 Oct 15, 2014 Feb CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB MYLAN PHARMS INC

10MG

A074116 001 Jun 15, 1993 May CAHN

AB 20MG

A074118 001 Jun 15, 1993 May CAHN

PODOFILOX

GEL; TOPICAL

CONDYLOX

+ ACTAVIS LABS UT INC

0.5%

N020529 001 Mar 13, 1997 Feb CAHN

SOLUTION; TOPICAL

CONDYLOX

AT + ACTAVIS LABS UT INC

0.5%

N019795 001 Dec 13, 1990 Jan CAHN

PODOFILOX

AT BAUSCH AND LOMB INC

0.5%

A090184 001 Jul 21, 2010 May CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT ALCON RES LTD

10,000 UNITS/ML; EQ 1MG BASE/ML

A064211 001 Apr 13, 1998 Jan CAHN

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

ARIAD

EQ 30MG BASE

N203469 003 Apr 23, 2015 Apr NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON

AB UPSHER SMITH

8MEQ

A203106 001 Jul 10, 2015 Jun NEWA

AB 10MEQ

A203106 002 Jul 10, 2015 Jun NEWA

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

PHARMA RES SOFTWARE

20MEQ

N208019 001 Aug 19, 2015 Aug NEWA

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB1 ADARE PHARMS INC

20MEQ

A076368 001 Aug 18, 2004 Jul CAHN

AB2 MYLAN PHARMS INC

8MEQ

A204662 001 Aug 21, 2014 Feb CPOT

AB2 10MEQ

A204662 002 Aug 21, 2014 Feb CPOT

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB GLENMARK GENERICS

0.75MG

A090781 006 Sep 11, 2015 Aug NEWA

TABLET, EXTENDED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB DR REDDYS LABS LTD

0.375MG

A203354 001 Aug 07, 2015 Jul NEWA

AB 0.75MG

A203354 002 Aug 07, 2015 Jul NEWA

AB 1.5MG

A203354 003 Aug 07, 2015 Jul NEWA

AB 3MG

A203354 004 Aug 07, 2015 Jul NEWA

AB 4.5MG

A203354 005 Aug 07, 2015 Jul NEWA

PREDNICARBATE

OINTMENT; TOPICAL

DERMATOP

AB + VALEANT PHARMS NORTH

0.1%

N019568 001 Sep 23, 1991 Apr CAHN

PREDNISONETABLET; ORAL
PREDNISONE

@ HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010	Aug DISC
----------------	-----	---------	-----	--------------	----------

PREGABALINCAPSULE; ORAL
LYRICA

PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Apr CTEC
	50MG	N021446	002	Dec 30, 2004	Apr CTEC
	75MG	N021446	003	Dec 30, 2004	Apr CTEC
	100MG	N021446	004	Dec 30, 2004	Apr CTEC
	150MG	N021446	005	Dec 30, 2004	Apr CTEC
	200MG	N021446	006	Dec 30, 2004	Apr CTEC
	225MG	N021446	007	Dec 30, 2004	Apr CTEC
+	300MG	N021446	008	Dec 30, 2004	Apr CTEC

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

@ IDT AUSTRALIA LTD	250MG	A089219	001	Jul 01, 1986	Jun CAHN
@	500MG	A089221	001	Jul 01, 1986	Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

@ IDT AUSTRALIA LTD	250MG	A089369	001	Aug 14, 1987	Jun CAHN
@	500MG	A089370	001	Jan 09, 1987	Jun CAHN
@	750MG	A089371	001	Aug 14, 1987	Jun CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb CAHN
----	---	--------------------	----------------	---------	-----	--------------	----------

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB		BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan CAHN
AB			200MG	A200900	002	Aug 16, 2013	Jan CAHN

GEL; VAGINAL

CRINONE

		ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb CAHN
+			8%	N020701	002	Jul 31, 1997	Feb CAHN

INJECTABLE; INJECTION

PROGESTERONE

AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar CAHN
----	---	---------------------	---------	---------	-----	--	----------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	25MG/ML	A083312	001		Jun CAHN
AP	+		50MG/ML	A083312	002		Jun CAHN

SUPPOSITORY; RECTAL

PHENERGAN

@	DELCOR ASSET CORP	12.5MG	N010926	002		Apr CAHN
@		25MG	N010926	001		Apr CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB		HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar CAHN
AB			25MG	A040673	002	Mar 05, 2008	Mar CAHN
AB			50MG	A040673	003	Mar 05, 2008	Mar CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

AB		WATSON LABS INC	225MG	A202688	001	Aug 24, 2015	Aug NEWA
AB			325MG	A202688	002	Aug 24, 2015	Aug NEWA
AB			425MG	A202688	003	Aug 24, 2015	Aug NEWA

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL						
PYRIDOSTIGMINE BROMIDE						
AB	@ ANI PHARMS INC	30MG	A040512	002	Jul 20, 2005	Aug CAHN
	@	60MG	A040512	001	Oct 08, 2003	Aug CAHN
	ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun NEWA
TABLET, EXTENDED RELEASE; ORAL						
MESTINON						
AB	+ VALEANT PHARMS LLC	180MG	N011665	001		Jun CFTG
PYRIDOSTIGMINE BROMIDE						
AB	ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	Jun NEWA
AB	IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Aug NEWA

PYRIMETHAMINE

TABLET; ORAL					
DARAPRIM					
+	TURING PHARMS AG	25MG	N008578	001	Aug CAHN

QUAZEPAM

TABLET; ORAL						
DORAL						
@	SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985	Jun DISC

QUETIAPINE FUMARATE

TABLET; ORAL							
SEROQUEL							
AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May CAHN
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May CAHN
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May CAHN
	@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May CAHN
AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May CAHN
AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	May CAHN
AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL							
QUINAPRIL HYDROCHLORIDE							
AB	SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr	CAHN
AB		EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr	CAHN
AB		EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr	CAHN
AB		EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr	CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL						
QUINIDINE GLUCONATE						
@ CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun	CAHN

QUINIDINE SULFATE

TABLET; ORAL							
QUINIDINE SULFATE							
@	CYCLE PHARMS LTD	200MG	A083640	001		Jun	CAHN
@		300MG	A085632	001		Jun	CAHN
TABLET, EXTENDED RELEASE; ORAL							
QUINIDINE SULFATE							
+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr	CAHN

QUININE SULFATE

CAPSULE;ORAL						
QUININE SULFATE						
AB	AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun NEWA
AB	LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr NEWA
AB	RICONPHARMA LLC	324MG	A204372	001	Jul 22, 2015	Jul NEWA

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL						
RABEPRAZOLE SODIUM						
AB	AMNEAL PHARMS	20MG	A204179	001	Jul 31, 2015	Jul NEWA

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

RALOXIFENE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	60MG	A204310	001	Aug 28, 2015	Aug NEWA
AB	WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan NEWA

RAMELTEON

TABLET; ORAL

RAMELTEON

AB	ACTAVIS LABS FL INC	8MG	A091610	001	Aug 19, 2015	Aug NEWA
----	---------------------	-----	---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP	+ CONCORDIA PHARMS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun CAHN
----	------------------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 150MG BASE

A075439 001 Apr 19, 2000 Apr CAHN

@ EQ 300MG BASE

A075439 002 Apr 19, 2000 Apr CAHN

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

AB	STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr NEWA
AB		1MG	A091517	002	Apr 24, 2015	Apr NEWA
AB		2MG	A091517	003	Apr 24, 2015	Apr NEWA

RIBAVIRIN

CAPSULE; ORAL

REBETOL

@ MERCK SHARP DOHME 200MG

N020903 001 Jun 03, 1998 Jun DISC

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE; ORAL

ATELVIA

AB	+ WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	May CFTG
----	-----------------------	------	---------	-----	--------------	----------

RISEDRONATE SODIUM

AB	TEVA PHARMS USA	35MG	A203217	001	May 18, 2015	May NEWA
----	-----------------	------	---------	-----	--------------	----------

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010	Apr CAHN
AB		1MG	A077542	002	Aug 06, 2010	Apr CAHN
AB		2MG	A077542	003	Aug 06, 2010	Apr CAHN
AB		3MG	A078474	001	Aug 06, 2010	Apr CAHN
AB		4MG	A078474	002	Aug 06, 2010	Apr CAHN

RIVAROXABAN

TABLET; ORAL

XARELTO

JANSSEN PHARMS 10MG

N022406 001 Jul 01, 2011 Apr CRLD

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

AB	NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007	Aug CFTG
AB	+	9.5MG/24HR	N022083	002	Jul 06, 2007	Aug CFTG
AB		13.3MG/24HR	N022083	005	Aug 31, 2012	Aug CFTG

RIVASTIGMINE

AB	ALVOGEN INC	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug NEWA
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Aug NEWA
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Aug NEWA
AB	ALVOGEN PINE BROOK	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Aug CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Aug CAHN

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB	ORCHID HLTHCARE	EQ 1.5MG BASE	A090879	001	Jun 10, 2015	May NEWA
AB		EQ 3MG BASE	A090879	002	Jun 10, 2015	May NEWA
AB		EQ 4.5MG BASE	A090879	003	Jun 10, 2015	May NEWA
AB		EQ 6MG BASE	A090879	004	Jun 10, 2015	May NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	SAGENT PHARMS	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Aug CAHN
AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Aug CAHN

ROFLUMILAST

TABLET; ORAL

DALIRESP

+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar CAHN
---	--------------------	--------	---------	-----	--------------	----------

>A> ROLAPITANT HYDROCHLORIDE

>A> TABLET; ORAL

>A> VARUBI

>A>	+	TESARO INC	EQ 90MG BASE	N206500	001	Sep 01, 2015	Sep NEWA
-----	---	------------	--------------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr CAHN
AB		EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr CAHN
AB		EQ 1MG BASE	A077460	003	May 05, 2008	Apr CAHN
AB		EQ 2MG BASE	A077460	004	May 05, 2008	Apr CAHN
AB		EQ 3MG BASE	A077460	005	May 05, 2008	Apr CAHN
AB		EQ 4MG BASE	A077460	006	May 05, 2008	Apr CAHN
AB		EQ 5MG BASE	A077460	007	May 19, 2008	Apr CAHN

SACUBITRIL; VALSARTAN

TABLET; ORAL

ENTRESTO

	NOVARTIS PHARMS CORP	24MG; 26MG	N207620	001	Jul 07, 2015	Jul NEWA
		49MG; 51MG	N207620	002	Jul 07, 2015	Jul NEWA
+		97MG; 103MG	N207620	003	Jul 07, 2015	Jul NEWA

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar CAHN
AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan NEWA
AB	+	NOVARTIS	1MG/72HR	N017874	001	Jan CFTG

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@	G AND W LABS INC	5MG	A074537	001	Aug 02, 1996	Apr CAHN
@		5MG	A074744	001	Jan 27, 1997	Apr CAHN
@		5MG	A074756	001	Nov 25, 1998	Apr CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May DISC
@		EQ 50MG BASE	A077864	002	Aug 10, 2009	May DISC
@		EQ 100MG BASE	A077864	003	Aug 10, 2009	May DISC
AB	SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr CAHN
AB		EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr CAHN
AB		EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr CAHN
		EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr CAHN
		EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr CAHN

SILDENAFIL CITRATESOLUTION;INTRAVENOUS
REVATIO

AP	+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar CFTG
AP		SILDENAFIL CITRATE AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar NEWA

SILODOSINCAPSULE;ORAL
RAPAFLO

	+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar CAHN
			8MG	N022206	002	Oct 08, 2008	Mar CAHN

SIMVASTATINTABLET;ORAL
SIMVASTATIN

AB		SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr CAHN
AB			10MG	A076285	002	Dec 20, 2006	Apr CAHN
AB			20MG	A076285	003	Dec 20, 2006	Apr CAHN
AB			40MG	A076285	004	Dec 20, 2006	Apr CAHN
AB			80MG	A076285	005	Jun 23, 2006	Apr CAHN

SODIUM CHLORIDEINJECTABLE;INJECTION
SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb CAHN
		SODIUM CHLORIDE 0.9% EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+		LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CAHN
			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CAHN
+			405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CPOT
			1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CPOT

SODIUM FERRIC GLUCONATE COMPLEXINJECTABLE;INJECTION
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun CAHN
----	--	--------------------	------------	---------	-----	--------------	----------

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

>A>	AP	PETNAT SOLUTIONS IN	10-200mCi/ML	A203890	001	Sep 28, 2015	Sep NEWA
	AP	CARDINAL HEALTH 414	10-200mCi/ML	A203780	001	Jul 30, 2015	Jul NEWA
	AP	HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Jul NEWA
	AP	IBA MOLECULAR N AM	10-200mCi/ML	A203592	001	Aug 18, 2015	Aug NEWA
	AP	MIPS CRF	10-200mCi/ML	A204517	001	Jul 21, 2015	Jul NEWA
	AP	PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA
	AP	SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr NEWA
	AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr NEWA

SODIUM IODIDE I-123CAPSULE;ORAL
SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr CAHN
	@		400uCi	N018671	003	May 27, 1982	Apr CAHN

SODIUM LACTATE

INJECTABLE;INJECTION

>D>		SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER					
>D>	AP	BAXTER HLTHCARE	1.87GM/100ML	N016692	001		Sep DISC
>A>		@	1.87GM/100ML	N016692	001		Sep DISC
		SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER					
>D>	AP	B BRAUN	1.87GM/100ML	N020004	001	Apr 21, 1992	Sep CTEC
>A>			1.87GM/100ML	N020004	001	Apr 21, 1992	Sep CTEC

SODIUM POLYSTYRENE SULFONATE

	POWDER;ORAL, RECTAL						
	KALEXATE						
	KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar	NEWA
	KAYEXALATE						
AA	+ CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr	CAHN

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION						
SOTRADECOL						
+	MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004	Jul CRLD

SOMATROPIN RECOMBINANT

	INJECTABLE;INJECTION						
	NORDITROPIN FLEXPRO						
	NOVO NORDISK INC	30MG/3ML	N021148	011	Jan 23, 2015	Jan NEWA	
	NORDITROPIN NORDIFLEX						
	@ NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009	Jul DISC	
		30MG/3ML	N021148	007	Mar 10, 2009	Mar CMFD	
	@	30MG/3ML	N021148	007	Mar 10, 2009	Jan DISC	
	NUTROPIN						
	@ GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Jun DISC	
	@	10MG/VIAL	N020168	002	Nov 17, 1993	Jun DISC	
BX	+	10MG/VIAL	N020168	002	Nov 17, 1993	Mar CTEC	
	NUTROPIN AQ						
	@ GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun DISC	
	NUTROPIN AQ NUSPIN						
	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun CTNA
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Jun NEWA
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun CTNA
	NUTROPIN AQ PEN						
	+	GENENTECH	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun NEWA
	ZOMACTON						
BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar CTNA
BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr CRLD
BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar NEWA

SONIDEGIB PHOSPHATE

CAPSULE;ORAL						
ODOMZO						
+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N205266	001	Jul 24, 2015	Jul NEWA

SOTALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS						
SOTALOL HYDROCHLORIDE						
	+ ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr CAHN
TABLET;ORAL						
BETAPACE						
AB1	COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar CAHN
AB1		120MG	N019865	005	Apr 20, 1994	Mar CAHN
AB1	+	160MG	N019865	002	Oct 30, 1992	Mar CAHN
AB1		240MG	N019865	003	Oct 30, 1992	Mar CAHN
	@	320MG	N019865	004	Oct 30, 1992	Mar CAHN

STERILE WATER FOR INJECTION

LIQUID;N/A						
STERILE WATER FOR INJECTION						
AP	EUROHLTH INTL SARL	100%	A206369	001	Sep 02, 2015	Aug NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION					
QUELICIN PRESERVATIVE FREE					
@ HOSPIRA	100MG/ML	N008845	004		Jun DISC

SUCRALFATE

TABLET;ORAL						
SUCRALFATE						
AB	MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May CAHN

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SUFENTANIL CITRATE

AP EUROHLTH INTL SARL EQ 0.05MG BASE/ML A074413 001 Dec 15, 1995 Jun CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL
KLARON

AB + VALEANT PHARMS NORTH 10% N019931 001 Dec 23, 1996 Mar CAHN

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

AT AKORN 10% A040215 001 May 25, 1999 Mar CMFD

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ ANI PHARMS INC 200MG/5ML; 40MG/5ML A070028 001 Jun 02, 1987 Jul CAHN

SULFANILAMIDE

CREAM; VAGINAL
SULFANILAMIDE

@ G AND W LABS INC 15% A088718 001 Sep 19, 1985 Apr CAHN

SULINDAC

TABLET; ORAL
SULINDAC

@ ANI PHARMS INC 150MG A072972 001 Feb 28, 1992 Aug CAHN

@ 200MG A072973 001 Feb 28, 1992 Aug CAHN

SUMATRIPTAN SUCCINATE

TABLET; ORAL
SUMATRIPTAN SUCCINATE

>D> AB SANDOZ EQ 25MG BASE A076976 001 Aug 10, 2009 Sep DISC

>A> @ EQ 25MG BASE A076976 001 Aug 10, 2009 Sep DISC

>D> AB EQ 50MG BASE A076976 002 Aug 10, 2009 Sep DISC

>A> @ EQ 50MG BASE A076976 002 Aug 10, 2009 Sep DISC

>D> AB EQ 100MG BASE A076976 003 Aug 10, 2009 Sep DISC

>A> @ EQ 100MG BASE A076976 003 Aug 10, 2009 Sep DISC

AB SUN PHARM INDS LTD EQ 25MG BASE A076554 001 Aug 10, 2009 Apr CAHN

AB EQ 50MG BASE A076554 002 Aug 10, 2009 Apr CAHN

AB EQ 100MG BASE A076572 001 Feb 09, 2009 Apr CAHN

TACROLIMUS

TABLET, EXTENDED RELEASE; ORAL
ENVARUS XR

VELOXIS PHARMS INC EQ 0.75MG BASE N206406 001 Jul 10, 2015 Jul NEWA

EQ 1MG BASE N206406 002 Jul 10, 2015 Jul NEWA

+ EQ 4MG BASE N206406 003 Jul 10, 2015 Jul NEWA

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL
NUCYNTA

+ DEPOMED INC EQ 20MG BASE/ML N203794 001 Oct 15, 2012 May CAHN

TABLET; ORAL
NUCYNTA

DEPOMED INC EQ 50MG BASE N022304 001 Nov 20, 2008 May CAHN

EQ 75MG BASE N022304 002 Nov 20, 2008 May CAHN

+ EQ 100MG BASE N022304 003 Nov 20, 2008 May CAHN

TABLET, EXTENDED RELEASE; ORAL
NUCYNTA ER

DEPOMED INC EQ 50MG BASE N200533 001 Aug 25, 2011 May CAHN

EQ 100MG BASE N200533 002 Aug 25, 2011 May CAHN

EQ 150MG BASE N200533 003 Aug 25, 2011 May CAHN

EQ 200MG BASE N200533 004 Aug 25, 2011 May CAHN

+ EQ 250MG BASE N200533 005 Aug 25, 2011 May CAHN

TEDIZOLID PHOSPHATEPOWDER; IV (INFUSION)
SIVEXTRO

>D>	+	CUBIST PHARMS INC	200MG/VIAL	N205436	001	Jun 20, 2014	Sep CAHN
>A>	+	CUBIST PHARMS LLC	200MG/VIAL	N205436	001	Jun 20, 2014	Sep CAHN

TABLET; ORAL
SIVEXTRO

>D>	+	CUBIST PHARMS INC	200MG	N205435	001	Jun 20, 2014	Sep CAHN
>A>	+	CUBIST PHARMS LLC	200MG	N205435	001	Jun 20, 2014	Sep CAHN

TELAPREVIRTABLET; ORAL
INCIVEK

@ VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan DISC
-----------------	-------	---------	-----	--------------	----------

TELMISARTANTABLET; ORAL
TELMISARTAN

AB	AMNEAL PHARMS	20MG	A204415	001	Sep 08, 2015	Aug NEWA
AB		40MG	A204415	002	Sep 08, 2015	Aug NEWA
AB		80MG	A204415	003	Sep 08, 2015	Aug NEWA
AB	AUROBINDO PHARMA LTD	20MG	A206511	001	Sep 03, 2015	Aug NEWA
AB		40MG	A206511	002	Sep 03, 2015	Aug NEWA
AB		80MG	A206511	003	Sep 03, 2015	Aug NEWA

TEMAZEPAMCAPSULE; ORAL
TEMAZEPAM

AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May NEWA
AB		15MG	A201781	002	Jun 04, 2015	May NEWA
AB		22.5MG	A201781	003	Jun 04, 2015	May NEWA
AB		30MG	A201781	004	Jun 04, 2015	May NEWA

TEMOZOLOMIDECAPSULE; ORAL
TEMOZOLOMIDE

AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr NEWA
AB		20MG	A203691	002	May 08, 2015	Apr NEWA
AB		100MG	A203691	003	May 08, 2015	Apr NEWA
AB		140MG	A203691	004	May 08, 2015	Apr NEWA
AB		180MG	A203691	005	May 08, 2015	Apr NEWA
AB		250MG	A203691	006	May 08, 2015	Apr NEWA

TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar NEWA
AB	VIREAD					
AB	+ GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar CFTG

TERBINAFINEGEL; TOPICAL
LAMISIL

@ GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998	Aug CAHN
------------------------	----	---------	-----	--------------	----------

TERBINAFINE HYDROCHLORIDESOLUTION; TOPICAL
LAMISIL

@ GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997	Aug CAHN
------------------------	----	---------	-----	--------------	----------

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

@ WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb DISC
-------------	---------------	---------	-----	--------------	----------

TERCONAZOLESUPPOSITORY; VAGINAL
TERCONAZOLE

>D>	@ TARO	80MG	A077553	001	Mar 09, 2007	Sep CMFD
>A>	AB	80MG	A077553	001	Mar 09, 2007	Sep CMFD

TESTOSTERONEGEL;TRANSDERMAL
ANDROGEL

AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan CTEC	
AB1	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan CTEC	
	TESTIM						
AB2	+	AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan CTEC
	TESTOSTERONE						
	@ ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar CAHN	
	@	1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar CAHN	
AB1		25MG/2.5GM PACKET	A076737	001	Jan 27, 2006	Jul CMFD	
AB1		50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jul CMFD	
BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May CAHN	
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May CAHN	
AB1	PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Aug CMFD	
AB1		50MG/5GM PACKET	A076744	002	May 23, 2007	Aug CMFD	
AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan CTEC	
AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan CTEC	
	VOGELXO						
AB2	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan CTEC	
	GEL, METERED;TRANSDERMAL						
	ANDROGEL						
AB	+	ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul CFTG
	FORTESTA						
AB	+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul CFTG
	TESTOSTERONE						
AB	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jul NEWA	
AB		12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Aug NEWA	
AB	PERRIGO ISRAEL	1.62% (20.25MG/1.25GM ACTUATION)	A204268	001	Aug 04, 2015	Jul NEWA	

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB	SUN PHARMA GLOBAL	12.5MG	A206129	001	Aug 17, 2015	Aug NEWA
AB		25MG	A206129	002	Aug 17, 2015	Aug NEWA
	XENAZINE					
AB	VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Aug CFTG
		12.5MG	N021894	001	Aug 15, 2008	Feb CAHN
AB	+	25MG	N021894	002	Aug 15, 2008	Aug CFTG
	+	25MG	N021894	002	Aug 15, 2008	Feb CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

AB	+	HERITAGE PHARMS INC	500MG	N050278	001		Apr CRLD
	TETRACYCLINE HYDROCHLORIDE						
>A>	@	CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Sep CAHN
>A>	@		500MG	A062752	002	Aug 12, 1988	Sep CAHN
	@	IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr DISC
	@		500MG	A060704	002		Apr DISC
>D>	@	LABS ATRAL	250MG	A062752	001	Aug 12, 1988	Sep CAHN
>D>	@		500MG	A062752	002	Aug 12, 1988	Sep CAHN

THEOPHYLLINE

TABLET;ORAL

THEOLAIR

@ MEDICIS

@

125MG

250MG

A086399 001

A086399 002

Mar DISC

Mar DISC

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB	MYLAN PHARMS INC	400MG	A040595	001	Apr 21, 2006	May CAHN
AB	+	600MG	A040560	002	Apr 21, 2006	May CAHN

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May CRLD
---	--------------------	-----------	---------	-----	--------------	----------

TICAGRELORTABLET; ORAL
BRILINTA

>A>	ASTRAZENECA LP	60MG	N022433	002	Sep 03, 2015	Sep NEWA
-----	----------------	------	---------	-----	--------------	----------

TIGECYCLINEINJECTABLE; IV (INFUSION)
TIGECYCLINE

AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	May NEWA
AP	TYGACIL					
AP	+ PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	May CFTG

TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC
ISTALOL

AT2	+ BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr CFTG
	TIMOLOL MALEATE					
AT1	AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr CTEC
AT1		EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr CTEC
AT1	ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr CTEC
AT2	APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr NEWA
AT1	BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr CTEC
AT1	FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr CTEC
AT1	HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr CTEC
AT1	PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr CTEC
AT1	WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr CTEC
	TIMOPTIC					
AT1	+ ATON	EQ 0.5% BASE	N018086	002		Apr CTEC

TINIDAZOLETABLET; ORAL
TINIDAZOLE

AB	EDENBRIDGE PHARMS	250MG	A203808	001	Aug 04, 2015	Jul NEWA
AB		500MG	A203808	002	Aug 04, 2015	Jul NEWA

TIOTROPIUM BROMIDESPRAY, METERED; INHALATION
SPIRIVA RESPIMAT

>A>	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015	Sep NEWA
-----	----------------------	-----------------------	---------	-----	--------------	----------

>A> TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE>A> TABLET; ORAL
>A> LONSURF

>A>	TAIHO ONCOLOGY	EQ 6.14MG BASE; 15MG	N207981	001	Sep 22, 2015	Sep NEWA
>A>	+	EQ 8.19MG BASE; 20MG	N207981	002	Sep 22, 2015	Sep NEWA

TOBRAMYCINSOLUTION; INHALATION
KITABIS PAK

AN	PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Feb CTEC
	TOBRAMYCIN					
AN	AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	Jun NEWA

SOLUTION/DROPS; OPHTHALMIC
TOBREX

AT	+ ALCON LABS INC	0.3%	N050541	001		Mar CAHN
----	------------------	------	---------	-----	--	----------

TOBRAMYCIN SULFATEINJECTABLE; INJECTION
TOBRAMYCIN SULFATE

	@ IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar CAHN
	@	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar CAHN
	@	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar CAHN
	@	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar CAHN
	TOBRAMYCIN SULFATE (PHARMACY BULK)					
	+ FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul CTEC
AP	+	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul CRLD
	@ HOSPIRA	EQ 40MG BASE/ML	A063116	001	May 18, 1992	Jul DISC
AP		EQ 40MG BASE/ML	A063116	001	May 18, 1992	Jul CTNA

TOLAZAMIDETABLET; ORAL
TOLAZAMIDE

@ G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr CAHN
@	250MG	N018894	002	Nov 02, 1984	Apr CAHN
@	500MG	N018894	003	Nov 02, 1984	Apr CAHN

TOLCAPONETABLET; ORAL
TASMAR

AB	+ VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar CFTG
AB	PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar NEWA

TOLMETIN SODIUMTABLET; ORAL
TOLMETIN SODIUM

@ G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May CAHN
@	EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr CAHN

TOLTERODINE TARTRATECAPSULE, EXTENDED RELEASE; ORAL
TOLTERODINE TARTRATE

AB	TORRENT PHARMS LTD	2MG	A203016	001	Aug 11, 2015	Jul NEWA
AB		4MG	A203016	002	Aug 11, 2015	Jul NEWA

TABLET; ORAL

TOLTERODINE TARTRATE

AB	IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb NEWA
AB		2MG	A077006	002	Feb 23, 2015	Feb NEWA
AB	MACLEODS PHARMS LTD	1MG	A203409	001	Aug 31, 2015	Aug NEWA
AB		2MG	A203409	002	Aug 31, 2015	Aug NEWA

TOPIRAMATETABLET; ORAL
TOPIRAMATE

AB	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr CAHN
AB		100MG	A076327	002	Mar 27, 2009	Apr CAHN
AB		200MG	A076327	003	Mar 27, 2009	Apr CAHN
@	WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr DISC
@		50MG	A090353	002	Sep 01, 2010	Apr DISC
@		100MG	A090353	003	Sep 01, 2010	Apr DISC
@		200MG	A090353	004	Sep 01, 2010	Apr DISC
	TOPIRAMATE					
@	HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May DISC
@		50MG	A091185	002	Nov 25, 2013	May DISC
@		100MG	A091185	003	Nov 25, 2013	May DISC
@		200MG	A091185	004	Nov 25, 2013	May DISC

TOPOTECAN HYDROCHLORIDECAPSULE; ORAL
HYCANTIN

NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar CAHN
+	EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar CAHN

INJECTABLE; INJECTION
HYCANTIN

AP	+ NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar CAHN
AP	TOPOTECAN HYDROCHLORIDE					
AP	CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May CAHN

TORSEMIDEINJECTABLE; INJECTION
TORSEMIDE

@ EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan DISC
@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan DISC
@ LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan DISC
@	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

>A> AB	MACLEODS PHARMS LTD	50MG	A205702	001	Sep 25, 2015	Sep NEWA
--------	---------------------	------	---------	-----	--------------	----------

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

NOVARTIS PHARMS CORP EQ 0.5MG NON-SOLVATED PARENT

N204114 001 May 29, 2013 Mar CAHN

EQ 1MG NON-SOLVATED PARENT

N204114 002 May 29, 2013 Mar CAHN

+ EQ 2MG NON-SOLVATED PARENT

N204114 003 May 29, 2013 Mar CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP	FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr CMFD
----	--------------------	----------	---------	-----	--------------	----------

TABLET;ORAL

TRANEXAMIC ACID

>A> AB	MYLAN	650MG	A205133	001	Sep 21, 2015	Sep NEWA
--------	-------	-------	---------	-----	--------------	----------

TRANLYCYPROMINE SULFATE

TABLET;ORAL

PARNATE

AB	+ CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun CAHN
----	------------------------	--------------	---------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

@ ALCON LABS INC

0.003%

N204822 001 May 15, 2014 Jul DISC

TRAVATAN Z

AT	+ ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun CTEC
----	--------------------	--------	---------	-----	--------------	----------

TRAVOPROST

AT	APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun NEWA
----	------------	--------	---------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

DESYREL

@ PRAGMA PHARMS LLC

50MG

N018207 001 May CAHN

@

100MG

N018207 002 May CAHN

@

150MG

N018207 003 Mar 25, 1985 May CAHN

@

300MG

N018207 004 Nov 07, 1988 May CAHN

TABLET, EXTENDED RELEASE;ORAL

OLEPTRO

@ ANGELINI PHARMA

150MG

N022411 001 Feb 02, 2010 Mar DISC

@

300MG

N022411 002 Feb 02, 2010 Mar DISC

TRETINOIN

CREAM;TOPICAL

RENOVA

AB2	+ VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr CAHN
-----	------------------------	-------	---------	-----	--------------	----------

AB2	+	0.05%	N019963	001	Dec 29, 1995	Apr CAHN
-----	---	-------	---------	-----	--------------	----------

RETIN-A

AB	+ VALEANT PHARMS NORTH	0.1%	N017340	001		Apr CAHN
----	------------------------	------	---------	-----	--	----------

GEL;TOPICAL

ATRALIN

AB	+ DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Jul CTEC
----	-------------	-------	---------	-----	--------------	----------

TRETINOIN

AB	SPEAR PHARMS INC	0.05%	A207955	001	Aug 13, 2015	Jul NEWA
----	------------------	-------	---------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr CMFD
----	--------------	--------	---------	-----	--------------	----------

AT		0.1%	A089798	001	May 31, 1991	Apr CMFD
----	--	------	---------	-----	--------------	----------

TRIDERM

AT	CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar NEWA
----	------------	--------	---------	-----	--------------	----------

AT		0.5%	A088042	003	Mar 25, 2015	Mar NEWA
----	--	------	---------	-----	--------------	----------

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar CMFD
----	------------------	------	---------	-----	--------------	----------

OINTMENT;TOPICAL
KENALOG

AT	DELCOR ASSET CORP	0.025%	N011600	003		Mar	CMFD
AT		0.1%	N011600	001		Mar	CMFD
	TRIAMCINOLONE ACETONIDE						
AT	G AND W LABS	0.025%	A089795	001	Dec 23, 1988	Aug	CMFD
AT		0.1%	A089796	001	Dec 23, 1988	Aug	CMFD

SPRAY;TOPICAL
KENALOG

AT	+ RANBAXY	0.147MG/GM	N012104	001		Mar	CFTG
AT	+ SUN PHARM INDS LTD	0.147MG/GM	N012104	001		Aug	CAHN
	TRIAMCINOLONE ACETONIDE						
AT	PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar	NEWA

TRIAMTERENE

CAPSULE;ORAL
DYRENIUM

	CONCORDIA PHARMS INC	50MG	N013174	001		Apr	CAHN
+		100MG	N013174	002		Apr	CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL
SURMONTIL

AB	+ ODYSSEY PHARMS	EQ 50MG BASE	N016792	002		Jun	CRLD
AB		EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun	CRLD

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL
VAGILIA

@	G AND W LABS INC	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987	Jul	CAHN
---	------------------	------------------	---------	-----	--------------	-----	------

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR
TRELSTAR

+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Jan	CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Jan	CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Jan	CAHN

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
SANCTURA XR

@	ALLERGAN	60MG	N022103	001	Aug 03, 2007	May	DISC
	TROSPIMUM CHLORIDE						
AB	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Jun	CRLD
AB	+	60MG	A091289	001	Oct 12, 2012	May	CRLD
AB	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	NEWA

TABLET;ORAL
SANCTURA

@	ALLERGAN	20MG	N021595	001	May 28, 2004	May	DISC
	TROSPIMUM CHLORIDE						
AB	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Jun	CRLD
AB	+	20MG	A091575	001	Aug 13, 2010	May	CRLD

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC
RESCULA

+	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	May	CAHN
+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Jan	CAHN

>A> URIDINE TRIACETATE

>A> GRANULE;ORAL
>A> XURIDEN

>A>	+	WELLSTAT THERAP	2GM/PACKET	N208169	001	Sep 04, 2015	Sep	NEWA
-----	---	-----------------	------------	---------	-----	--------------	-----	------

URSODIOL

CAPSULE;ORAL
ACTIGALL

@	ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
AB	+	300MG	N019594	002	Dec 31, 1987	Mar	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	HETERO LABS LTD V	EQ 500MG BASE	A203047	001	Apr 08, 2015	Mar NEWA
AB		EQ 1GM BASE	A203047	002	Apr 08, 2015	Mar NEWA
AB	SUN PHARM INDS LTD	EQ 500MG BASE	A076588	001	Jan 31, 2007	Apr CAHN
AB		EQ 1GM BASE	A076588	002	Jan 31, 2007	Apr CAHN

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

AB	BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan CAHN
	CAPSULE, DELAYED RELEASE; ORAL					
	STAVZOR					
	@ BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan CAHN
	@	250MG	N022152	002	Jul 29, 2008	Jan CAHN
	@	500MG	N022152	003	Jul 29, 2008	Jan CAHN

VALSARTAN

TABLET; ORAL

VALSARTAN

AB	PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May NEWA
AB		80MG	A204821	002	Jun 09, 2015	May NEWA
AB		160MG	A204821	003	Jun 09, 2015	May NEWA
AB		320MG	A204821	004	Jun 09, 2015	May NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

AB	LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan NEWA
AB		EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan NEWA

INJECTABLE; INJECTION

VANCOLED

	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun CAHN
	@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun CAHN
	@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun CAHN
	@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun CAHN
	@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun CAHN

VANCOMYCIN HYDROCHLORIDE

AP	XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015	Aug NEWA
AP		EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015	Aug NEWA

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

AB	+ BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG
	VARDENAFIL HYDROCHLORIDE					
AB	WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
AB		EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
AB		EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA
AB		EQ 75MG BASE	A202036	004	May 28, 2015	May NEWA
AB		EQ 100MG BASE	A202036	005	May 28, 2015	May NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

AB	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr CAHN
AB		180MG	N019614	003	Jan 09, 1992	Apr CAHN
AB		240MG	N019614	002	May 29, 1990	Apr CAHN
	+	360MG	N019614	004	May 10, 1996	Apr CAHN

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN PM

AB	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr CAHN
AB		200MG	N020943	002	Nov 25, 1998	Apr CAHN
AB	+	300MG	N020943	003	Nov 25, 1998	Apr CAHN

INJECTABLE;INJECTION

CALAN

@	EXELA PHARMA SCS LLC	2.5MG/ML	N018925	001	Mar 30, 1984	Aug CAHN
---	----------------------	----------	---------	-----	--------------	----------

ISOPTIN

@	MT ADAMS	2.5MG/ML	N018485	001		Apr CAHN
---	----------	----------	---------	-----	--	----------

TABLET;ORAL

ISOPTIN

@	MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr CAHN
---	----------	------	---------	-----	--------------	----------

@		80MG	N018593	001	Mar 08, 1982	Apr CAHN
---	--	------	---------	-----	--------------	----------

@		120MG	N018593	002	Mar 08, 1982	Apr CAHN
---	--	-------	---------	-----	--------------	----------

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar CAHN
---	--------------------	-----------	---------	-----	--------------	----------

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar CAHN
---	-----------------	------	---------	-----	--------------	----------

		20MG	N022567	002	Jan 21, 2011	Mar CAHN
--	--	------	---------	-----	--------------	----------

		40MG	N022567	003	Jan 21, 2011	Mar CAHN
--	--	------	---------	-----	--------------	----------

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

>A>	AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Sep CAHN
-----	----	--------------------	-----------------	---------	-----	--------------	----------

>D>	AP	HIKMA MAPLE	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Sep CAHN
-----	----	-------------	-----------------	---------	-----	--------------	----------

VORICONAZOLE

TABLET;ORAL

VORICONAZOLE

AB	GLENMARK PHARMS LTD	50MG	A203503	001	Sep 02, 2015	Aug NEWA
----	---------------------	------	---------	-----	--------------	----------

AB		200MG	A203503	002	Sep 02, 2015	Aug NEWA
----	--	-------	---------	-----	--------------	----------

ZAFIRLUKAST

TABLET;ORAL

ACCOLATE

AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb CAHN
----	---------------	------	---------	-----	--------------	----------

AB	+	20MG	N020547	001	Sep 26, 1996	Feb CAHN
----	---	------	---------	-----	--------------	----------

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr NEWA
----	--------------------	-----------------	---------	-----	--------------	----------

AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar NEWA
----	-------------	-----------------	---------	-----	--------------	----------

AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Jul CAHN
----	----------------	-----------------	---------	-----	--------------	----------

AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CPOT
----	-------------------	-----------------	---------	-----	--------------	----------

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

>A>	AB	ALEMBIC PHARMS LTD	2.5MG	A204232	001	Sep 30, 2015	Sep NEWA
-----	----	--------------------	-------	---------	-----	--------------	----------

>A>	AB		5MG	A204232	002	Sep 30, 2015	Sep NEWA
-----	----	--	-----	---------	-----	--------------	----------

>A>	AB	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015	Sep NEWA
-----	----	---------------------	-------	---------	-----	--------------	----------

>A>	AB		5MG	A203772	002	Sep 30, 2015	Sep NEWA
-----	----	--	-----	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

>A>	AB	JUBILANT GENERICS	2.5MG	A202956	001	Sep 17, 2015	Sep NEWA
-----	----	-------------------	-------	---------	-----	--------------	----------

>A>	AB		5MG	A202956	002	Sep 17, 2015	Sep NEWA
-----	----	--	-----	---------	-----	--------------	----------

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL
ZOLPIMIST

>A>	+	AMHERST PHARMS LLC	5MG/SPRAY	N022196	001	Dec 19, 2008	Sep CAHN
>D>	+	NOVADEL	5MG/SPRAY	N022196	001	Dec 19, 2008	Sep CAHN

TABLET;ORAL

ZOLPIDEM TARTRATE

	@	HIKMA	5MG	A078129	001	Apr 30, 2008	Mar DISC
	@		10MG	A078129	002	Apr 30, 2008	Mar DISC
AB		SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr CAHN
AB			10MG	A078055	002	Apr 23, 2007	Apr CAHN

TABLET;SUBLINGUAL

INTERMEZZO

AB		PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May CFTG
AB	+		3.5MG	N022328	002	Nov 23, 2011	May CFTG
		ZOLPIDEM TARTRATE					
AB		NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May NEWA
AB			3.5MG	A204299	002	Jun 03, 2015	May NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB		BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB			50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB			100MG	A077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL
 TYLENOL

@ J AND J CONSUMER INC 120MG
 @ 650MG

N017756 002 Aug CAHN
 N017756 001 Aug CAHN

TABLET, EXTENDED RELEASE;ORAL
 ACETAMINOPHEN

SUN PHARM INDS LTD 650MG
 @ 650MG
 TYLENOL

A078569 001 Dec 14, 2011 Apr CAHN
 A090205 001 Nov 18, 2009 Apr CAHN

+ J AND J CONSUMER INC 650MG
 + 650MG

N019872 001 Jun 08, 1994 Aug CAHN
 N019872 002 Jan 11, 2001 Aug CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL
 SHADE UVAGUARD

+ BAYER HEALTHCARE LLC 3%;7.5%;3%

N020045 001 Dec 07, 1992 Mar CAHN

BUDESONIDE

SPRAY, METERED;NASAL
 RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS 0.032MG/SPRAY

N020746 003 Mar 23, 2015 Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL
 LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC 1%

N021307 001 Dec 07, 2001 Mar CAHN

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL
 PEPCID COMPLETE

+ J AND J CONSUMER INC 800MG;10MG;165MG

N020958 001 Oct 16, 2000 Aug CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES 5MG
 + 10MG

N022429 001 Jul 23, 2009 Jan CAHN
 N022429 004 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES 5MG
 + 10MG

N022429 003 Jul 23, 2009 Jan CAHN
 N022429 002 Jul 23, 2009 Jan CAHN

SYRUP;ORAL

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG/5ML
 CHILDREN'S ZYRTEC HIVES RELIEF

N022155 002 Nov 16, 2007 Aug CAHN

+ J AND J CONSUMER INC 5MG/5ML

N022155 001 Nov 16, 2007 Aug CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA LTD 5MG
 10MG
 SUN PHARM INDS LTD 5MG
 10MG

A090760 001 Aug 05, 2015 Jul NEWA
 A090760 003 Aug 05, 2015 Jul NEWA
 A077498 001 Dec 27, 2007 Apr CAHN
 A077498 002 Dec 27, 2007 Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD 5MG
 10MG

A077498 003 Dec 27, 2007 Apr CAHN
 A077498 004 Dec 27, 2007 Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA LTD 5MG
 10MG

A090760 002 Aug 05, 2015 Jul NEWA
 A090760 004 Aug 05, 2015 Jul NEWA

ZYRTEC ALLERGY

J AND J CONSUMER INC 5MG
 + 10MG

N019835 003 Nov 16, 2007 Aug CAHN
 N019835 004 Nov 16, 2007 Aug CAHN

ZYRTEC HIVES RELIEF

J AND J CONSUMER INC 5MG
 + 10MG

N019835 005 Nov 16, 2007 Aug CAHN
 N019835 006 Nov 16, 2007 Aug CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS 5MG
 10MG
 SANDOZ 5MG

A091116 001 Feb 19, 2015 Feb NEWA
 A091116 002 Feb 19, 2015 Feb NEWA
 A078692 001 Feb 14, 2008 Feb CTNA

TABLET, CHEWABLE;ORAL				
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY				
+	10MG	A078692	002	Feb 14, 2008 Feb CTNA
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF				
	JUBILANT GENERICS 5MG	A091116	003	Feb 19, 2015 Feb NEWA
	10MG	A091116	004	Feb 19, 2015 Feb NEWA
CHILDREN'S ZYRTEC ALLERGY				
@	J AND J CONSUMER INC 5MG	N021621	003	Nov 16, 2007 Aug CAHN
@	10MG	N021621	004	Nov 16, 2007 Aug CAHN
CHILDREN'S ZYRTEC HIVES RELIEF				
@	J AND J CONSUMER INC 5MG	N021621	005	Nov 16, 2007 Aug CAHN
@	10MG	N021621	006	Nov 16, 2007 Aug CAHN
TABLET, ORALLY DISINTEGRATING;ORAL				
CETIRIZINE HYDROCHLORIDE ALLERGY				
	PAR PHARM INC 10MG	A205490	001	Sep 02, 2015 Aug NEWA
ZYRTEC ALLERGY				
+	J AND J CONSUMER INC 10MG	N022578	001	Sep 03, 2010 Aug CAHN
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>				
TABLET, EXTENDED RELEASE;ORAL				
ZYRTEC-D 12 HOUR				
+	J AND J CONSUMER INC 5MG;120MG	N021150	002	Nov 09, 2007 Aug CAHN
<u>CHLORPHENIRAMINE MALEATE</u>				
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
@	BAYER HEALTHCARE LLC 8MG	N007638	001	Mar CAHN
+	12MG	N007638	002	Mar CAHN
<u>CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE</u>				
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
+	BAYER HEALTHCARE LLC 8MG;120MG	N018397	001	Mar CAHN
<u>CLEMASTINE FUMARATE</u>				
TABLET;ORAL				
CLEMASTINE FUMARATE				
@	ANI PHARMS INC 1.34MG	A073282	002	Dec 03, 1992 Jul CAHN
<u>CLOTTRIMAZOLE</u>				
CREAM;VAGINAL				
GYNE-LOTRIMIN				
+	BAYER HEALTHCARE LLC 1%	N018052	002	Nov 30, 1990 Mar CAHN
GYNE-LOTRIMIN 3				
+	BAYER HEALTHCARE LLC 2%	N020574	001	Nov 24, 1998 Mar CAHN
CREAM, TABLET;TOPICAL, VAGINAL				
GYNE-LOTRIMIN COMBINATION PACK				
+	BAYER HEALTHCARE LLC 1%,100MG	N020289	002	Apr 26, 1993 Mar CAHN
TABLET;VAGINAL				
GYNE-LOTRIMIN				
+	BAYER HEALTHCARE LLC 100MG	N017717	002	Nov 30, 1990 Mar CAHN
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN</u>				
TABLET, EXTENDED RELEASE;ORAL				
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE				
	ACTAVIS LABS FL INC 30MG;600MG	A091070	001	Aug 31, 2015 Aug NEWA
	60MG;1.2GM	A091070	002	Aug 31, 2015 Aug NEWA
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN</u>				
CAPSULE;ORAL				
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE				
	BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010 Jan CAHN
<u>FAMOTIDINE</u>				
TABLET;ORAL				
FAMOTIDINE				
	SUN PHARM INDS LTD 10MG	A090283	001	Nov 17, 2009 Apr CAHN
	20MG	A090283	002	Nov 17, 2009 Apr CAHN
PEPCID AC				
	J AND J CONSUMER INC 10MG	N020325	001	Apr 28, 1995 Jul CAHN

TABLET;ORAL							
PEPCID AC							
+	20MG	N020325	002	Sep 23, 2003	Jul	CAHN	
PEPCID AC							
J AND J CONSUMER INC	10MG	N020902	001	Aug 05, 1999	Aug	CAHN	
TABLET, CHEWABLE;ORAL							
PEPCID AC							
@ J AND J CONSUMER INC	10MG	N020801	001	Sep 24, 1998	Aug	CAHN	
+	20MG	N020801	002	Dec 17, 2007	Aug	CAHN	
<u>FEXOFENADINE HYDROCHLORIDE</u>							
TABLET;ORAL							
FEXOFENADINE HYDROCHLORIDE ALLERGY							
SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015	Aug	NEWA	
	180MG	A204507	003	Sep 16, 2015	Aug	NEWA	
FEXOFENADINE HYDROCHLORIDE HIVES							
SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015	Aug	NEWA	
	180MG	A204507	005	Sep 16, 2015	Aug	NEWA	
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015	Jan	NEWA	
<u>GUAIFENESIN</u>							
TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN							
ACTAVIS LABS FL INC	1.2GM	A091009	002	Sep 03, 2015	Aug	NEWA	
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE							
ACTAVIS LABS FL INC	600MG;60MG	A091071	001	May 27, 2015	May	NEWA	
	1.2GM;120MG	A091071	002	May 27, 2015	May	NEWA	
<u>IBUPROFEN</u>							
CAPSULE;ORAL							
IBUPROFEN							
BANNER LIFE SCIENCES	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan	CAHN	
MIDOL LIQUID GELS							
+	200MG	N021472	001	Oct 18, 2002	Jan	CAHN	
SUSPENSION;ORAL							
CHILDREN'S MOTRIN							
+	100MG/5ML	N020516	001	Jun 16, 1995	Aug	CAHN	
SUSPENSION/DROPS;ORAL							
CHILDREN'S MOTRIN							
+	40MG/ML	N020603	001	Jun 10, 1996	Aug	CAHN	
TABLET;ORAL							
IBUPROFEN							
@ ANI PHARMS INC	200MG	A072901	001	Dec 19, 1991	Aug	CAHN	
@	200MG	A072903	001	Dec 19, 1991	Aug	CAHN	
JUNIOR STRENGTH MOTRIN							
J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996	Aug	CAHN	
MOTRIN IB							
+	200MG	N019012	003	Dec 17, 1990	Aug	CAHN	
MOTRIN MIGRAINE PAIN							
+	200MG	N019012	004	Feb 25, 2000	Aug	CAHN	
NUPRIN							
@ J AND J CONSUMER INC	200MG	N019012	001	May 18, 1984	Aug	CAHN	
@	200MG	N019012	002	Jul 29, 1987	Aug	CAHN	
TABLET, CHEWABLE;ORAL							
CHILDREN'S MOTRIN							
J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996	Aug	CAHN	
JUNIOR STRENGTH MOTRIN							
+	100MG	N020601	003	Nov 15, 1996	Aug	CAHN	

IBUPROFEN SODIUM

TABLET; ORAL

IBUPROFEN SODIUM

PERRIGO R AND D

EQ 200MG BASE

A206581 001 Aug 03, 2015 Jul NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S MOTRIN COLD

+ J AND J CONSUMER INC 100MG/5ML; 15MG/5ML

N021128 001 Aug 01, 2000 Aug CAHN

TABLET; ORAL

SINE-AID IB

J AND J CONSUMER INC 200MG; 30MG

N019899 001 Dec 31, 1992 Aug CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

BAUSCH AND LOMB

EQ 0.035% BASE

N021996 002 Feb 11, 2015 Feb NEWA

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

LOTUS PHARM CO LTD

1.5MG

A202246 001 Jun 05, 2015 May NEWA

OC PHARMA

1.5MG

A202380 001 May 29, 2015 May NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES

1MG

N021855 001 Aug 04, 2005 Jan CAHN

+ 2MG

N021855 002 Aug 04, 2005 Jan CAHN

SOLUTION; ORAL

IMODIUM A-D

+ J AND J CONSUMER INC 1MG/5ML

N019487 001 Mar 01, 1988 Aug CAHN

SUSPENSION; ORAL

IMODIUM A-D

+ J AND J CONSUMER INC 1MG/7.5ML

N019487 002 Jul 08, 2004 Aug CAHN

TABLET; ORAL

IMODIUM A-D

+ J AND J CONSUMER INC 2MG

N019860 001 Nov 22, 1989 Aug CAHN

TABLET, CHEWABLE; ORAL

IMODIUM A-D EZ CHEWS

+ J AND J CONSUMER INC 2MG

N020448 001 Jul 24, 1997 Aug CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG; 125MG

N021140 001 Nov 30, 2000 Aug CAHN

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD 2MG; 125MG

A077500 001 Sep 06, 2006 Apr CAHN

TABLET, CHEWABLE; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG; 125MG

N020606 001 Jun 26, 1996 Aug CAHN

LORATADINE

CAPSULE; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG

N021952 001 Jun 16, 2008 Mar CAHN

SYRUP; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML

N020641 002 Nov 27, 2002 Mar CAHN

CLARITIN HIVES RELIEF

@ BAYER HEALTHCARE LLC 1MG/ML

N020641 003 Nov 19, 2003 Mar CAHN

LORATADINE

TARO

1MG/ML

A201865 001 Jul 31, 2015 Jul NEWA

TABLET; ORAL

LORATADINE

SUN PHARM INDS LTD

10MG

A076134 001 Aug 18, 2003 Apr CAHN

TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG

N021891 001 Aug 23, 2006 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL					
CLARITIN REDITABS					
+	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006 Mar CAHN
LORATADINE REDIDOSE					
	SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007 Apr CAHN
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE</u>					
TABLET, EXTENDED RELEASE;ORAL					
CLARITIN-D					
+	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002 Mar CAHN
CLARITIN-D 24 HOUR					
+	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002 Mar CAHN
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
	SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004 Apr CAHN
<u>NAPROXEN SODIUM</u>					
CAPSULE;ORAL					
NAPROXEN SODIUM					
+	BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006 Jan CAHN
	CATALENT	EQ 200MG BASE	A202807	001	Feb 13, 2015 Feb NEWA
	OHM LABS INC	EQ 200MG BASE	A202807	001	Feb 13, 2015 Jun CAHN
TABLET;ORAL					
NAPROXEN SODIUM					
	SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011 Apr CAHN
<u>NICOTINE POLACRILEX</u>					
GUM, CHEWING;BUCCAL					
NICOTINE POLACRILEX					
@	IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009 Mar DISC
@		EQ 4MG BASE	A077850	001	Feb 18, 2009 Mar DISC
<u>OMEPRAZOLE MAGNESIUM</u>					
TABLET, DELAYED RELEASE;ORAL					
OMEPRAZOLE MAGNESIUM					
	PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015 Jul NEWA
<u>OMEPRAZOLE; SODIUM BICARBONATE</u>					
CAPSULE;ORAL					
ZEGERID OTC					
+	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009 Mar CAHN
FOR SUSPENSION;ORAL					
ZEGERID OTC					
+	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013 Mar CAHN
<u>OXYMETAZOLINE HYDROCHLORIDE</u>					
SOLUTION/DROPS;OPHTHALMIC					
OCUCLEAR					
	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986 Mar CAHN
<u>POLYETHYLENE GLYCOL 3350</u>					
FOR SOLUTION;ORAL					
MIRALAX					
+	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006 Mar CAHN
POLYETHYLENE GLYCOL 3350					
	RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012 Jan CAHN
<u>PSEUDOEPHEDRINE HYDROCHLORIDE</u>					
TABLET, EXTENDED RELEASE;ORAL					
PSEUDOEPHEDRINE HYDROCHLORIDE					
	SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005 Apr CAHN
SUDAFED 24 HOUR					
+	J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992 Aug CAHN
<u>RANITIDINE HYDROCHLORIDE</u>					
TABLET;ORAL					
RANITIDINE HYDROCHLORIDE					
@	SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000 Apr CAHN
@	WOCKHARDT	EQ 75MG BASE	A078884	001	Jul 31, 2008 Jan DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER 2015

NO SEPTEMBER 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9056100	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	7223387	Jul 24, 2021	DP U-1006			
	7223387	Jul 24, 2021	DP U-1484			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Jul 12, 2027	U-1078		NP	Jul 15, 2018
	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	8785420	Dec 23, 2022	U-1078			
	8909305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jun 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jun 04, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8778924	Dec 08, 2026	DS DP U-897			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Feb 03, 2023	DS DP U-1167			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
	6967208	Feb 03, 2023	DS DP U-1729			
	6967208	Feb 03, 2023	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6413980	Dec 22, 2019	DS DP U-1301			
	6413980	Dec 22, 2019	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREPITANT - EMEND</u>						
N 021549 001	>A> 6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	>A> 6096742	Jul 01, 2018	DS DP U-1743			
	>A> 6096742	Jul 01, 2018	DS DP U-1744			
	>A> 8258132	Sep 26, 2027	DP U-901			
	>A> 8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 002	>A> 6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	>A> 6096742	Jul 01, 2018	DS DP U-1743			
	>A> 6096742	Jul 01, 2018	DS DP U-1744			
	>A> 8258132	Sep 26, 2027	DP U-901			
	>A> 8258132	Sep 26, 2027	DP U-1743			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - EMEND</u>						
N 021549 003	>A> 6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	>A> 6096742	Jul 01, 2018	DS DP U-1743			
	>A> 6096742	Jul 01, 2018	DS DP U-1744			
	>A> 8258132	Sep 26, 2027	DP U-901			
	>A> 8258132	Sep 26, 2027	DP U-1743			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A> 9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A> 9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A> 9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A> 9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A> 9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A> 9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A> 9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A> 9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 0202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9101637	Mar 23, 2022	U-1731			
	9101637	Mar 23, 2022	U-1732			
	9101637	Mar 23, 2022	U-1733			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	5849911*PED	Dec 20, 2017			>A> NPP	Sep 24, 2018
>A>	6087383	Dec 21, 2018	DS DP		PED	Dec 02, 2017
>A>	6087383*PED	Jun 21, 2019			>A> PED	Mar 24, 2019
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	6730288	Sep 08, 2019	DP		NP	Jul 29, 2018
	7700076	Sep 18, 2027	DP			
	8435498	Mar 01, 2024	U-1727			
	8722021	Oct 24, 2023	DP			
	8900554	Oct 24, 2023	DP			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9066936	Mar 26, 2028	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8895070	Jun 03, 2029	U-124			
	>A> 9078870	Jun 03, 2029	DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BEXAROTENE - TARGRETIN</u>						
N 021055 001					>A> M-164	Jul 29, 2018
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
	8541466	Jan 31, 2021	U-1217			
	8986715	Jan 15, 2023	U-1217			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	5780454*PED	Nov 03, 2017			D-142	Oct 08, 2017
	6713446	Jan 25, 2022	DS DP		I-695	Oct 08, 2017
	6713446*PED	Jul 25, 2022			M-139	Aug 08, 2017
	6958319	Jan 25, 2022	DS DP		>A> M-165	Sep 14, 2018
	6958319*PED	Jul 25, 2022			ODE	Oct 08, 2021
					PED	Feb 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					>A> PED	Mar 14, 2019
					PED	Apr 08, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	5780454*PED	Nov 03, 2017			D-142	Oct 08, 2017
	6713446	Jan 25, 2022	DS DP		I-695	Oct 08, 2017
	6713446*PED	Jul 25, 2022			M-139	Aug 08, 2017
	6958319	Jan 25, 2022	DS DP		>A> M-165	Sep 14, 2018
	6958319*PED	Jul 25, 2022			ODE	Oct 08, 2021
					PED	Feb 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					>A> PED	Mar 14, 2019
					PED	Apr 08, 2022
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9044484	Oct 30, 2030	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8877708	Jun 07, 2030	DP U-1706			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9132093	Sep 07, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
	9107837	Jun 04, 2027	U-1639			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	9089528	Jul 20, 2027	U-1469			
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026 001					ODE	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER</u>						
N 207026 002					ODE	Jan 13, 2022
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					I-712	Jul 24, 2018
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001					>A> NCE	Sep 17, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002					>A> NCE	Sep 17, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003					>A> NCE	Sep 17, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004					>A> NCE	Sep 17, 2020
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 004					PC	Jun 02, 2015
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
N 206323 001	6248363	Nov 23, 2019	DP U-1716			
	6383471	Apr 06, 2019	DP U-1716			
	9066942	Jan 03, 2032	U-1716			
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					ODE	Mar 17, 2022
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Feb 01, 2028	U-1356			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Feb 01, 2028	U-1357			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898 001					PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS		>A> M-163	Sep 14, 2018
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS		>A> M-163	Sep 14, 2018
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001					NPP	Aug 14, 2018
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002					NPP	Aug 14, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	8703781	Oct 15, 2030	DS DP U-1713			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	8703781	Oct 15, 2030	DS DP U-1713			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001					ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001					M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002					M-157	Mar 11, 2018
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016	U-1635			
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERASIROX - JADENU</u>						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU</u>						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001 >A>	7049328	Jun 28, 2021	U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001 >A>	7049328	Jun 28, 2021	U-735		>A> NCE	Oct 14, 2016
	>A> 8703156	Oct 29, 2029	DP U-735		>A> ODE	Oct 14, 2016
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP U-1412			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020	U-1205			
	8088407	Oct 20, 2020	U-1205			
	9012437	Oct 20, 2020	U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9011926	Feb 24, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 003					PC	Dec 19, 2015
<u>DICHLORPHENAMIDE - KEVEYIS</u>						
N 011366 002					>A> ODE	Aug 07, 2022
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387 9017721	Apr 23, 2030 Apr 23, 2030	U-55 DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387 9017721	Apr 23, 2030 Apr 23, 2030	U-55 DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079 8946292	Jun 18, 2019 Mar 22, 2027	DP U-1659			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9066913 9101591 9132110	Oct 17, 2027 Oct 17, 2027 Oct 17, 2027	DP U-1488 DP U-1488 U-1488			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001					>A> M-166	Jul 30, 2018
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703 5061703*PED 8058291 8168209 8168209*PED 8173708 8173708*PED 8283379 8283379*PED 8293794	Apr 11, 2015 Oct 11, 2015 Dec 05, 2029 Nov 22, 2025 May 22, 2026 Nov 22, 2025 May 22, 2026 Nov 22, 2025 May 22, 2026 Nov 22, 2025	U-1641 U-1641 DP U-1641 U-1641 U-1641 DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703 5061703*PED 8039009 8039009*PED 8058291 8168209 8168209*PED 8173708 8173708*PED 8283379 8283379*PED 8293794 8329752 8329752*PED 8338485	Apr 11, 2015 Oct 11, 2015 Mar 24, 2029 Sep 24, 2029 Dec 05, 2029 Nov 22, 2025 May 22, 2026 Nov 22, 2025 May 22, 2026 Nov 22, 2025 May 22, 2026 Nov 22, 2025 Nov 22, 2025 May 22, 2026 Nov 22, 2025	U-1641 U-1641 U-1641 DP U-1641 U-1641 U-1641 DP DP DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9107898	May 01, 2028	DP U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9107898	May 01, 2028	DP U-620			
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	9107900	Apr 16, 2029	U-1726			
	9107900	Apr 16, 2029	U-1728			
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090694 003					PC	Jan 11, 2016
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-714			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293*PED	Nov 21, 2023				
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
	8052995*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	>A> 6280959	Oct 30, 2018	DS DP U-1736		D-149	Jun 11, 2018
	>A> 7160870	Nov 20, 2022	DS DP U-1736		I-711	Jun 11, 2018
	>A> 7332481	May 24, 2021	U-1736		ODE	Nov 20, 2015
	>A> 7452874	May 24, 2021	DS DP		PED	Dec 11, 2018
	>A> 7473686	May 24, 2021	DS DP U-1736		PED	Dec 11, 2018
	>A> 7547719	Jul 13, 2025	DS DP U-1736			
	>A> 7790704	May 24, 2021	U-1736			
	>A> 7795293	May 24, 2023	U-1736			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	>A> 9115091	Jul 07, 2028	DS DP U-1738			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	>A> 9115091	Jul 07, 2028	DS DP U-1738			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	8981103	Oct 26, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001					M-160 M-161	Jun 26, 2018 Jun 26, 2018
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002					M-160 M-161	Jun 26, 2018 Jun 26, 2018
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	>A> 7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	>A> 7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	>A> 7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	>A> 7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	>A> 9126941	May 15, 2026	U-1588			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9119876	Mar 13, 2035	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	>A> 5753646	Jun 27, 2016	DS DP U-1451		>A> D-150	Aug 27, 2018
	>A> 5753646	Jun 27, 2016	DS DP U-1746		>A> I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	>A> 5753646	Jun 27, 2016	DS DP U-1451		>A> D-150	Aug 27, 2018
	>A> 5753646	Jun 27, 2016	DS DP U-1746		>A> I-715	Aug 27, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	>A> 5753646	Jun 27, 2016	DS DP U-1451		>A> D-150	Aug 27, 2018
	>A> 5753646	Jun 27, 2016	DS DP U-1746		>A> I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	>A> 5753646	Jun 27, 2016	DS DP U-1451		>A> D-150	Aug 27, 2018
	>A> 5753646	Jun 27, 2016	DS DP U-1746		>A> I-715	Aug 27, 2018
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001					>A> M-162	Sep 24, 2018
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	9107912	Sep 08, 2031	U-1346			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	9107912	Sep 08, 2031	U-1346			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9078814	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9078814	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Jan 17, 2033	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
	9119859	Jul 02, 2030	U-1679			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001	7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
	7420057	Aug 01, 2022	DS DP			
	8227471	May 09, 2023	U-1734			
<u>FLUOROURACIL - TOLAK</u>						
N 022259 001					>A> NP	Sep 18, 2018
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GEFITINIB - IRESSA</u>						
N 206995 001	5770599	May 05, 2017	DS DP U-1403		NP ODE	Jul 13, 2018 Jul 13, 2022
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
	>A> 9155776	Aug 19, 2030	U-441			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9095559	Mar 09, 2032	U-1383			
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003					M-154	Mar 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	004				M-154	Mar 18, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	001 >A> 9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	002 >A> 9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	003 >A> 9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	004 >A> 9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	005 >A> 9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	006 >A> 9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	001	9023401	Oct 30, 2021	DP		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	002	9023401	Oct 30, 2021	DP		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	003	9023401	Oct 30, 2021	DP		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	004	9023401	Oct 30, 2021	DP		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	005	9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
	8497277	Dec 28, 2026	U-1650			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
>A>	9125889	Jun 03, 2031	U-1745			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029	U-1599			
	9012508	Sep 14, 2030	U-981			
>A>	9114068	Sep 30, 2029	U-1735			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2019	DS DP U-1187			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
>A>	9138432	Sep 30, 2025	U-1737			
>A>	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
>A>	9138432	Sep 30, 2025	U-1737			
>A>	9157121	Apr 05, 2030	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
>A>	9138432	Sep 30, 2025	U-1737			
>A>	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
>A>	9138432	Sep 30, 2025	U-1737			
>A>	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
>A>	9138432	Sep 30, 2025	U-1737			
>A>	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
>A>	9138432	Sep 30, 2025	U-1737			
>A>	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
>A>	9138432	Sep 30, 2025	U-1737			
>A>	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
>A>	9138432	Sep 30, 2025	U-1737			
>A>	9157121	Apr 05, 2030	U-1674			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8658673	Jun 02, 2020	DS DP U-1168			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	>A> 5866538	Jun 20, 2017	DP		>A> NCE	Sep 25, 2020
	>A> 6899699	Jan 02, 2022	DP			
	>A> 7615532	May 25, 2025	DS DP			
	>A> 7686786	Aug 03, 2026	DP			
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	>A> 6899699	Jan 02, 2022	DP		>A> NCE	Sep 25, 2020
	>A> 7615532	May 25, 2025	DS DP			
	>A> 7686786	Aug 03, 2026	DP			
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	>A> 6899699	Jan 02, 2022	DP		>A> NCE	Sep 25, 2020
	>A> 7615532	May 25, 2025	DS DP			
	>A> 7686786	Aug 03, 2026	DP			
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747 001	6034054	Jun 11, 2018	DP U-1707			
	6034054	Jun 11, 2018	DP U-1708			
	6551992	Jun 11, 2018	DP U-1707			
	6551992	Jun 11, 2018	DP U-1708			
	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8912193	Jun 12, 2029	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	7943572	Aug 10, 2026	U-1539			
	8424518	Oct 17, 2031	DP			
	8623817	Sep 18, 2029	U-1537			
	8912193	Jun 12, 2029	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	8474447	Jan 17, 2030	DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	>A> 9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	>A> 9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	>A> 9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	>A> 9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	>A> 9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	>A> 9089534	Sep 21, 2021	DP			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027		U-1311		
	8354427	Jul 06, 2026		U-1311		
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Apr 18, 2027		U-1311	ODE	Jul 02, 2022
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Nov 08, 2026	DP	U-1718		
	8741933	Nov 08, 2026		U-1717		
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028		U-1717		
	8993600	Dec 11, 2030	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018		U-1631		
	6133310	Apr 26, 2019		U-1631		
	7550440	Apr 22, 2024	DP	U-1631		
	8080530	Apr 22, 2024	DP	U-1631		
	8093219	Apr 22, 2024	DP	U-1631		
	8415311	Apr 22, 2024	DP	U-1631		
	8470788	Apr 22, 2024	DP	U-1631		
	8815816	Apr 22, 2024	DP	U-1631		
	9089587	Mar 13, 2034		U-1631		
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024		U-1662		
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMDRIA</u>						
N 205388 001	9066856	Oct 23, 2033	DP			
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP	U-248		
	6004968*PED	Sep 20, 2018				
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-1663		
	7435734	Oct 21, 2022		U-1663		
	7754731	Mar 11, 2029	DS DP	U-1663		
	7820660	Apr 25, 2023	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 005					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 006					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004					M-159	May 18, 2018
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	8980327	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	8980327	Dec 01, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	8821927	Sep 18, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9085573	Mar 21, 2028	DS DP U-1470			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS	U-1211	I-706	Feb 17, 2018
	9056120	Apr 11, 2023		U-1215	ODE	Feb 17, 2022
	9101621	May 15, 2023		U-1216		
	9101622	May 15, 2023		U-1216		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					M-156	Mar 12, 2018
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	6471992	Feb 20, 2018	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 001					PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 002					PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927 8853156	May 04, 2027 Mar 05, 2031	U-1503 U-1642			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503			
<u>LINEZOLID - LINEZOLID</u>						
A 078061 001					PC	Dec 19, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					PC	Jul 04, 2015
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 26, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7674774	Feb 24, 2023	DP U-842			
	>A> 7678770	Feb 24, 2023	U-842			
	>A> 7678771	Feb 24, 2023	DP U-842			
	>A> 7687467	Feb 24, 2023	DP U-842			
	>A> 7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7674774	Feb 24, 2023	DP U-842			
	>A> 7678770	Feb 24, 2023	U-842			
	>A> 7678771	Feb 24, 2023	DP U-842			
	>A> 7687467	Feb 24, 2023	DP U-842			
	>A> 7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7674774	Feb 24, 2023	DP U-842			
	>A> 7678770	Feb 24, 2023	U-842			
	>A> 7678771	Feb 24, 2023	DP U-842			
	>A> 7687467	Feb 24, 2023	DP U-842			
	>A> 7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	>A> 7105486	Feb 24, 2023	U-842			
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7674774	Feb 24, 2023	DP U-842			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	>A> 7678770	Feb 24, 2023	U-842			
	>A> 7678771	Feb 24, 2023	DP U-842			
	>A> 7687467	Feb 24, 2023	DP U-842			
	>A> 7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	>A> 7105486	Feb 24, 2023	U-842		I-703	Jan 30, 2018
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7674774	Feb 24, 2023	DP U-842			
	>A> 7678770	Feb 24, 2023	U-842			
	>A> 7678771	Feb 24, 2023	DP U-842			
	>A> 7687467	Feb 24, 2023	DP U-842			
	>A> 7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	>A> 7105486	Feb 24, 2023	U-842			
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7674774	Feb 24, 2023	DP U-842			
	>A> 7678770	Feb 24, 2023	U-842			
	>A> 7678771	Feb 24, 2023	DP U-842			
	>A> 7687467	Feb 24, 2023	DP U-842			
	>A> 7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	>A> 7223735	Feb 24, 2023	DP		I-703	Jan 30, 2018
	>A> 7655630	Feb 24, 2023	DS			
	>A> 7659253	Feb 24, 2023	DS DP U-727			
	>A> 7659254	Feb 24, 2023	U-1034			
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662788	Feb 24, 2023	U-727			
	>A> 7671030	Feb 24, 2023	DP U-727			
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7674774	Feb 24, 2023	DP U-842			
	>A> 7678770	Feb 24, 2023	U-842			
	>A> 7678771	Feb 24, 2023	DP			
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687467	Feb 24, 2023	DP U-842			
	>A> 7700561	Feb 24, 2023	DP			
	>A> 7713936	Feb 24, 2023	U-727			
	>A> 7718619	Feb 24, 2023	DP U-842			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025		U-1252		
	8980881	Dec 20, 2025		U-1253		
	8980881	Dec 20, 2025		U-1254		
	8980881	Dec 20, 2025		U-1255		
	8999970	Feb 07, 2033		U-1688		
	8999970	Feb 07, 2033		U-1689		
	8999970	Feb 07, 2033		U-1692		
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP	U-540		
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	RE45573	Jun 23, 2025	DS			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001	9040088	Apr 22, 2024		U-755		
	9101540	Apr 22, 2024	DP	U-755		
	9101549	Apr 22, 2024		U-755		
	9107827	Apr 22, 2024		U-755		
<u>MESALAMINE - ASACOL HD</u>						
N 021830 001	>A> 9089492	Nov 15, 2021	DP			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	9060941	Sep 19, 2023	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
>A>	9144549	Jul 31, 2017	U-1747			
>A>	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
>A>	9144549	Jul 31, 2017	U-1747			
>A>	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
>A>	9144549	Jul 31, 2017	U-1747			
>A>	9144549	Jul 31, 2017	U-1748			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
>A>	9144549	Jul 31, 2017	U-1747			
>A>	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
>A>	9144549	Jul 31, 2017	U-1747			
>A>	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028	U-1643			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9084802	May 12, 2031	U-282			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	7699609	Mar 29, 2022	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP U-702			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029	U-1640			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029	U-1640			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	9114168	May 29, 2029	DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
	5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
	6060499	Aug 14, 2017	DP U-1719			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-1719			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	8921337	Mar 31, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027			U-1634	
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031			U-1634	
	8912187	Mar 12, 2024			U-1634	
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
	6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP		U-1703	
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025			U-1702	
	8044046	Nov 10, 2023			U-1702	
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP		U-1702	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
	6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1703			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1702			
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP	Jan 30, 2018
					PED	Jul 30, 2018
<u>OMBITASVIR; PARITAPREVR; RITONAVIR - TECHNIVIE</u>						
N 207931 001	6037157	Jun 26, 2016	U-1635		NCE	Dec 19, 2019
	6037157*PED	Dec 26, 2016			NP	Jul 24, 2018
	6703403	Jun 26, 2016	U-1635			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP U-1638			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
>A>	9132112	Feb 07, 2025	DP U-1511			
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032 001	9023391	Aug 16, 2025	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	9095577	Jul 13, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	9095577	Jul 13, 2030	DP			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Jul 09, 2028	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9119791	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9119791	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9119791	Apr 13, 2027	U-1298			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9101543	Feb 21, 2026	U-1434			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9125905	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9125905	Jan 30, 2024	DP			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003					I-710	Jun 19, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006					I-710	Jun 19, 2018
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7696236	Dec 18, 2027	U-1601			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	>A> RE40640	Oct 14, 2016	DS DP U-1462			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					I-707	Apr 23, 2018
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-1701			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	9040085	Apr 23, 2024	U-1362			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9045519	Jun 22, 2019	DP			
	9085601	Feb 02, 2027	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Feb 16, 2031	DS DP			
	8680124	Jun 02, 2030	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
	6861053	Aug 11, 2019	U-1708			
	7452857	Aug 11, 2019	U-1707			
	7452857	Aug 11, 2019	U-1708			
	7605240	Aug 11, 2019	U-1707			
	7605240	Aug 11, 2019	U-1708			
	7718608	Aug 11, 2019	U-1707			
	7718608	Aug 11, 2019	U-1708			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	7935799	Aug 11, 2019	U-1707			
	7935799	Aug 11, 2019	U-1708			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	>A> 7125879	Apr 14, 2023	DS DP U-1153		NPP	Aug 26, 2018
	>A> 7125879	Apr 14, 2023	DS DP U-1307			
	>A> 7125879	Apr 14, 2023	DS DP U-1740			
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 001					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 002					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 003					PC	Nov 28, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVASTIGMINE - RIVASTIGMINE</u>						
A 204403	003				PC	Feb 29, 2016
<u>ROFLUMILAST - DALIRESP</u>						
N 022522	001	5712298	Jan 27, 2020	DS DP U-1115		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500	001	>A> 7049230	Dec 08, 2023	DS DP U-1741	>A> NCE	Sep 01, 2020
		>A> 7563801	Apr 04, 2027	DP		
		>A> 7981905	Apr 04, 2027	U-1741		
		>A> 7981905	Apr 04, 2027	U-1742		
		>A> 8178550	Apr 04, 2027	DS DP		
		>A> 8361500	Oct 09, 2029	DP		
		>A> 8404702	Oct 09, 2029	U-1741		
		>A> 8470842	Jan 18, 2029	U-1741		
		>A> 8796299	Dec 17, 2022	U-1741		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	001	9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	002	9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	003	9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	004	9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	005	9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	001	7468390	Nov 27, 2023	DP	NCE	Jul 07, 2020
		8101659	Jan 14, 2023	DP		
		8404744	Jan 14, 2023	DP		
		8796331	Jan 14, 2023	U-1723		
		8877938	May 27, 2027	DS DP		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	002	7468390	Nov 27, 2023	DP	NCE	Jul 07, 2020
		8101659	Jan 14, 2023	DP		
		8404744	Jan 14, 2023	DP		
		8796331	Jan 14, 2023	U-1723		
		8877938	May 27, 2027	DS DP		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	003	7468390	Nov 27, 2023	DP	NCE	Jul 07, 2020
		8101659	Jan 14, 2023	DP		
		8404744	Jan 14, 2023	DP		
		8796331	Jan 14, 2023	U-1723		
		8877938	May 27, 2027	DS DP		
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123	001	9040562	Jul 28, 2026	DS DP U-1467		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004					ODE	May 28, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	9050302	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9085573	Mar 21, 2028	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DS DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Feb 06, 2029	DS U-1722			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8124630	Jan 12, 2020	U-1459			
	8841330	Jan 12, 2020	U-1696			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	8983594	Nov 19, 2030	DP U-1328			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001 >A>	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002 >A>	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003 >A>	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004 >A>	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005 >A>	8536130	Sep 22, 2028	U-1739			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9060995	Jan 25, 2033	U-1710			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2016	DS DP U-1320			
	9060992	Nov 01, 2025	U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
>A>	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
>A>	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
>A>	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	9125816	Aug 30, 2020	U-1103			
>A>	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	9125816	Aug 30, 2020	U-1103			
>A>	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	9125816	Aug 30, 2020	U-1103			
>A>	9132089	Aug 30, 2020	U-1103			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8435944	Sep 27, 2027	U-1390			
	8993520	Jun 02, 2026	U-1390			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					>A> I-714	Sep 03, 2018
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	>A> 6251910	Jul 15, 2018	DS		>A> NS	Sep 03, 2018
	>A> 6525060	Dec 02, 2019	DS DP U-1171			
	>A> 7250419	Dec 02, 2019	DS DP U-1171			
	>A> 7265124	Jul 09, 2021	DS DP U-1171			
	>A> 8425934	Apr 17, 2017	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	>A> 5964416	Oct 04, 2016	DP		>A> NP	Sep 15, 2018
	>A> 6149054	Dec 16, 2016	DP			
	>A> 6176442	May 31, 2016	DP			
	>A> 6453795	Dec 05, 2016	DP			
	>A> 6726124	Oct 04, 2016	DP			
	>A> 6846413	Aug 28, 2018	DP			
	>A> 6977042	Aug 28, 2018	DP			
	>A> 6988496	Feb 23, 2020	DP			
	>A> 7104470	Oct 04, 2016	DP			
	>A> 7246615	May 31, 2016	DP			
	>A> 7284474	Aug 26, 2024	DP			
	>A> 7396341	Oct 10, 2026	DP			
	>A> 7802568	Feb 26, 2019	DP			
	>A> 7837235	Mar 13, 2028	DP			
	>A> 7896264	May 26, 2025	DP			
	>A> 7988001	Aug 04, 2021	DP			
	>A> 8733341	Dec 16, 2029	DP			
	>A> 9027967	Mar 31, 2027	DP			
	>A> RE39820	Jan 30, 2018	DS DP			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001					>A> NCE	Sep 22, 2020
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002					>A> NCE	Sep 22, 2020
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	>A> 8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	>A> 8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	>A> 8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	>A> 8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	>A> 8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9101545	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8178582	Oct 10, 2029	DP			
	>A> 9144561	Mar 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 002	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 003	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 004	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8962603	Jun 12, 2030	U-1657			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001					>A> NCE	Sep 04, 2020
					>A> ODE	Sep 04, 2022
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003					NPP	Jun 12, 2018
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 004					NPP	Jun 12, 2018

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>